Shire (SHPG) 10-Q 2 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Central Index Key	936,402
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Trading Symbol	SHP, SHPG
Entity Registrant Name	Shire plc
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	Yes
Entity Common Stock, Shares Outstanding		903,175,914
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 728.6	$ 135.5
Restricted cash	20.1	86
Accounts receivable, net	2,633.4	1,201.2
Inventories	4,857.1	635.4
Prepaid expenses and other current assets	665.3	197.4
Total current assets	8,904.5	2,255.5
Investments	191.8	50.8
Property, plant and equipment, net	6,527.7	828.1
Goodwill	14,850.6	4,147.8
Intangible assets, net	38,871.5	9,173.3
Deferred tax asset	109	121
Other non-current assets	296.2	33.3
Total assets	69,751.3	16,609.8
Current liabilities:
Accounts payable and accrued expenses	4,021.7	2,050.6
Short-term borrowings	2,737.1	1,511.5
Other current liabilities	352.1	144
Total current liabilities	7,110.9	3,706.1
Long-term borrowings	20,988.9	69.9
Deferred tax liability	9,326.5	2,205.9
Other non-current liabilities	2,539.3	798.8
Total liabilities	39,965.6	6,780.7
Commitments and contingencies
Equity:
Common stock of 5p par value; 1,000 million shares authorized; and 910.9 million shares issued and outstanding (2015: 1,000 million shares authorized; and 601.1 million shares issued and outstanding)	81.3	58.9
Additional paid-in capital	24,631.3	4,486.3
Treasury stock: 9.1 million shares (2015: 9.7 million shares)	(302.2)	(320.6)
Accumulated other comprehensive loss	(134.2)	(183.8)
Retained earnings	5,509.5	5,788.3
Total equity	29,785.7	9,829.1
Total liabilities and equity	$ 69,751.3	$ 16,609.8

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - £ / shares shares in Millions	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Common Stock, Par Value (in GBP per share)	£ 0.05	£ 0.05
Common Stock, Shares Authorized	1,000	1,000
Common Stock, Shares, Issued	910.9	601.1
Common Stock, Shares, Outstanding	910.9	601.1
Treasury Stock, Shares	9.1	9.7

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales	$ 3,315.4	$ 1,576.8	$ 7,264.8	$ 4,476.2
Royalties and other revenues	136.7	78.2	325.7	224.8
Total revenues	3,452.1	1,655	7,590.5	4,701
Costs and expenses:
Cost of sales	1,736.2	262.7	2,762.9	718.5
Research and development	511.1	241.2	1,023	1,210.8
Selling, general and administrative	875.6	442.3	2,025.8	1,356.6
Amortization of acquired intangibles	354.9	132.7	702.5	352.3
Integration and acquisition costs	284.5	89.9	738.6	(46.8)
Reorganization costs	101.4	31.1	115.7	59.6
Gain on sale of product rights	(5.7)	(0.7)	(12.2)	(13)
Total operating expenses	3,858	1,199.2	7,356.3	3,638
Operating (loss)/income from continuing operations	(405.9)	455.8	234.2	1,063
Interest income	9.3	0.8	11.9	3.4
Interest expense	(186.9)	(10.7)	(318.8)	(31.6)
Other (expense)/income, net	(13.7)	9.6	(16.2)	11.9
Total other expense, net	(191.3)	(0.3)	(323.1)	(16.3)
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(597.2)	455.5	(88.9)	1,046.7
Income tax benefit	229.6	22.3	218.4	9
Equity in losses of equity method investees, net of taxes	(0.9)	(0.7)	(1.9)	(1.6)
(Loss)/income from continuing operations, net of taxes	(368.5)	477.1	127.6	1,054.1
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Net (loss)/income	$ (386.8)	$ 452.8	$ (129.9)	$ 1,022.8
(Loss)/earnings per ordinary share - basic
(Loss)/earnings from continuing operations (in usd per share)	$ (0.41)	$ 0.81	$ 0.18	$ 1.79
Loss from discontinued operations (in usd per share)	(0.02)	(0.04)	(0.36)	(0.06)
(Loss)/earnings per ordinary share - basic (in usd per share)	(0.43)	0.77	(0.18)	1.73
(Loss)/earnings per ordinary share - diluted
(Loss)/earnings from continuing operations (in usd per share)	(0.41)	0.80	0.18	1.78
Loss from discontinued operations (in usd per share)	(0.02)	(0.04)	(0.36)	(0.06)
(Loss)/earnings per ordinary share - diluted (in usd per share)	(0.43)	0.76	(0.18)	1.72
Cash dividends declared and paid per ordinary share (in usd per share)	$ 0	$ 0	$ 0.22	$ 0.19
Weighted average number of ordinary shares:
Basic (in shares)	900.2	590.9	725.5	590.2
Diluted (in shares)	900.2	593.4	725.5	593.2

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income/(Loss) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Statement of Comprehensive Income [Abstract]
Net (loss)/income	$ (386.8)	$ 452.8	$ (129.9)	$ 1,022.8
Other comprehensive (loss)/income:
Foreign currency translation adjustments	234.3	(41.6)	38.8	(124.9)
Unrealized gain/(loss) on available-for-sale securities (net of tax expense of $2.4 and $1.0 for the three and nine months ended September 30, 2016 and $nil for both the three and nine months ended September 30, 2015)	15.1	(2)	10.4	1.3
Hedging activities, net of tax expense of $1.2 and tax benefit of $0.5 for the three and nine months ended September 30, 2016, respectively and $nil for both the three and nine months ended September 30, 2015	2.2	0	0.4	0
Comprehensive (loss)/income	(135.2)	$ 409.2	(80.3)	$ 899.2
Components of accumulated other comprehensive income
Foreign currency translation adjustments	(143.3)		(143.3)		$ (182.1)
Unrealized holding gain/(loss) on available-for-sale securities, net of taxes	8.7		8.7		(1.7)
Hedging activities, net of taxes	0.4		0.4		0
Accumulated other comprehensive loss	$ (134.2)		$ (134.2)		$ (183.8)

Consolidated Statements of Com6

Consolidated Statements of Comprehensive Income/(Loss) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Statement of Comprehensive Income [Abstract]
Unrealized holding (loss)/gain on available-for-sale securities, tax	$ 2.4	$ 0	$ 1	$ 0
Hedging activities, tax expense (benefit)	$ 1.2	$ 0	$ (0.5)	$ 0

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - 9 months ended Sep. 30, 2016 - USD ($) shares in Millions, $ in Millions	Total	Common stock	Additional paid-in capital	Treasury stock	Accumulated other comprehensive loss	Retained earnings
Beginning balance at Dec. 31, 2015	$ 9,829.1	$ 58.9	$ 4,486.3	$ (320.6)	$ (183.8)	$ 5,788.3
Beginning balance (in shares) at Dec. 31, 2015	601.1	601.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (129.9)					(129.9)
Other comprehensive income net of tax	49.6				49.6
Options exercised	90.4	$ 0.4	90
Option exercised (in shares)		4.6
Share-based compensation	269.6		269.6
Tax benefit associated with exercise of stock options	7.8		7.8
Shares released by employee benefit trust to satisfy exercise of stock options	(0.3)			18.4		(18.7)
Shares issued for the acquisition of Baxalta	19,799.6	$ 22	19,777.6
Shares issued for the acquisition of Baxalta (in shares)		305.2
Dividends	(130.2)					(130.2)
Ending balance at Sep. 30, 2016	$ 29,785.7	$ 81.3	$ 24,631.3	$ (302.2)	$ (134.2)	$ 5,509.5
Ending balance (in shares) at Sep. 30, 2016	910.9	910.9

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss)/income	$ (129.9)	$ 1,022.8
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	877.8	457.4
Share-based compensation	269.6	70.8
Amortization of deferred financing fees	121.7	8
Amortization of inventory fair value step-up	1,097.3	23
Changes in deferred taxes	(546.9)	(178.3)
Change in fair value of contingent consideration	(34.8)	(196.5)
Impairment of intangible assets	8.9	523.3
Impairment of property, plant and equipment	89.2	0
Other, net	35.3	(23.2)
Changes in operating assets and liabilities
Increase in accounts receivable	(411.2)	(288.1)
Increase in sales deduction accruals	108.2	100
Increase in inventory	(228)	(21.7)
(Increase)/decrease in prepayments and other assets	(66.4)	21.2
Increase in accounts payable and other liabilities	315.2	56.5
Net cash provided by operating activities	1,506	1,575.2
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment and non-current investments	(402.5)	(67.3)
Purchases of businesses, net of cash acquired	(17,476.2)	(5,553.4)
Proceeds from short-term investments	0	67
Proceeds from disposal of non-current investments	0.6	18.5
Movements in restricted cash	68.3	(48)
Proceeds from sale of product rights	7.8	14.5
Other, net	(9.3)	2.7
Net cash used in investing activities	(17,811.3)	(5,566)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	31,742.3	3,650.8
Repayment of revolving line of credit, long term and short term borrowings	(14,632.9)	(2,486.1)
Payment of dividend	(130.2)	(110.2)
Debt issuance costs	(171)	(3.3)
Proceeds from exercise of options	98.9	0
Other, net	(6.5)	3.7
Net cash provided by financing activities	16,900.6	1,054.9
Effect of foreign exchange rate changes on cash and cash equivalents	(2.2)	(1.6)
Net increase/(decrease) in cash and cash equivalents	593.1	(2,937.5)
Cash and cash equivalents at beginning of period	135.5	2,982.4
Cash and cash equivalents at end of period	728.6	44.9
Supplemental information:
Interest paid	223.4	13.1
Income taxes paid	$ 355.8	$ 20.5

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation These interim financial statements of Shire plc and its subsidiaries (collectively “Shire” or the “Company”) are unaudited. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The balance sheet as of December 31, 2015 was derived from audited financial statements. These interim Unaudited Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on February 23, 2016, and as updated by a Current Report on Form 8-K filed with the SEC on September 2, 2016 (the “Shire 2015 Form 10-K”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period and the Company believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. On June 3, 2016, the Company completed its acquisition of Baxalta for $32.4 billion , representing the preliminary fair value of purchase consideration. The Company’s Unaudited Consolidated Financial Statements include the results of Baxalta from the date of acquisition. For further details regarding the acquisition, please refer to Note 2, Business Combinations, of these Unaudited Consolidated Financial Statements. During the second quarter of 2016, due to the Baxalta acquisition, the Company concluded that it was appropriate to reclassify the Amortization of Acquired Intangibles from Selling, General and Administrative on the Unaudited Consolidated Statements of Operations. Accordingly, the Company reclassified the Amortization of Acquired Intangibles from Selling, General and Administrative in comparative periods to conform to the current classification. Use of Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. Estimates and assumptions are primarily made in relation to the valuation of intangible assets, sales deductions, income taxes (including provisions for uncertain tax positions and the realization of deferred tax assets), provisions for litigation and legal proceedings, measurement of pension and other post-employment plan obligations and net periodic benefit cost, contingent consideration receivable from product divestments and contingent consideration payable in respect of business combinations and asset purchases and valuation of other assets and liabilities acquired in business combinations. On an on-going basis the Company evaluates its estimates, judgments and methodologies. Actual results may differ from these estimates under different assumptions or conditions. Accounting Policy Updates The Company’s significant accounting policies are discussed in the Shire 2015 Form 10-K. The following significant accounting policies have been updated as a result of the Baxalta acquisition. Financial instruments - derivatives The Company uses derivative financial instruments to manage its exposure to foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The Company has assumed derivatives related to the Baxalta acquisition and has elected to apply hedge accounting for certain derivatives. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (“AOCI”) and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in revenues and cost of sales and primarily relate to forecasted third-party sales denominated in foreign currencies and forecasted intercompany sales denominated in foreign currencies, respectively. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in interest income and interest expense, as they hedge the interest rate risk associated with certain of the Company’s fixed-rate debt. In its application of hedge accounting, the Company assesses, both at inception and on a prospective basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. The Company also assesses hedge effectiveness on a retrospective basis every quarter with any hedge ineffectiveness recorded to the Consolidated Statement of Operations. The Company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the Company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments generally are not formally designated as hedges and the terms of these instruments generally do not exceed three months. The fair values of these instruments are included on the balance sheet in current assets/liabilities, with changes in the fair value recognized in the Consolidated Statements of Operations. The cash flows relating to these instruments are presented within net cash provided by operating activities in the Consolidated Statement of Cash Flows, unless the derivative instruments are economically hedging specific investing or financing activities. New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. Adopted during the current period Reporting requirements for development stage entities In June 2014, the FASB simplified the existing guidance for development stage entities by removing all incremental financial reporting requirements and the exception available for development stage entities when determining whether the development stage entity is a variable interest entity. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Debt Issuance Costs In April 2015, the FASB issued a new standard that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued additional guidance which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. The recognition and measurement guidance for debt issuance costs were not affected by these amendments. Shire adopted this guidance as of January 1, 2016 with retroactive application. The Short-term borrowings and Long-term borrowings line items in the Consolidated Balance Sheets and related footnote disclosures for all periods presented have been adjusted. The adoption of this guidance did not impact the Company’s results of operations or cash flows. Cloud Computing Arrangement In April 2015, the FASB issued guidance to simplify the accounting for fees paid in a cloud computing arrangement. Under the standard, if a cloud computing arrangement includes a software license, then the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Measurement-Period Adjustments In September 2015, the FASB issued guidance to simplify the accounting for adjustments related to business combinations arising within one year of the acquisition. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and record the effect on earnings of those changes as if the accounting had been completed at the acquisition date, and sets forth new disclosure requirements related to the adjustments. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance impacted the recognition and disclosure of measurement period adjustments identified during the three months ended September 30, 2016 related to the Baxalta acquisition. Refer to Note 2, Business Combinations, of these Unaudited Consolidated Financial Statements for further information. Financial Instrument Accounting In March 2016, the FASB issued new guidance that clarifies the requirements for assessing whether contingent call and put options that can accelerate the payment of principal of debt instruments are clearly and closely related to their debt host. This guidance will be effective beginning on January 1, 2017, and modified retrospective application is required. Early adoption is permitted. This guidance was adopted in the third quarter of 2016 and had no impact on the Company's financial position or results of operations. Pension Plans In May 2015, the FASB issued new guidance which removes the disclosure requirement to categorize within the fair value hierarchy all investments that measure fair value using the net asset value per share as a practical expedient and certain disclosures associated with these types of investments. This guidance became effective beginning on January 1, 2016, and retrospective application is required. This guidance was adopted during the current period and impacted the disclosure of certain acquired pension plan assets in the fair value hierarchy in Note 15, Retirement and Other Benefit Programs, but did not impact the Company's financial position or results of operations. To be adopted in future periods Revenue from Contracts with Customers In May 2014, the FASB issued new accounting guidance for recognizing revenue from contracts with customers. This new standard supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The new standard also requires additional qualitative and quantitative disclosures. In August 2015, the FASB issued additional guidance that delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued additional guidance on when and how much revenue to recognize when another party (an agent), along with the entity, is involved in providing a good or a service to a customer. In April 2016, the FASB issued additional guidance on accounting for licenses of intellectual property and identifying performance obligations. In May 2016, the FASB issued additional guidance on assessing collectability, presentation of sales taxes, noncash consideration, and completed contracts and contract modifications. In May 2016, the FASB rescinded several SEC Staff Announcements that are codified in ASC 605, including, among other items, guidance relating to accounting for shipping and handling fees and freight services. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Inventory In July 2015, the FASB issued new guidance which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard is effective for the Company as of January 1, 2017. Early adoption is permitted. The Company does not believe the adoption of this guidance will have a material impact on its financial position or results of operations. Financial Instrument Accounting In January 2016, the FASB issued a new standard that amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in Other Comprehensive Income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for the Company as of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Leases In February 2016, the FASB issued new accounting guidance that will require the recognition of all lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. The standard requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. This standard is effective for the Company as of January 1, 2019. Early adoption is permitted. The Company is currently evaluating the potential impact on its financial position and results of operations of adopting this guidance. Share-Based Payment Accounting In March 2016, the FASB issued a new standard that requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. The Company is currently evaluating the method of adoption and potential impact on its financial position, results of operations and statement of cash flow of adopting this guidance. Statement of Cash Flows In August 2016, the FASB issued new accounting guidance to reduce diversity in practice regarding how certain transactions are classified in the statement of cash flows. This amendment is effective for the Company as of January 1, 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a significant impact on the Company's Consolidated Statement of Cash Flows.

Business Combinations

Business Combinations	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Business Combinations	Business Combinations Combination with Baxalta On June 3, 2016, Shire acquired all of the outstanding common stock of Baxalta for $18.00 per share in cash and 0.1482 Shire American Depository Shares (“ADSs”) per Baxalta share, or if a former Baxalta shareholder properly elected, 0.4446 Shire ordinary shares per Baxalta share. Baxalta was a global biopharmaceutical company that focused on developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. The preliminary fair value of the purchase price consideration consisted of the following: (in millions) Estimated fair value Cash paid to shareholders $ 12,366.7 Fair value of stock issued to shareholders 19,353.2 Fair value of partially vested stock options and RSUs assumed 497.6 Contingent consideration payable 161.0 Total Purchase Consideration $ 32,378.5 The acquisition of Baxalta was accounted for as a business combination using the acquisition method. Shire issued 305.2 million shares to former Baxalta shareholders at the date of the acquisition. For a more detailed description of the fair value of the partially vested stock options and RSUs assumed, please see Note 22, Share-based compensation plans, to these Unaudited Consolidated Financial Statements. The assets acquired and the liabilities assumed from Baxalta have been recorded at their preliminary fair value as of June 3, 2016, the date of acquisition. The Company’s Unaudited Consolidated Financial Statements included the results of Baxalta from the date of acquisition. The amount of Baxalta’s post-acquisition revenues included in the Company’s Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2016 is $1,586.4 million and $2,166.7 million , respectively. After the closing of the acquisition, the Company began integrating Baxalta and as such the combined business is now sharing various research and development and selling, general and administrative functions. As a result, computing a separate measure of Baxalta’s stand-alone profitability for periods after the acquisition date is not practical. The Company's preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date, including measurement period adjustments identified during the three months ended September 30, 2016, is outlined below. (in millions) Preliminary values as of June 30, 2016 Measurement period adjustments Preliminary values as of September 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 583.2 $ — $ 583.2 Accounts receivable, net 1,382.8 17.0 1,399.8 Inventories 5,341.1 (276.4 ) 5,064.7 Other current assets 362.2 — 362.2 Total current assets 7,669.3 (259.4 ) 7,409.9 Property, plant and equipment, net 5,687.7 (118.4 ) 5,569.3 Investments 128.2 — 128.2 Goodwill 6,106.4 1,894.6 8,001.0 Other intangible assets, net Currently marketed products 24,550.0 (400.0 ) 24,150.0 In-Process Research and Development ("IPR&D") 2,940.0 (1,460.0 ) 1,480.0 Contract based arrangements 72.2 10.0 82.2 Other non-current assets 103.3 — 103.3 Total assets $ 47,257.1 $ (333.2 ) $ 46,923.9 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 1,509.5 $ 27.5 $ 1,537.0 Other current liabilities 15.4 77.5 92.9 Long-term borrowings 5,424.9 — 5,424.9 Deferred tax liability 6,831.7 (446.4 ) 6,385.3 Other non-current liabilities 1,092.1 13.2 1,105.3 Total liabilities 14,873.6 (328.2 ) 14,545.4 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 32,383.5 $ (5.0 ) $ 32,378.5 Consideration Preliminary fair value of purchase consideration $ 32,383.5 $ (5.0 ) $ 32,378.5 The measurement period adjustments for Other intangible assets reflect changes in the estimated fair value of Currently marketed products and IPR&D. The measurement period adjustments for Property, plant and equipment ("PP&E") primarily reflect changes in the estimated fair value of acquired buildings, machinery and equipment. The changes in the estimated fair values for Other intangible assets and PP&E are primarily to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The Company is currently completing its evaluation of information, assumptions and valuation methodologies it used in its preliminary fair value of the purchase price consideration. The purchase price allocation is preliminary pending final determination of the fair values of certain assets and liabilities. As of September 30, 2016 , certain items related to the fair values of inventories, intangible assets, PP&E, other current and non-current liabilities and current and deferred taxes have not been finalized and may be subject to change as additional information is received and certain tax returns are finalized. The finalization of these matters may result in changes to the underlying assets, liabilities and goodwill. These changes may be material. The final determination of these fair values will be completed as soon as possible but no later than one year from the acquisition date. Intangible Assets The fair value of the identifiable intangible assets has been estimated using an income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of the incremental after tax cash flows an asset would generate over its remaining useful life. Currently marketed products totaling $24,150.0 million relate to intellectual property (“IP”) rights acquired for Baxalta’s currently marketed products. The estimated useful life of the intangible assets related to currently marketed products range from 11 to 38 years (weighted average 30 years), with amortization being recorded on a straight line basis. IPR&D intangible assets totaling $1,480.0 million represent the value assigned to research and development ("R&D") projects acquired. The IPR&D intangible assets are capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. Upon successful completion of each project, the Company will make a separate determination of the estimated useful life of the IPR&D intangible asset and the related amortization will be recorded as an expense over the estimated useful life. Some of the more significant assumptions inherent in the development of those asset valuations include the estimated net cash flows for each year for each asset or product (including net revenues, cost of sales, R&D costs, selling and marketing costs, working capital/asset contributory asset charges and other cash flow assumptions), the appropriate discount rate to select in order to measure the risk inherent in each future cash flow stream, the assessment of each asset’s life cycle, the potential regulatory and commercial success risks, competitive trends impacting the asset and each cash flow stream as well as other factors. The discount rate used to arrive at the present value at the acquisition date of the IPR&D intangible assets was 10.0% to reflect the internal rate of return and incremental commercial uncertainty in the cash flow projections. No assurances can be given that the underlying assumptions used to prepare the discounted cash flow analysis will not change. For these and other reasons, actual results may vary significantly from estimated results. Goodwill Goodwill of $8,001.0 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of Baxalta with Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. In the three and nine months ended September 30, 2016 , the Company expensed $254.1 million and $696.4 million , respectively, relating to the acquisition and integration of Baxalta, which have been recorded within Integration and Acquisition costs in the Company’s Unaudited Consolidated Statements of Operations. Contingent Consideration The Company acquired certain contingent obligations classified as contingent consideration related to Baxalta’s historical business combinations. Additional consideration is conditionally due upon the achievement of certain milestones related to the development, regulatory, first commercial sale and other sales milestones, which could total up to approximately $1.5 billion . The Company may also pay royalties based on certain product sales. The Company estimated the fair value of the assumed contingent consideration to be $161.0 million using a probability weighting approach that considered the possible outcomes based on assumptions related to the timing and probability of the product launch date, discount rates matched to the timing of first payment, and probability of success rates and discount adjustments on the related cash flows. Retirement plans The Company assumed pension plans as part of the acquisition of Baxalta, including defined benefit and post-retirement benefit plans in the United States and foreign jurisdictions which had a net liability balance of $610.4 million . As of June 3, 2016, the Baxalta defined benefit pension plans had assets with a fair value of $358.5 million . Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and Baxalta as if the acquisition of Baxalta had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2015. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2016 2015 Revenues $ 3,250.0 $ 10,193.5 $ 9,086.0 Net (loss)/income from continuing operations (52.0 ) 1,406.6 (1,152.1 ) Per share amounts: Net (loss)/income from continuing operations per share - basic $ (0.06 ) $ 1.94 $ (1.29 ) Net (loss)/income from continuing operations per share - diluted $ (0.06 ) $ 1.92 $ (1.29 ) The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the nine months ended September 30, 2016 by $562.6 million to eliminate integration and acquisition related costs incurred by Shire and Baxalta and a corresponding decrease in net income for the nine months ended September 30, 2015 by $562.6 million to give effect to the integration and acquisition of Baxalta as if it had occurred on January 1, 2015; (ii) an adjustment to increase net income for the nine months ended September 30, 2016 by $873.6 million and a corresponding decrease in the three and nine months ended September 30, 2015 by $592.5 million and $1,777.5 million , respectively, to reflect amortization of the fair value adjustments for inventory as inventory is sold; (iii) an adjustment to increase amortization expense for the nine months ended September 30, 2016 by $198.8 million and for the three and nine months ended to September 30, 2015 by $153.6 million and $478.0 million , respectively, related to the identifiable intangible assets acquired; and (iv) an adjustment to decrease net income for the nine months ended September 30, 2016 by $97.2 million and for the three and nine months ended September 30, 2015 by $64.0 million and $215.1 million , respectively, primarily related to the additional interest expense associated with the debt incurred to partially fund the acquisition of Baxalta and the amortization of related deferred debt issuance costs. The adjustments above are stated net of their tax effects, where applicable. Acquisition of Dyax On January 22, 2016, Shire acquired all of the outstanding common stock of Dyax for $37.30 per share in cash. Under the terms of the merger agreement, former Dyax shareholders may receive additional value through a non-tradable contingent value right worth $4.00 per share, payable upon U.S. Food and Drug Administration (“FDA”) approval of SHP643 (formerly DX-2930) in Hereditary Angioedema (“HAE”). Dyax was a publicly-traded, Massachusetts-based rare disease biopharmaceutical company primarily focused on the development of plasma kallikrein (“pKal”) inhibitors for the treatment of HAE. Dyax’s most advanced clinical program was SHP643, a Phase 3 program with the potential for improved efficacy and convenience for HAE patients. SHP643 has received Fast Track, Breakthrough Therapy, and Orphan Drug Designations by the FDA and has also received Orphan Drug status in the EU. Dyax’s sole marketed product, KALBITOR, is a pKal inhibitor for the treatment of acute attacks of HAE in patients 12 years of age and older. The acquisition of Dyax was accounted for as a business combination using the acquisition method. The preliminary acquisition-date fair value consideration was $6,330.0 million , comprising cash paid on closing of $5,934.0 million and the preliminary fair value of the contingent value right of $396.0 million (maximum payable $646.0 million ). The assets acquired and the liabilities assumed from Dyax have been recorded at their preliminary fair value as of January 22, 2016, the date of acquisition. The Company’s Unaudited Consolidated Financial Statements include the results of Dyax as of January 22, 2016. The amount of Dyax’s post-acquisition revenues included in the Company’s Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2016 is $16.7 million and $51.3 million , respectively. After the closing of the acquisition, the Company began integrating Dyax and as such the combined business is now sharing various research and development and selling, general and administrative functions. As a result, computing a separate measure of Dyax's stand-alone profitability for periods after the acquisition date is not practical. In the third quarter of 2016 , the Company adjusted its preliminary valuation and allocation of purchase price consideration. The adjustment, which was not material, decreased goodwill and deferred tax liabilities. The revised preliminary allocation of the total purchase price is as follows: (in millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 241.2 Accounts receivable, net 22.5 Inventories 20.2 Other current assets 8.1 Total current assets 292.0 Property, plant and equipment, net 5.8 Goodwill 2,688.8 Other intangible assets, net Currently marketed projects 135.0 IPR&D 4,100.0 Contract based royalty arrangements 425.0 Other non-current assets 28.6 Total assets $ 7,675.2 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 30.0 Other current liabilities 1.7 Deferred tax liability 1,312.1 Other non-current liabilities 1.4 Total liabilities 1,345.2 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 6,330.0 Consideration Preliminary fair value of purchase consideration $ 6,330.0 The purchase price allocation is preliminary pending final determination of the fair values of certain assets and liabilities. In particular, intangible assets and current and deferred taxes are preliminary pending receipt of the final valuations for those items. The final determination of these fair values will be completed as soon as possible, but no later than one year from the acquisition date. Currently marketed products Currently marketed products totaling $135.0 million relate to intellectual property rights acquired for KALBITOR. The fair value of the currently marketed product has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to KALBITOR. The estimated useful life of the KALBITOR intangible asset is 18 years, with amortization being recorded on a straight-line basis. IPR&D The IPR&D asset of $4,100.0 million relates to Dyax’s clinical program SHP643, a Phase 3 program with the potential for improved efficacy and convenience for HAE patients. The IPR&D intangible asset is capitalized and accounted for as indefinite-lived intangible assets and will be subject to impairment testing until completion or abandonment of the projects. The fair value of this IPR&D asset was estimated based on an income approach, using the present value of incremental after tax cash flows expected to be generated by this development project. The estimated cash flows have been probability adjusted to take into account the development stage of completion and the remaining risks and uncertainties surrounding the future development and commercialization. The estimated probability adjusted after tax cash flows used to estimate the fair value of other intangible assets have been discounted at 9% . Royalty rights Other intangible assets totaling $425.0 million relate to royalty rights arising from licensing agreements of a portfolio of product candidates. This portfolio includes two approved products, marketed by Eli Lilly & Company, and various development-stage products. Multiple product candidates with other pharmaceutical companies are in various stages of clinical development for which the Company is eligible to receive future royalties and/or milestone payments. The fair value of these royalty rights is preliminary and has been estimated using an income approach, based on the present value of incremental after-tax cash flows attributable to each royalty right. The estimated useful lives of these royalty rights range from seven to nine years (weighted average eight years), with amortization being recorded on a straight-line basis. Goodwill Goodwill of $2,688.8 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of Dyax with Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. For the three and nine months ended September 30, 2016 , the Company expensed $11.3 million and $65.0 million , respectively, relating to the acquisition and integration of Dyax, which have been recorded within Integration and Acquisition costs in the Company’s Unaudited Consolidated Statements of Operations. Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and Dyax as if the acquisitions of Dyax had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed at the date indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2016 2015 Revenues $ 1,679.7 $ 7,596.4 $ 4,772.5 Net income from continuing operations 438.0 25.9 837.1 Per share amounts: Net income from continuing operations per share - basic $ 0.74 $ 0.04 $ 1.42 Net income from continuing operations per share - diluted $ 0.74 $ 0.04 $ 1.41 The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the nine months ended September 30, 2016 by $108.4 million to eliminate acquisition related costs incurred by Shire and Dyax and a corresponding decrease in net income for the nine months ended September 30, 2015 by $108.4 million to give effect to the acquisition of Dyax as if it had occurred on January 1, 2015; (ii) an adjustment to decrease net income for the three and nine months ended September 30, 2015 by $1.6 million and $3.9 million , respectively, to reflect amortization of the fair value adjustments for inventory as inventory is sold; (iii) an adjustment to increase amortization expense for the nine months ended September 30, 2016 by $1.3 million and a corresponding adjustment to decrease net income for the three and nine months ended September 30, 2015 by $5.4 million and $16.2 million , respectively, related to the identifiable intangible assets acquired; and (iv) an adjustment to record interest expense for the three and nine months ended September 30, 2015 of $20.4 million and $61.2 million , respectively associated with the debt incurred to partially fund the acquisition of Dyax and the amortization of related deferred debt issuance costs. The adjustments above are stated net of their tax effects, where applicable. Acquisition of NPS On February 21, 2015, Shire completed its acquisition of all of the outstanding common stock of NPS. As of the acquisition date, fair value of the cash consideration paid on closing was $5,219.6 million . The acquisition of NPS added GATTEX/REVESTIVE and NATPARA/NATPAR to Shire’s portfolio of currently marketed products. GATTEX/REVESTIVE is approved in the U.S. and EU for the treatment of adults with short bowel syndrome (“SBS”) who are dependent on parenteral support, a rare and potentially fatal gastrointestinal disorder. NATPARA/NATPAR is approved in the U.S. and indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism (“HPT”), a rare endocrine disease. The acquisition of NPS was accounted for as a business combination using the acquisition method. The assets acquired and the liabilities assumed from NPS have been recorded at their fair values at the date of acquisition, February 21, 2015. The Company’s Unaudited Consolidated Financial Statements include the results of NPS from February 21, 2015. The purchase price allocation for the acquisition of NPS was finalized in the fourth quarter of 2015 . The Company’s allocation of the purchase price to the fair value of assets acquired and liabilities assumed is outlined below: (in millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Other current assets 11.1 Total current assets 242.5 Property, plant and equipment, net 4.8 Goodwill 1,551.0 Other intangible assets Currently marketed products 4,640.0 Royalty rights (categorized as "Other amortized intangible assets") 353.0 Total assets $ 6,791.3 LIABILITIES Current liabilities: Accounts payable and other current liabilities $ 75.7 Short-term debt 27.4 Long-term debt, less current portion 78.9 Deferred tax liabilities 1,385.2 Other non-current liabilities 4.5 Total liabilities 1,571.7 Fair value of identifiable assets acquired and liabilities assumed $ 5,219.6 Consideration Cash consideration paid $ 5,219.6 Currently marketed products Currently marketed products totaling $4,640.0 million relate to intellectual property rights of NATPARA/NATPAR and GATTEX/REVESTIVE. The fair value of the currently marketed products has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each separately identifiable intangible asset. The estimated useful lives of the NATPARA/NATPAR and GATTEX/REVESTIVE intangible assets are 24 years, with amortization being recorded on a straight-line basis. Royalty rights Other intangible assets totaling $353.0 million relate to the royalty rights arising from the collaboration agreements with Amgen Inc (“Amgen”), Janssen Pharmaceutica N.V. (“Janssen”) and Kyowa Hakko Kirin Co. Ltd (“Kyowa Hakko Kirin”). Amgen markets cinacalcet HCl as Sensipar in the U.S. and as Mimpara in the EU; Janssen markets tapentadol as Nucynta in the U.S.; and Kyowa Hakko Kirin markets cinacalcet HCI as Regpara in Japan, Hong Kong, Malaysia, Macau, Singapore, and Taiwan. From the acquisition of NPS, the Company is entitled to royalties from the net sales of these products. The fair value of these royalty rights has been estimated using an income approach, based on the present value of incremental after tax cash flows attributable to each royalty right. The estimated useful lives of these royalty rights range from four to five years (weighted average four years) with amortization being recorded on a straight-line basis. Goodwill Goodwill of $1,551.0 million , which is not deductible for tax purposes, includes the expected synergies that will result from combining the operations of NPS with the operations of Shire; intangible assets that do not qualify for separate recognition at the time of the acquisition; the value of the assembled workforce; and impacted by establishing a deferred tax liability for the acquired identifiable intangible assets which have no tax basis. Supplemental disclosure of pro forma information The following unaudited pro forma financial information presents the combined results of the operations of Shire and NPS as if the acquisitions of NPS had occurred as of January 1, 2014. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2014. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2015 Revenues $ 1,655.0 $ 4,730.9 Net income from continuing operations 479.1 1,005.6 Per share amounts: Net income from continuing operations per share - basic $ 0.81 $ 1.70 Net income from continuing operations per share - diluted $ 0.81 $ 1.69 The unaudited pro forma financial information above reflects the following pro forma adjustments: (i) an adjustment to increase net income for the three and nine months ended September 30, 2015 by $2.0 million and $105.2 million , respectively, to eliminate acquisition related costs incurred by Shire and NPS; (ii) an adjustment to increase net income by $4.2 million and $13.4 million for the three and nine months ended September 30, 2015 respectively, to reflect charges on the unwind of inventory fair value adjustments as acquisition date inventory is sold; and (iii) an adjustment to increase amortization expense for the three and nine months ended September 30, 2015 by $ nil and $21.2 million , respectively, related to the identifiable intangible assets acquired. The adjustments above are stated net of their tax effects, where applicable.

Collaborative and other licensi

Collaborative and other licensing arrangements	9 Months Ended
	Sep. 30, 2016
Collaborative and Other Licensing Arrangements Disclosure [Abstract]
Collaborative and other licensing arrangements	Collaborative and other licensing arrangements The Company is party to certain collaborative or licensing arrangements. In some of these arrangements, Shire and the licensee are both actively involved in the development and commercialization of the licensed product and have exposure to risks and rewards dependent on its commercial success. Out-licensing arrangements The Company has entered into various collaborative and licensing arrangements where it has licensed certain product or intellectual property rights for consideration such as up-front payments, development milestones, sales milestones and/or royalty payments. Under the terms of these collaborative and licensing arrangements, the Company may receive development milestone payments up to an aggregate amount of $17.3 million and sales milestones up to an aggregate amount of $17.7 million . The receipt of these substantive milestones is uncertain and contingent on the achievement of certain development milestones or the achievement of a specified level of annual net sales by the licensee. In the three and nine months ended September 30, 2016 , the Company received cash related to up-front and milestone payments of $3.0 million and $3.5 million , respectively, compared to $ nil and $12.6 million , respectively, in the three and nine months ended September 30, 2015. In the three and nine months ended September 30, 2016 , the Company recognized milestone income of $1.7 million and $4.0 million , respectively (2015: $0.5 million and $1.5 million , respectively), in other revenues, and $16.4 million and $47.7 million , respectively (2015: $13.8 million and $37.2 million , respectively), in product sales for shipment of product to the relevant licensee. Collaboration and in-licensing arrangements The Company is party to various collaborative and in-licensing arrangements, many of which were acquired through the acquisition of Baxalta. The Company also entered into a new collaboration agreement during the nine months ended September 30, 2016. These agreements generally provide for commercialization rights to a product or products being developed by the counterparty, and in exchange often resulted in an upfront payment upon execution of the agreement and an obligation that the Company make future development, regulatory approval or commercial milestone payments as well as royalty payments. The following is a description of the Company's significant collaboration agreements acquired by the Company through the acquisition of Baxalta or entered into by the Company during the nine months ended September 30, 2016. The acquisition-date fair value of the collaboration agreements acquired from Baxalta was included in the IPR&D. Precision BioSciences In June 2016, the Company acquired a strategic immuno-oncology collaboration with Precision BioSciences (“Precision”), a private biopharmaceutical company based in the United States, specializing in genome editing technology. The Company acquired the collaboration through the acquisition of Baxalta, which previously entered into the agreement in February 2016. Together, Shire and Precision will develop chimeric antigen receptor (“CAR”) T cell therapies for up to six unique targets, with the first program expected to enter clinical studies in late 2017. On a product-by-product basis, following successful completion of early-stage research activities up to Phase 2, Shire will have exclusive option rights to complete late-stage development and worldwide commercialization. Precision is responsible for development costs for each target prior to option exercise. Precision also has the right to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States. As of the date the agreement was acquired, June 3, 2016, and as of the balance sheet date, the Company had the potential to make future payments related to option fees and development, regulatory and commercial milestones totaling up to $1.6 billion , in addition to future royalty payments on worldwide sales. Symphogen In June 2016, the Company acquired a research, option and commercial agreement with Symphogen, a private biopharmaceutical company headquartered in Denmark that is developing recombinant antibodies and antibody mixtures. The Company acquired the agreement through the acquisition of Baxalta, which previously entered into the agreement in December 2015. Under the terms of the agreement, the Company has options to obtain exclusive licensing rights for four specified proteins in development for the treatment of immune-oncology diseases as well as two additional proteins that may be selected at a later date. Each option is exercisable for a period of 90 days when each protein is ready for Phase 2 clinical trials. Symphogen is responsible for development costs for each protein until option exercise, at which point Shire would become responsible for development costs. Each option exercise fee is variable depending on when it is exercised, with a maximum exercise price of up to €20 million for each protein. As of the date the agreement was acquired, June 3, 2016 and as of the balance sheet date, the Company had the potential to make additional future payments of up to approximately €1.2 billion related to development, regulatory and commercial milestones achieved after option exercise for all six proteins, in addition to future royalty payments. Merrimack Pharmaceuticals, Inc. In June 2016, the Company acquired an exclusive license agreement with Merrimack Pharmaceuticals, Inc. (“Merrimack”) relating to the development and commercialization of ONIVYDE (nanoliposomal irinotecan injection), also known as “nal-IRI” or MM-398. The Company acquired the agreement through the acquisition of Baxalta, which previously entered into the agreement in September 2014. The arrangement includes all potential indications for nal-IRI across all markets with the exception of the United States and Taiwan. The first indication being pursued is for the treatment of patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based therapy. As of the date the agreement was acquired, June 3, 2016 and as of the balance sheet date, the Company had the potential to make future payments of up to approximately $678 million related to the achievement of development, regulatory and commercial milestones, in addition to future royalty payments. Coherus Biosciences, Inc. In June 2016, the Company acquired a license agreement with Coherus Biosciences, Inc. (“Coherus”) to develop and commercialize a biosimilar to ENBREL® (etanercept). The Company acquired the agreement through the acquisition of Baxalta, which previously entered into the agreement in August 2013. The Company also obtained the right of first refusal to certain other biosimilars in the collaboration. Under the terms of the agreement, Coherus was responsible for the development plan, preparation of regulatory filings, and manufacture of the product, subject to certain cost reimbursement by the Company. In September 2016, the Company terminated the licensing agreement with Coherus in accordance with its terms. Momenta Pharmaceuticals, Inc. In June 2016, the Company acquired an exclusive license agreement with Momenta Pharmaceuticals, Inc. (“Momenta”) to develop and commercialize biosimilars, including adalimumab (BAX 2923), a biosimilar product candidate for HUMIRA® (adalimumab). The agreement was acquired through the acquisition of Baxalta, which initially entered into the agreement in February 2012. The arrangement includes specified funding by the Company, as well as other responsibilities, relating to development and commercialization activities. In September 2016, the Company exercised its right to terminate its license agreement with Momenta. The effective date of the termination is twelve months from the date that Momenta received the Company’s written notice of termination. Prior to the effective date of the termination, the Company and Momenta are required to satisfy certain ongoing obligations. Pfizer Inc. In July 2016, the Company licensed the global rights to all indications for SHP647 from Pfizer Inc. SHP647 is an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease. Under the terms of the agreement, Pfizer received an upfront payment of $90 million , and is eligible to receive between $75 million to $460 million in milestone payments based on clinical, regulatory and commercialization milestones and low double-digit royalties on any potential sales if the product is approved. Other arrangements SFJ Pharmaceuticals Group In June 2015, Baxalta entered into a co-development agreement with SFJ Pharmaceuticals IX, L.P., a SFJ Pharmaceuticals Group company (“SFJ”) relating to BAX 2923, whereby SFJ would fund specified development costs related to the BAX 2923 program, in exchange for payments in the event the product obtains regulatory approval in the United States and Europe. There were certain termination provisions that could have triggered payment of the contingent success payments prior to regulatory approval. The preliminary fair value of the assumed contingency was recorded as a long-term liability at June 3, 2016 and as of the balance sheet date, as part of Company’s purchase accounting for the Baxalta acquisition. The fair value of the assumed contingency on the date of acquisition was $288.6 million . This co-development agreement was terminated by mutual agreement of the Company and SFJ in September 2016 and the Company made a one-time $288.0 million payment to SFJ in connection with the termination, in full satisfaction of the Company’s financial obligations under the agreement.

Integration and Acquisition Cos

Integration and Acquisition Costs	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Integration and Acquisition Costs	Integration and Acquisition Costs For the three and nine months ended September 30, 2016 , Shire recorded integration and acquisition costs of $284.5 million and $738.6 million , respectively, primarily due to the acquisition and integration of Baxalta and Dyax and related contract termination costs. The Baxalta integration is estimated to be completed by mid to late 2019 and the integration of Dyax is substantially complete as of September 30, 2016 . As part of the Company’s activities to integrate Baxalta, it terminated certain employees and announced plans to close certain offices. For the three and nine months ended September 30, 2016 , the Company incurred costs relating to employee termination benefits of $120.0 million and $373.1 million , respectively, including severance and acceleration of stock compensation. The Baxalta integration activities are ongoing and the Company is continuing to evaluate the total costs expected to be incurred and the time-frame. The following table summarizes the employee termination related reserve as of September 30, 2016 : (in millions) Severance and Employee Benefits As of January 1, 2016 $ — Amount charged to integration costs 202.3 Paid/utilized (128.1 ) As of September 30, 2016 $ 74.2 For the three months ended September 30, 2015 , Shire recorded integration and acquisition costs of $89.9 million of which $30.7 million related to the acquisition and integration of NPS, Viropharma and charges related to the acquisition of Baxalta. Additionally, Shire recorded $59.2 million in charges related to the change in the fair value of contingent consideration liabilities in relation to the acquisition of Lumena Pharmaceuticals, Inc. (“Lumena”), following the agreement to settle all future contingent milestones payable to former Lumena shareholders through a one-time $90 million payment. For the nine months ended September 30, 2015 , Shire recorded a net credit to integration and acquisition costs of $46.8 million . The net credit principally comprises costs related to the acquisition and integration of NPS, Viropharma and preliminary work on the proposed combination with Baxalta totaling $149.7 million offset by a net credit relating to the change in the fair value of contingent consideration liabilities of $196.5 million . The change in fair value of contingent consideration liabilities relates to the acquisition of Lumena and Lotus Tissue Repair Inc. The Lumena contingent consideration decreased as the probability of success for the SHP625 asset (for the treatment of cholestatic liver diseases) decreased following the receipt of data from certain Phase 2 studies and the agreement in the third quarter of 2015 to settle all future contingent milestones payable to former Lumena shareholders. The contingent consideration from the Lotus Tissue Repair acquisition decreased as the probability of success for the SHP608 asset (for the treatment of Dystrophic Epidermolysis Bullosa (“DEB”)) decreased upon receiving certain preclinical toxicity findings.

Reorganization Costs

Reorganization Costs	9 Months Ended
	Sep. 30, 2016
Reorganizations [Abstract]
Reorganization Costs	Reorganization Costs The Company incurred reorganization costs totaling $101.4 million and $115.7 million during the three and nine months ended September 30, 2016, respectively. The charge during the three months and nine months ended September 30, 2016 primarily relates to the planned closure of certain manufacturing facilities and associated asset impairments of $77.4 million and employee termination and other costs of $18.4 million . As of September 30, 2016, there were no cash payments associated with these costs. Other restructuring charges recorded, which were not significant, during the nine months ended September 30, 2016 relate to the closure of other offices and the employee relocation. The Company incurred reorganization costs totaling $31.1 million and $59.6 million during the three and nine months ended September 30, 2015, respectively, primarily related to the Company's One Shire business reorganization.

Accounts Receivable

Accounts Receivable	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Accounts Receivable	Accounts Receivable Accounts receivable at September 30, 2016 of $2,633.4 million (December 31, 2015: $1,201.2 million ), are net of reserve for discounts and allowances of $127.4 million (December 31, 2015: $55.8 million ). Reserve for discounts and allowances: (in millions) 2016 2015 As of January 1, $ 55.8 $ 48.5 Provision charged to operations 569.9 293.8 Payments/credits related to sales (498.3 ) (286.6 ) As of September 30, $ 127.4 $ 55.7 As of September 30, 2016, accounts receivable included $89.9 million (December 31, 2015: $79.0 million ) related to royalty income.

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2016
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Discontinued Operations Following the sale of the Company’s DERMAGRAFT business in January 2014, the operating results associated with the DERMAGRAFT business have been classified as discontinued operations in the Company’s Unaudited Consolidated Statements of Operations for all periods presented. For the three and nine months ended September 30, 2016 , the Company recorded a loss of $18.3 million (net of tax benefit of $5.7 million ) and $257.5 million (net of tax benefit of $101.1 million ), respectively, primarily related to legal contingencies related to the divested DERMAGRAFT business. For details of the legal provision see Note 21, Legal and other proceedings, to these Unaudited Consolidated Financial Statements. For the three and nine months ended September 30, 2015 , the Company recorded a loss of $24.3 million (net of tax benefit of $14.0 million ) and $31.3 million (net of tax benefit of $18.0 million ), respectively, related to costs associated with the divestment.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or market. Inventories comprise: (in millions) September 30, 2016 December 31, 2015 Finished goods $ 1,597.6 $ 184.9 Work-in-progress 2,431.3 302.0 Raw materials 828.2 148.5 $ 4,857.1 $ 635.4 For a more detailed description of the inventories acquired with Baxalta and Dyax, please see Note 2, Business Combinations, to these Unaudited Consolidated Financial Statements.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: (in millions) September 30, 2016 December 31, 2015 Land $ 356.3 $ 96.7 Buildings and leasehold improvements 1,999.5 606.4 Machinery, equipment and other 2,440.5 827.4 Assets under construction 2,647.0 93.7 7,443.3 1,624.2 Less: Accumulated depreciation (915.6 ) (796.1 ) $ 6,527.7 $ 828.1 Depreciation expense for the three and nine months ended September 30, 2016 was $93.1 million and $175.3 million , respectively, and for the three and nine months ended September 30, 2015 was $32.9 million and $105.1 million , respectively.

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Assets	Intangible Assets The following table summarizes the Company's intangible assets: (in millions) Currently marketed products IPR&D Other intangible assets Total September 30, 2016 Gross acquired intangible assets $ 34,104.6 $ 6,522.8 $ 882.2 $ 41,509.6 Accumulated amortization (2,467.7 ) — (170.4 ) (2,638.1 ) Other intangible assets, net $ 31,636.9 $ 6,522.8 $ 711.8 $ 38,871.5 December 31, 2015 Gross acquired intangible assets $ 9,371.9 $ 1,362.0 $ 375.0 $ 11,108.9 Accumulated amortization (1,852.1 ) — (83.5 ) (1,935.6 ) Other intangible assets, net $ 7,519.8 $ 1,362.0 $ 291.5 $ 9,173.3 Other intangible assets are comprised primarily of royalty rights and other contract rights associated with Baxalta, Dyax and NPS. The change in the net book value of intangible assets for the nine months ended September 30, 2016 and 2015 is shown in the table below: (in millions) 2016 2015 As of January 1, $ 9,173.3 $ 4,934.4 Acquisitions 30,377.7 5,473.7 Amortization charged (702.5 ) (352.3 ) Impairment charges (8.9 ) (523.3 ) Foreign currency translation 31.9 (81.9 ) As of September 30, $ 38,871.5 $ 9,450.6 In connection with the acquisition of Baxalta on June 3, 2016, the Company acquired IP rights related to currently marketed products of $24,150.0 million , IPR&D assets of $1,480.0 million and other contract rights of $82.2 million . For a more detailed description of this acquisition, please see Note 2, Business Combinations, to these Unaudited Consolidated Financial Statements. In connection with the acquisition of Dyax on January 22, 2016, the Company acquired IP rights related to currently marketed products of $135.0 million , IPR&D assets of $4,100.0 million and royalty rights of $425.0 million . For a more detailed description of this acquisition, please see Note 2, Business Combinations, to these Unaudited Consolidated Financial Statements. The Company reviews its amortized intangible assets for impairment whenever events or circumstances suggest that their carrying value may not be recoverable. Unamortized intangible assets are reviewed for impairment annually or whenever events or circumstances suggest that their carrying value may not be recoverable. The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows: (in millions) Anticipated future amortization 2016 (remaining three months) $ 358.1 2017 1,429.9 2018 1,424.2 2019 1,344.8 2020 1,340.9 2021 1,336.5

Goodwill

Goodwill	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Goodwill The following table provides a roll-forward of the goodwill balance: (in millions) 2016 2015 As of January 1, $ 4,147.8 $ 2,474.9 Acquisitions 10,689.8 1,837.0 Foreign currency translation 13.0 (22.3 ) As of September 30, $ 14,850.6 $ 4,289.6 The increase in goodwill during the nine months ended September 30, 2016 relates to our acquisitions of Baxalta and Dyax. For a more detailed description of these transactions, please see Note 2, Business Combinations, to these Unaudited Consolidated Financial Statements.

Fair Value Measurement

Fair Value Measurement	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement Assets and liabilities that are measured at fair value on a recurring basis As of September 30, 2016 and December 31, 2015, the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). Fair value (in millions) Total Level 1 Level 2 Level 3 At September 30, 2016 Financial assets: Marketable equity securities $ 69.7 $ 69.7 $ — $ — Marketable debt securities 16.5 3.7 12.8 — Contingent consideration receivable 15.7 — — 15.7 Derivative instruments 50.6 — 50.6 — Total assets 152.5 73.4 63.4 15.7 Financial liabilities: Derivative instruments 13.3 — 13.3 — Contingent consideration payable 996.7 — — 996.7 Total liabilities $ 1,010.0 $ — $ 13.3 $ 996.7 (in millions) Total Level 1 Level 2 Level 3 At December 31, 2015 Financial assets: Marketable equity securities $ 17.2 $ 17.2 $ — $ — Contingent consideration receivable 13.8 — — 13.8 Derivative contracts 1.9 — 1.9 — Total assets 32.9 17.2 1.9 13.8 Financial liabilities: Derivative contracts 11.5 — 11.5 — Contingent consideration payable 475.9 — — 475.9 Total liabilities $ 487.4 $ — $ 11.5 $ 475.9 Marketable equity securities are included within Investments in the Unaudited Consolidated Balance Sheets. Contingent consideration receivable is included within Prepaid expenses and Other current assets and Other non-current assets in the Unaudited Consolidated Balance Sheets. Contingent consideration payable is included within Other current liabilities and Other non-current liabilities in the Unaudited Consolidated Balance Sheets. For a discussion of the Company's derivative arrangements, see Note 13, Financial Instruments, to these Unaudited Consolidated Financial Statements. Certain estimates and judgments were required to develop the fair value amounts. The estimated fair value amounts shown above are not necessarily indicative of the amounts that the Company would realize upon disposition, nor do they indicate the Company’s intent or ability to dispose of the financial instrument. The following methods and assumptions were used to estimate the fair value of each material class of financial instrument: • Marketable equity securities: the fair values of marketable equity securities are estimated based on quoted market prices for those investments. • Marketable debt securities: the fair values of debt securities are obtained from pricing services or broker/dealers who either use quoted prices in an active market or proprietary pricing applications, which include observable market information for like or same securities. • Contingent consideration receivable: the fair value of the contingent consideration receivable has been estimated using the income approach (using a probability weighted discounted cash flow method). • Derivative contracts: the fair values of the swap and forward foreign exchange contracts have been determined using the month-end interest rate and foreign exchange rates, respectively. • Contingent consideration payable: the fair value of the contingent consideration payable has been estimated using the income approach (using a probability weighted discounted cash flow method). Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) The following table provides a roll forward of the fair values of our contingent consideration receivable and payables which include Level 3 measurements: Contingent consideration receivable (in millions) 2016 2015 Balance at January 1, $ 13.8 $ 15.9 Change in fair value included in earnings 3.6 9.8 Other (1.7 ) (10.8 ) Balance at September 30, $ 15.7 $ 14.9 Contingent consideration payable (in millions) 2016 2015 Balance at January 1, $ 475.9 $ 629.9 Additions 557.0 92.8 Change in fair value included in earnings (34.8 ) (196.5 ) Other (1.4 ) (5.6 ) Balance at September 30, $ 996.7 $ 520.6 The increase in contingent consideration payable is primarily related to the Company’s acquisition of Dyax as well as contingent consideration payable assumed in the acquisition of Baxalta. Other primarily includes foreign currency adjustments. Of the $996.7 million of contingent consideration payable as of September 30, 2016, $48.0 million is recorded within Other current liabilities and $948.7 million is recorded within Other non-current liabilities in the Company’s Unaudited Consolidated Balance Sheets. Quantitative Information about Assets and Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3) Quantitative information about the Company’s recurring Level 3 fair value measurements is as follows: Financial assets: Fair Value at the Measurement Date At September 30, 2016 (in millions, except percentages) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration receivable $ 15.7 Income approach (probability weighted discounted cash flow) • Probability weightings applied to different sales scenarios • 10 to 90% • Future forecast consideration receivable based on contractual terms with purchaser • $0 to $23 • Assumed market participant discount rate • 8.4% Financial liabilities: Fair Value at the Measurement Date At September 30, 2016 (in millions, except percentages) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration payable $ 996.7 Income approach (probability weighted discounted cash flow) • Cumulative probability of milestones being achieved • 4 to 90% • Assumed market participant discount rate • 1.2 to 10.5% • Periods in which milestones are expected to be achieved • 2016 to 2030 • Forecast quarterly royalties payable on net sales of relevant products • $3.5 to $7.1 Contingent consideration payable represents future milestones and royalties the Company may be required to pay in conjunction with various business combinations and license agreements. The fair value of the Company’s contingent consideration receivable and payable could significantly increase or decrease due to changes in certain assumptions which underpin the fair value measurements. Each set of assumptions is specific to the individual contingent consideration receivable or payable. Financial assets and liabilities that are not measured at fair value on a recurring basis The carrying amounts and estimated fair values as of September 30, 2016 and December 31, 2015 of the Company’s financial assets and liabilities that are not measured at fair value on a recurring basis are as follows: September 30, 2016 December 31, 2015 (in millions) Carrying amount Fair value Carrying amount Fair value Financial liabilities: Senior notes $ 12,037.0 $ 12,080.9 $ — $ — Baxalta notes 5,104.4 5,467.7 — — Capital lease obligation 348.6 348.6 13.4 13.4 The estimated fair values of long-term debt were based upon recent observable market prices and are considered level 2 in the fair value hierarchy. The estimated fair value of capital lease obligations is based on Level 2 inputs. The carrying amounts of other financial assets and liabilities approximate their estimated fair value due to their short-term nature, such as liquidity and maturity of these amounts, or because there have been no significant changes since the asset or liability was last re-measured to fair value on a non-recurring basis.

Financial Instruments

Financial Instruments	9 Months Ended
	Sep. 30, 2016
Derivative Instrument Detail [Abstract]
Financial Instruments	Financial Instruments Foreign Currency Contracts Due to the global nature of our operations, portions of the Company’s revenues and operating expenses are recorded in currencies other than the U.S. dollar. The value of revenues and operating expenses measured in U.S. dollars is therefore subject to changes in foreign currency exchange rates. In order to mitigate these changes, the Company uses foreign currency forward contracts to lock in exchange rates associated with a portion of its forecasted international revenues and operating expenses. The main trading currencies of the Company are the U.S. dollar, Euro, Pounds Sterling, Swiss Franc, Canadian dollar and Japanese Yen. Transactional exposure arises where transactions occur in currencies different to the functional currency of the relevant subsidiary. It is the Company’s policy that these exposures are minimized to the extent practicable by denominating transactions in the subsidiary’s functional currency. Where significant exposures remain, the Company uses foreign exchange contracts (spot, forward and swap contracts) to manage the exposure for balance sheet assets and liabilities that are denominated in currencies different to the functional currency of the relevant subsidiary. The Company has master netting agreements with a number of counterparties to these foreign exchange contracts and on the occurrence of specified events, the Company has the ability to terminate contracts and settle them with a net payment by one party to the other. The Company has elected to present derivative assets and derivative liabilities on a gross basis in the Unaudited Consolidated Balance Sheet. The Company does not have credit risk related contingent features or collateral linked to the derivatives. Designated Derivative Instruments In connection with the acquisition of Baxalta, the Company assumed foreign currency forward contracts and elected to apply hedge accounting. These contracts have been designated as cash flow hedges and accordingly, to the extent effective, any unrealized gains or losses on these foreign currency forward contracts are reported in AOCI. Realized gains and losses for the effective portion of such contracts are recognized in revenue or cost of sales when the sale of product in the currency being hedged is recognized. To the extent ineffective, hedge transaction gains and losses are reported in Other income/(expense), net. The amount of ineffectiveness for the three and nine months ended September 30, 2016 was immaterial. As of September 30, 2016 , the foreign currency forward contracts had a total notional value of $350.0 million with a maximum duration of nine months. The Company did not have any designated forward contracts as of December 31, 2015. As of September 30, 2016 , the fair value of these contracts was a net liability of $3.3 million (2015: nil ) presented within accounts payable and accrued expenses. The portion of the fair value of these foreign currency forward contracts that was included in AOCI in total equity reflected net losses of $0.1 million as of September 30, 2016 . The Company expects all contracts to be settled over the next nine months and any amounts in AOCI to be reported as an adjustment to revenue or cost of sales. The Company considers the impact of its and its counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2016 , credit risk did not change the fair value of the Company’s foreign currency forward contracts. Undesignated Derivative Instruments The Company uses forward contracts to mitigate the foreign currency risk related to certain balance sheet positions, including intercompany and third-party receivables and payables. The Company has not elected hedge accounting for these derivative instruments as the duration of these contracts is typically three months or less. The changes in fair value of these derivatives are reported in earnings. The notional amount of undesignated derivative instruments was $508.8 million and $639.6 million as of September 30, 2016 and 2015, respectively. The Company also has option contracts assumed from Baxalta that were previously designated as cash flow hedges. The notional amount of these option contracts totaled $26.1 million as of September 30, 2016 . Upon acquisition, the Company did not elect to redesignate these option contracts as cash flow hedges. In addition, the company also assumed undesignated forward contracts from Baxalta. The notional amount of these undesignated forward contracts totaled $659.3 million as of September 30, 2016 . As of September 30, 2016 , the fair value of these contracts was a net liability of $2.0 million (2015: nil ) presented within accounts payable and accrued expenses. Interest Rate Contracts The Company is exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in benchmark interest rates relating to its debt obligations on which interest is set at floating rates. The Company’s policy is to manage this risk to an acceptable level. The Company is principally exposed to interest rate risk on any borrowings under the Company’s various debt facilities and on part of the senior notes assumed in connection with the acquisition of Baxalta. Interest on each of these debt obligations is set at fixed and/or floating rates, to the extent utilized. Shire’s exposure under these facilities is to changes in U.S. dollar interest rates. For further details related to interest rates on the Company’s various debt facilities, see Note 14, Borrowings and capital lease obligations, to these Unaudited Consolidated Financial Statements. Designated Derivative Instruments In connection with the acquisition of Baxalta, the Company assumed interest rate swap contracts on certain borrowing transactions. These interest rate swap contracts were related to the issuance of Baxalta’s Senior Notes with an aggregate notional amount of $1.0 billion , mature in June 2020 and June 2025. Subsequent to the acquisition of Baxalta, the Company redesignated these interest rate swap contracts as fair value hedges, based on their contractual terms, economic conditions, historic operating or accounting policies, and other conditions that existed at the acquisition date. The effective portion of the changes in the fair value of interest rate swap contracts are recorded as a component of the senior notes assumed in connection with the acquisition of Baxalta with the ineffective portion recorded in income. Any net interest payments made or received on the interest rate swap contracts are recognized as a component of interest expense in the Unaudited Consolidated Statements of Operations. For further details related to Baxalta’s Senior Notes, please see Note 14, Borrowings and capital lease obligations, to these Unaudited Consolidated Financial Statements. As of September 30, 2016 , the fair value of these contracts was $43.7 million (2015: $ nil ) presented within other non-current assets. For the nine months ended September 30, 2016 , the Company recognized $2.1 million (2015: $ nil ) of gain related to these contracts, which was recognized as a component of interest expense. Undesignated Derivative Instruments During the nine months ended September 30, 2016 , the Company entered into interest rate swap contracts with a total notional amount of $5.1 billion related to the November 2015 Facilities Agreement. The Company has not elected hedge accounting for these contracts. As of September 30, 2016 , the fair value of these contracts was $1.1 million (2015: $ nil ), which is presented within other current liabilities. For the nine months ended September 30, 2016 , the Company recognized $1.1 million (2015: $ nil ) loss related to these contracts, which was recognized as a component of interest expense. The following tables summarize the income statement locations and gains and losses on the Company’s designated and undesignated derivative instruments for the nine months ended September 30, 2016 . There were no designated derivatives for the nine months ended September 30, 2015. As of September 30, 2016 , the Company had in total 270 swaps and forward foreign exchange contracts. (in millions) Gain (loss) recognized in OCI Income Statement location Gain (loss) reclassified from AOCI into income Nine months ended September 30, 2016 2015 2016 2015 Designated Derivative Instruments Cash flow hedges Foreign exchange contracts $ (0.1 ) $ — Cost of sales $ — $ — (in millions) Location of gain (loss) in Income Statement Gain (loss) recognized in income Nine months ended September 30, 2016 2015 Fair value hedges Interest rate contracts Interest expense $ 2.1 $ — Undesignated Derivative Instruments Foreign exchange contracts Other (expense)/income, net (50.0 ) 12.0 Interest rate swap contracts Interest expense (1.1 ) — As of September 30, 2016 , $5.0 million of deferred, net after-tax gains on derivative instruments included in AOCI are expected to be recognized in earnings during the next 12 months, coinciding with when the hedged items are expected to impact earnings. The following table presents the classification and estimated fair value of the Company’s derivative instruments as of September 30, 2016 : Derivatives in asset positions Derivatives in liability positions (in millions) Balance Sheet location Fair Value Balance Sheet location Fair Value Designated Derivative Instruments Foreign exchange contracts Prepaid expenses and other current assets $ 2.8 Accounts payable and accrued expenses $ 6.1 Interest rate contracts Long term borrowings 43.7 — $ 46.5 $ 6.1 Undesignated Derivative Instruments Foreign exchange forward contracts Prepaid expenses and other current assets $ 4.1 Accounts payable and accrued expenses $ 6.1 Interest rate swap contracts Prepaid expenses and other current assets — Accounts payable and accrued expenses 1.1 $ 50.6 $ 13.3 As of September 30, 2016 , the potential effect of rights to offset associated with the Interest rate swap and foreign exchange forward contracts would be an offset to both assets and liabilities of $7.9 million , resulting in net derivative assets and derivative liabilities of $42.7 million and $5.4 million , respectively.

Borrowings and Capital Lease Ob

Borrowings and Capital Lease Obligations	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Borrowings and Capital Lease Obligations	Borrowings and Capital Lease Obligations (in millions) September 30, 2016 December 31, 2015 Short term borrowings: Borrowings under the Revolving Credit Facilities Agreement $ 920.0 $ 750.0 Borrowings under the November 2015 Facilities Agreement 1,796.3 — Borrowings under the January 2015 Facilities Agreement — 750.0 Other borrowings 20.8 11.5 $ 2,737.1 $ 1,511.5 Long term borrowings: Senior notes $ 12,037.0 $ — Baxalta notes 5,104.4 — Borrowings under the November 2015 Facilities Agreement 3,788.3 — Other borrowings 59.2 69.9 Capital lease obligations (long term portion) 348.6 — $ 24,074.6 $ 1,581.4 Capital lease obligations are recorded within other non-current liabilities. The future payments on debt maturities and capital lease obligations as of September 30, 2016 are as follows: (in millions) 2016 (remaining three months) $ 605.7 2017 2,626.7 2018 3,184.1 2019 3,344.1 2020 1,960.1 2021 3,318.7 Thereafter 9,110.7 Total obligations 24,150.1 Fair value hedges, unamortized bond premium and deferred financing costs (75.5 ) Total debt and capital lease obligations $ 24,074.6 For a more detailed description of the Company's financing agreements, please see below, as well as Note 15, Borrowings, of the Shire 2015 Form 10-K. Senior Notes Issuance On September 23, 2016, Shire Acquisitions Investments Ireland Designated Activity Company ("SAIIDAC"), a wholly owned subsidiary of the Company, issued senior notes pursuant to a public offering with a total aggregate principal value of $12.1 billion (“SAIIDAC Notes”), guaranteed by Shire plc. SAIIDAC used the net proceeds to fully repay amounts outstanding under the January 2016 Facilities Agreement (discussed below), which was used to finance the cash consideration payable related to the Company’s acquisition of Baxalta. Below is a summary of the SAIIDAC Notes as of September 30, 2016: (in millions, except for percentage information) Aggregate Amount Coupon Rate Effective interest rate in 2016 Carrying amount at September 30, 2016 Fixed-rate notes due 2019 $ 3,300.0 1.900 % 2.05 % 3,286.5 Fixed-rate notes due 2021 3,300.0 2.400 % 2.53 % 3,282.4 Fixed-rate notes due 2023 2,500.0 2.875 % 2.97 % 2,487.8 Fixed-rate notes due 2026 3,000.0 3.200 % 3.30 % 2,980.3 $ 12,100.0 $ 12,037.0 The SAIIDAC Notes are senior unsecured obligations and may be redeemed at the Company's option at the greater of (1) 100% of the principal amount plus accrued and unpaid interest or (2) the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis at the applicable treasury rate (as defined) plus an incremental margin, plus, in either case, accrued and unpaid interest. The SAIIDAC Notes also contain a change of control provision that may require that the Company offer to purchase the SAIIDAC Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of purchase under certain circumstances. The costs associated with this offering of approximately $ 62.7 million have been recorded as a reduction to the carrying amount of the debt on the Unaudited Consolidated Balance Sheets. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method. Interest on the SAIIDAC Notes is payable March 23 and September 23 of each year, beginning on March 23, 2017. Baxalta Senior Notes Guaranteed by Shire Shire plc guaranteed senior notes issued by Baxalta with a total aggregate principal amount of $5 billion in connection with the Baxalta acquisition (“Baxalta Notes”). Below is a summary of the Baxalta Notes as of September 30, 2016 : (in millions, except for percentage information) Aggregate Principal Coupon Rate Effective interest rate in 2016 Carrying amount at September 30, 2016 Variable-rate notes due 2018 $ 375.0 LIBOR plus 0.78% 1.65 % $ 370.9 Fixed-rate notes due 2018 375.0 2.000 % 2.20 % 374.8 Fixed-rate notes due 2020 1,000.0 2.875 % 2.80 % 1,014.8 Fixed-rate notes due 2022 500.0 3.600 % 3.30 % 508.8 Fixed-rate notes due 2025 1,750.0 4.000 % 3.90 % 1,803.0 Fixed-rate notes due 2045 1,000.0 5.250 % 5.20 % 1,032.1 Total assumed Senior Notes $ 5,000.0 $ 5,104.4 The effective interest rates above exclude the effect of any related interest rate swaps. The book values above include any premiums and adjustments related to hedging instruments. For further details related to the interest rate derivative contracts, please see Note 13, Financial Instruments, to these Unaudited Consolidated Financial Statements. Revolving Credit Facilities Agreement On December 12, 2014 , Shire entered into a $2,100.0 million revolving credit facilities agreement (the “RCF”) with a number of financial institutions. As of September 30, 2016 , the Company utilized $920.0 million of the RCF. The RCF, which terminates on December 12, 2020 , may be used for financing the general corporate purposes of Shire. The RCF incorporates a $250.0 million U.S. dollar and Euro swingline facility operating as a sub-limit thereof. Term Loan Facilities Agreements January 2016 Facilities Agreement On January 11, 2016 , Shire entered into an $18.0 billion bridge facilities agreement (the “January 2016 Facilities Agreement”). The January 2016 Facilities Agreement comprised two credit facilities: (i) a $13.0 billion term loan facility originally maturing on January 11, 2017 ("January 2016 Facility A") and (ii) a $5.0 billion revolving loan facility originally maturing on January 11, 2017 ("January 2016 Facility B"). January 2016 Facility A was utilized to finance the cash consideration payable in respect of the acquisition of Baxalta on June 3, 2016 in the amount of $12,390.0 million . The Company used the net proceeds from the issuance of the SAIIDAC Notes to fully repay the amounts outstanding under January 2016 Facility A. January 2016 Facility B was canceled effective July 11, 2016 , in accordance with its terms. November 2015 Facilities Agreement On November 2, 2015 , Shire entered into a $5.6 billion facilities agreement (the “November 2015 Facilities Agreement”). The November 2015 Facilities Agreement comprises three credit facilities: (i) a $1.0 billion term loan facility of which, following the exercise of the one year extension option in the amount of $400.0 million , $600.0 million matures on November 2, 2016 and $400.0 million matures on November 2, 2017 (“November 2015 Facility A”), (ii) a $2.2 billion amortizing term loan facility which matures on November 2, 2017 (“November 2015 Facility B”) and (iii) a $2.4 billion amortizing term loan facility which matures on November 2, 2018 (“November 2015 Facility C”). As of September 30, 2016 , the November 2015 Facilities Agreement was fully utilized to finance the cash consideration payable and certain costs related to the acquisition of Dyax. January 2015 Facilities Agreement On January 11, 2015 , Shire entered into an $850 million term facilities agreement with, among others, Citigroup Global Markets Limited acting as mandated lead arranger and bookrunner (the “January 2015 Facilities Agreement”) with an original maturity date of January 10, 2016 . The maturity date was subsequently extended to July 11, 2016 in line with the provisions within the January 2015 Facilities Agreement allowing the maturity date to be extended twice, at Shire’s option, by six months on each occasion. The January 2015 Facilities Agreement was utilized to finance the purchase price paid in respect of Shire’s acquisition of NPS (including certain related costs). On September 28, 2015, the Company reduced the January 2015 Facilities Agreement by $100 million . In January 2016 and at various points thereafter, the Company canceled parts of the January 2015 Facilities Agreement. On February 22, 2016 , the Company repaid the remaining balance of $100 million of the January 2015 Facilities Agreement in full. Short-term uncommitted lines of credit (“Credit lines”) Shire has access to various Credit lines from a number of banks which provide flexibility to short-term cash management procedures. These Credit lines can be withdrawn by the banks at any time. The Credit lines are not relied upon for core liquidity. As of September 30, 2016 , these Credit lines were not utilized. Capital Lease Obligations The Company assumed certain capital lease obligations related to the Baxalta acquisition. These leases are primarily related to office and manufacturing facilities. As of September 30, 2016 , the total capital lease obligations, including current portions, was $348.6 million .

Retirement and Other Benefit Pr

Retirement and Other Benefit Programs	9 Months Ended
	Sep. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Retirement and Other Benefit Programs	Retirement and Other Benefit Programs As part of the acquisition of Baxalta, the Company assumed certain pension and other post-employment benefit (“OPEB”) plan obligations and plan assets. The following is a summary of the fair value of the pension and OPEB-related balances assumed as of June 3, 2016, the acquisition date. (in millions) U.S. pensions International pensions OPEB Projected Benefit Obligation and Plan Assets Assumed Projected benefit obligation $ 441.6 $ 503.8 $ 23.5 Plan assets 218.0 140.5 — Funded status as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 ) Amounts Recognized in the Consolidated Balance Sheet Other current liabilities $ (0.2 ) $ (3.1 ) $ — Other non-current liabilities (223.4 ) (360.2 ) (23.5 ) Net liability recognized as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 ) The Company did not assume any gains or losses deferred in AOCI. Accumulated Benefit Obligation Information The pension obligation information in the table above represents the projected benefit obligation (“PBO”) assumed as of June 3, 2016. The PBO incorporates assumptions relating to future compensation levels. The accumulated benefit obligation (“ABO”) is the same as the PBO except that it includes no assumptions relating to future compensation levels. The ABO for all of the Company’s U.S. pension plans was $369.2 million as of June 3, 2016. The ABO for all of the Company’s International pension plans was $386.8 million as of June 3, 2016. The information in the funded status table above represents the totals for all of the Company’s pension plans. The following is information relating to the individual plans as of June 3, 2016 in the funded status table above that have an ABO in excess of plan assets. (in millions) June 3, 2016 U.S. ABO $ 369.2 Fair value of plan assets 218.0 International ABO 364.9 Fair value of plan assets 118.2 Expected Net Pension and OPEB Plan Payments for the Next 10 Years (in millions) U.S. pensions International pensions OPEB 2016 (after June 3, 2016) $ 0.9 $ 7.3 $ — 2017 3.6 14.7 0.2 2018 5.4 14.6 0.3 2019 7.3 16.2 0.4 2020 9.3 16.7 0.5 2021 through 2025 75.6 104.8 3.5 Total expected benefit payments for next 10 years $ 102.1 $ 174.3 $ 4.9 The expected net benefit payments above reflected the Company’s share of the total net benefits expected to be paid from the plans’ assets (for funded plans) or from the Company’s assets (for unfunded plans) as of June 3, 2016. The federal subsidies relating to the Medicare Prescription Drug, Improvement and Modernization Act are not expected to be significant. Weighted-Average Assumptions Used in Determining Benefit Obligations at the Measurement Date and Net Periodic Benefit Cost U.S. pensions International pensions OPEB Discount rate 4.1 % 1.0 % 4.2 % Rate of compensation increase 3.8 % 3.2 % n/a Annual rate of increase in the per-capita cost n/a n/a 6.5 % Rate decreased to n/a n/a 5.0 % by the year ended n/a n/a 2022 The assumptions above, which were used in calculating the June 3, 2016 measurement date benefit obligations, are used in the calculation of net periodic benefit cost in 2016 along with the expected return on plan asset assumption. The Company establishes the expected return on plan assets assumption primarily based on a review of historical compound average asset returns, both Company-specific and relating to the broad market (based on the Company’s asset allocation), as well as an analysis of current market and economic information and future expectations. The Company is using weighted-average assumptions of 7.0% and 4.5% for its U.S. and International funded plans, respectively, in its calculation of net period benefit cost in 2016. Pension Plan Assets A committee of members of senior management is responsible for supervising, monitoring and evaluating the invested assets of the Company’s funded pension plans. The committee abides by policies and procedures relating to investment goals, targeted asset allocations, risk management practices, allowable and prohibited investment holdings, diversification, use of derivatives, the relationship between plan assets and benefit obligations, and other relevant factors and considerations. In the United States, Goldman Sachs Asset Management acts as an outsourced chief investment officer (“oCIO”) to perform the day-to-day management of pension assets. The policies and procedures include the following: • Ability to pay all benefits when due; • Targeted long-term performance expectations relative to applicable market indices, such as Standard & Poor’s, Russell, MSCI EAFE, and other indices; • Targeted asset allocation percentage ranges (summarized below), and periodic reviews of these allocations; • Specified investment holding and transaction prohibitions (for example, private placements or other restricted securities, securities that are not traded in a sufficiently active market, short sales, certain derivatives, commodities and margin transactions); • Specified portfolio percentage limits on holdings in a single corporate or other entity (generally 5% , except for holdings in U.S. government or agency securities); • Specified average credit quality for the fixed-income securities portfolio (at least A- by Standard & Poor’s or A3 by Moody’s); • Specified portfolio percentage limits on foreign holdings; and • Periodic monitoring of oCIO performance and adherence to policies. Plan assets are invested using a total return investment approach whereby a mix of equity securities, debt securities and other investments are used to preserve asset values, diversify risk and exceed the planned benchmark investment return. Investment strategies and asset allocations are based on consideration of plan liabilities, the plans’ funded status and other factors, such as the plans’ demographics and liability durations. Investment performance is reviewed on a quarterly basis and asset allocations are reviewed at least annually. Plan assets are managed in a balanced equity and fixed income portfolio. The target allocations for plan assets are 75 percent in an equity portfolio and 25 percent in a fixed income portfolio. The documented policy includes an allocation range based on each individual investment type within the major portfolios that allows for a variance from the target allocations of approximately 5% . The equity portfolio may include common stock of U.S. and international companies, common/collective trust funds, mutual funds, hedge funds and real asset investments. The fixed income portfolio may include cash, money market funds with an original maturity of three months or less, U.S. and foreign government and governmental agency issues, common/collective trust funds, corporate bonds, municipal securities, derivative contracts and asset-backed securities. While the committee provides oversight over plan assets for U.S. and international plans, the summary above is specific to the plans in the U.S. The plan assets for international plans are managed and allocated by the entities in each country, with input and oversight provided by the committee. The following pension assets are recorded at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). U.S. pension plan assets (in millions) Balance at June 3, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash equivalents* $ 4.4 $ — $ — $ — Collective trust funds* 42.7 — — — Mutual fund* 10.7 — — — Equity Collective trust funds* 96.5 — — — Mutual fund* 53.0 17.0 — — Hedge funds* 10.7 — — — Fair value of pension plan assets $ 218.0 $ 17.0 $ — $ — *Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not required to be classified in the fair value hierarchy. The following tables summarize the bases used to measure the pension plan assets and liabilities that are carried at fair value on a recurring basis for the international funded plans. International pension plan assets (in millions) Balance at June 3, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash and cash equivalents $ 9.7 $ 9.7 $ — $ — Government agency issues 1.5 1.5 — — Corporate bonds 30.1 30.1 — — Mutual funds 40.5 40.5 — — Equity Common stock: Large cap 15.7 15.7 — — Mid cap 1.6 1.6 — — Total common stock 17.3 17.3 — — Mutual funds 21.5 21.5 — — Real estate funds* 10.2 8.4 — — Other holdings 9.7 0.1 9.6 — Fair value of pension plan assets $ 140.5 $ 129.1 $ 9.6 $ — *Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not required to be classified in the fair value hierarchy. The assets and liabilities of the Company’s pension plans are valued using the following valuation methods: Investment category Valuation methodology Cash and cash equivalents These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value Government agency issues Values are based on quoted prices in an active market Corporate bonds Values are based on the valuation date in an active market Common stock Values are based on the closing prices on the valuation date in an active market on national and international stock exchanges Mutual funds Values are based on the net asset value of the units held in the respective fund which are obtained from national and international exchanges or as reported by the fund managers Collective trust funds and hedge funds Values are based on the net asset value of the units held at year end Real estate funds The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from national and international exchanges or based on the net asset value of the underlying assets of the fund provided by the fund manager Other holdings The value of these assets vary by investment type and are primarily based on reputable pricing vendors that typically use pricing matrices or models Net Periodic Benefit Cost The net periodic benefit cost presented below is from the June 3, 2016 through September 30, 2016. June 3, 2016 through September 30, 2016 (in millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 7.4 $ 10.5 $ 0.5 Interest cost 6.4 1.8 0.3 Expected return on plan assets (5.1 ) (2.2 ) — Net periodic benefit cost $ 8.7 $ 10.1 $ 0.8 The net periodic benefit cost presented below is for the three months ended September 30, 2016. Three months ended September 30, 2016 (in millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 5.5 $ 7.9 $ 0.4 Interest cost 4.8 1.4 0.2 Expected return on plan assets (3.8 ) (1.7 ) — Net periodic benefit cost $ 6.5 $ 7.6 $ 0.6 Expected Pension and OPEB Plan Funding The Company’s funding policy for its pension plans is to contribute amounts sufficient to meet legal funding requirements, plus any additional amounts that the Company may determine to be appropriate considering the funded status of the plans, tax deductibility, the cash flows generated by the Company, and other factors. Volatility in the global financial markets could have an unfavorable impact on future funding requirements. The Company has no obligation to fund its principal plans in the U.S. in 2016. The Company made cash contributions to its international plans of approximately $4 million from the June 3, 2016 acquisition date through September 30, 2016. The Company did not make any significant voluntary contributions to its U.S. Qualified plan from the June 3, 2016 acquisition date through September 30, 2016. During the three months ended December 31, 2016, the Company expects to make cash contributions to its pension plans of at least $1 million , primarily related to its international plans, and expects to have net cash outflows relating to its OPEB plan of less than $1 million . The Company continually reassesses the amount and timing of any discretionary contributions, which could be significant in any period. The table below details the funded status percentage of the Company’s assumed pension plans from Baxalta as of the acquisition date, including certain plans that are unfunded in accordance with the guidelines of the Company’s funding policy outlined above. United States International (in millions, except percentages) Qualified plans Nonqualified plans Funded plans Unfunded plans Total Fair value of plan assets $ 218.0 n/a $ 140.5 n/a $ 358.5 PBO 410.9 30.7 324.0 179.8 945.4 Funded status percentage 53 % n/a 43 % n/a 38 %

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The changes in accumulated other comprehensive loss, net of their related tax effects, for the nine months ended September 30, 2016 and 2015 are included below: (in millions) Foreign currency translation adjustment Unrealized holding (loss)/gain on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2016 $ (182.1 ) $ (1.7 ) $ — $ (183.8 ) Net current period other comprehensive income 38.8 10.4 0.4 49.6 As of September 30, 2016 $ (143.3 ) $ 8.7 $ 0.4 $ (134.2 ) (in millions) Foreign currency translation adjustment Unrealized holding (loss)/gain on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2015 $ (25.7 ) $ (5.8 ) $ — $ (31.5 ) Net current period other comprehensive (loss)/income (124.9 ) 1.3 — (123.6 ) As of September 30, 2015 $ (150.6 ) $ (4.5 ) — $ (155.1 ) Reclassifications out of AOCI and into earnings during the three and nine months ended September 30, 2016 and September 30, 2015 were not material.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings per Share	Earnings per Share The following table reconciles net income and loss and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented: Three Months Ended Nine Months Ended (in millions) 2016 2015 2016 2015 (Loss)/Income from continuing operations, net of taxes $ (368.5 ) $ 477.1 $ 127.6 $ 1,054.1 Loss from discontinued operations (18.3 ) (24.3 ) (257.5 ) (31.3 ) Numerator for basic and diluted (loss)/earnings per share $ (386.8 ) $ 452.8 $ (129.9 ) $ 1,022.8 Weighted average number of shares: Basic 900.2 590.9 725.5 590.2 Effect of dilutive shares: Share-based awards to employees — 2.5 — 3.0 Diluted 900.2 593.4 725.5 593.2 Weighted average number of basic shares excludes shares purchased by the Employee Benefit Trust and those under the shares buy-back program, which are both presented by Shire as treasury stock. Share-based awards to employees are calculated using the treasury method. The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below: Three Months Ended Nine Months Ended (in millions) 2016 No. of shares 2015 No. of shares 2016 No. of shares 2015 No. of shares Share-based awards to employees 14.6 3.9 9.7 3.3 Certain stock options have been excluded from the calculation of diluted Earnings per Share (“EPS”) for the three and nine months ended September 30, 2015 because either their exercise prices exceeded Shire’s average share price during the calculation period or the required performance conditions were not satisfied as of the balance sheet date. Stock options for the three and nine months ended September 30, 2016 have been excluded from the calculation of diluted EPS because the inclusion of these shares would have been antidilutive.

Taxation

Taxation	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
Taxation	Taxation For the three and nine months ended September 30, 2016 , the effective tax rate on income from continuing operations was 38% (2015: -5% ) and 246% (2015: -1% ), respectively. The effective tax rate for the three and nine months ended September 30, 2016 is affected by the combined impact of the relative quantum of the profit before tax for the period by jurisdiction and of the reversal of deferred tax liabilities from the Baxalta acquisition (including in higher tax territories such as the U.S.) of inventory and intangible assets amortization as well as significant acquisition and integration costs. The effective tax rate for the three and nine months ended September 30, 2015 was negative primarily due to the release of certain valuation allowances, the effect of the finalization of various tax returns and the re-measurement of uncertain tax positions relating to ongoing tax audits all recognized during the third quarter of 2015. The Company has historically calculated the provision for income taxes during interim reporting periods by applying an estimate of the annual effective tax rate for the full year to ordinary income or loss for the reporting period. For the three and nine months ended September 30, 2016, the impact of certain items arising from the Baxalta acquisition has caused significant variations in the estimated effective tax rate. As a result, the Company has applied a permitted exception to the general rule by including the actual income tax effect of certain portions of its business discretely when calculating the provision for income taxes for the three and nine months ended September 30, 2016.

Segment Reporting

Segment Reporting	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting	Segment Reporting Shire operates as one operating and reportable segment engaged in the research, development, licensing, manufacturing, marketing, distribution and sale of innovative specialist medicines to meet significant unmet patient needs. For a more detailed description of segment disclosures about products, geographic areas and major customers, please read Note 23, Segmental Reporting, of the Shire 2015 Form 10-K. In the periods set out below, revenues by major product were as follows: Nine Months Ended (in millions) 2016 2015 Product sales: HEMOPHILIA $ 978.0 $ — INHIBITOR THERAPIES 255.7 — Hematology total 1,233.7 — CINRYZE 502.6 474.4 ELAPRASE 424.3 405.5 FIRAZYR 411.3 319.8 REPLAGAL 340.5 325.5 VPRIV 259.3 256.2 KALBITOR 39.2 — Genetic Diseases total 1,977.2 1,781.4 VYVANSE 1,539.5 1,268.9 ADDERALL XR 281.1 259.7 Other Neuroscience 81.2 81.9 Neuroscience total 1,901.8 1,610.5 IMMUNOGLOBULIN THERAPIES 610.7 — BIO THERAPEUTICS 185.3 — Immunology total 796.0 — LIALDA/MEZAVANT 570.3 483.0 PENTASA 222.3 232.7 GATTEX/REVESTIVE 154.3 95.2 NATPARA 58.8 12.8 Other Internal Medicine 260.6 260.6 Internal Medicine total 1,266.3 1,084.3 Oncology total 75.7 — Opthalmology Total 14.1 — Total product sales 7,264.8 4,476.2 Royalties and Other Revenues: SENSIPAR Royalties 112.2 80.0 3TC and ZEFFIX Royalties 43.3 29.9 FOSRENOL Royalties 34.3 32.4 ADDERALL XR Royalties 15.7 22.2 Other Royalties and Revenues 120.2 60.3 Total Royalties and Other Revenues 325.7 224.8 Total Revenues $ 7,590.5 $ 4,701.0 `

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Leases Future minimum lease payments under operating leases as of September 30, 2016 are presented below: (in millions) Operating leases 2016 (remaining three months) $ 42.6 2017 118.9 2018 94.8 2019 84.5 2020 80.1 2021 74.6 Thereafter 333.7 $ 829.2 The Company leases land, facilities, motor vehicles and certain equipment under operating leases expiring through 2039. For the three and nine months ended September 30, 2016 , lease and rental expense totaled $32.7 million and $63.0 million , respectively (2015: $6.3 million and $30.6 million , respectively), which is predominantly included in cost of sales and SG&A expenses in the Company’s Unaudited Consolidated Statements of Operations. Letters of credit and guarantees As of September 30, 2016 , the Company had irrevocable standby letters of credit and guarantees with various banks and insurance companies totaling $130.0 million (being the contractual amounts), providing security for the Company’s performance of various obligations. These obligations are primarily in respect of the recoverability of insurance claims, lease obligations and supply commitments. On June 3, 2016, the Company provided a full and unconditional guarantee for Baxalta’s obligations related to the Baxalta Senior Notes. On September 23, 2016, as part of the issuance of SAIIDAC Notes, the Company provided a full and unconditional guarantee for SAIIDAC's obligations under the SAIIDAC Notes. For additional details please see Note 24, Guarantor financial information, to these Unaudited Consolidated Financial Statements. Commitments Clinical testing At September 30, 2016 , the Company had committed to pay approximately $1,202 million (December 31, 2015: $490 million ) to contract vendors for administering and executing clinical trials. The timing of these payments is dependent upon actual services performed by the organizations as determined by patient enrollment levels and related activities. Contract manufacturing At September 30, 2016 , the Company had committed to pay approximately $608 million (December 31, 2015: $325 million ) in respect of contract manufacturing. The Company expects to pay $213 million of these commitments in 2016. Other purchasing commitments At September 30, 2016 , the Company had committed to pay approximately $1,993 million (December 31, 2015: $485 million ) for future purchases of goods and services, predominantly relating to active pharmaceutical ingredients sourcing. The Company expects to pay $865 million of these commitments in 2016. Investment commitments At September 30, 2016 , the Company had outstanding commitments to purchase common stock and interests in companies and partnerships, respectively, for amounts totaling $70 million (December 31, 2015: $22 million ) which may all be payable in 2016, depending on the timing of capital calls. The investment commitments include additional funding to certain variable interest entities ("VIEs") for which Shire is not the primary beneficiary. Capital commitments At September 30, 2016 , the Company had committed to spend $130 million (December 31, 2015: $60 million ) on capital projects. Baxter related tax indemnification Baxter International Inc. ("Baxter") and Baxalta entered into a tax matters agreement, effective on the date of Baxalta’s separation from Baxter, which employs a direct tracing approach, or where direct tracing approach is not feasible, an allocation methodology, to determine which company is liable for pre-separation income tax items for U.S. federal, state and foreign jurisdictions. With respect to tax liabilities that are directly traceable or allocated to Baxalta but for which Baxalta was not the primary obligor, Baxalta recorded a tax indemnification amount that would be due to Baxter upon Baxter discharging the associated tax liability to the taxing authority. At September 30, 2016 , the amount of the net tax indemnification amount was $42.2 million .

Legal and other proceedings

Legal and other proceedings	9 Months Ended
	Sep. 30, 2016
Legal Proceedings [Abstract]
Legal and other proceedings	Legal and other proceedings The Company expenses legal costs when incurred. The Company recognizes loss contingency provisions for probable losses when management is able to reasonably estimate the loss. When the estimated loss lies within a range, the Company records a loss contingency provision based on its best estimate of the probable loss. If no particular amount within that range is a better estimate than any other amount, the minimum amount is recorded. Estimates of losses may be developed before the ultimate loss is known, and are therefore refined each accounting period as additional information becomes known. An outcome that deviates from the Company’s estimate may result in an additional expense or release in a future accounting period. As of September 30, 2016, provision for litigation losses, insurance claims and other disputes totaled $399.7 million (December 31, 2015: $9.9 million ). The Company’s principal pending legal and other proceedings are disclosed below. The outcomes of these proceedings are not always predictable and can be affected by various factors. For those legal and other proceedings for which it is considered at least reasonably possible that a loss has been incurred, the Company discloses the possible loss or range of possible loss in excess of the recorded loss contingency provision, if any, where such excess is both material and estimable. VYVANSE In May and June 2011, Shire was notified that six separate Abbreviated New Drug Applications ("ANDAs") were submitted under the Hatch-Waxman Act seeking permission to market generic versions of all approved strengths of VYVANSE. The notices were from Sandoz, Inc. ("Sandoz"); Amneal Pharmaceuticals LLC ("Amneal"); Watson Laboratories, Inc.; Roxane Laboratories, Inc. ("Roxane"); Mylan Pharmaceuticals, Inc. (“Mylan”); and Actavis Elizabeth LLC and Actavis Inc. (collectively, "Actavis"). Since filing suit against these ANDA filers, along with API suppliers Johnson Matthey Inc. and Johnson Matthey Pharmaceuticals Materials (collectively, “Johnson Matthey”), Shire has been engaged in a consolidated patent infringement litigation in the U.S. District Court for the District of New Jersey against the aforementioned parties (except Watson, who withdrew their ANDA). On June 23, 2014, the U.S. District Court for the District of New Jersey granted Shire’s summary judgment motion holding that 18 claims of the patents-in-suit were both infringed and valid. On September 24, 2015, the U.S. Court of Appeals of the Federal Circuit (“CAFC”) affirmed that ruling against all of the ANDA filers and remanded the case to the trial court for further proceedings. The CAFC ruling overturned the infringement ruling against Johnson Matthey and the case against Johnson Matthey has been dismissed. Following remand to the U.S. District Court for the District of New Jersey, the case has been fully resolved as a result of the Stipulation of Dismissal and Final Judgment entered by the court on August 30, 2016 in which the court imposed an injunction preventing all of the ANDA filers (Sandoz, Roxane, Amneal, Actavis and Mylan) from launching generic versions of VYVANSE until the expiration of these patents in 2023. In March, April and May 2016, Shire received Notices of Allegation (“NOA”) from Apotex Inc. (“Apotex”) informing Shire that Apotex filed an Abbreviated New Drug Submission (“ANDS”) with Health Canada seeking approval to market a generic version of VYVANSE in Canada. Within the requisite 45 days, Shire filed for orders of prohibition and, as a result, a 24-month stay of approval of the ANDS has been put into effect. Apotex has withdrawn the first two NOAs. On July 4, 2016, Apotex filed a Statement of Claim in Federal Court seeking a judicial declaration of invalidity and noninfringement of Shire’s Canadian patent relating to VYVANSE which Shire is actively defending. On April 14, 2016, Shire prevailed in upholding its European patent for ELVANSE. Shire initially prevailed in an opposition to its patent lodged by Johnson Matthey plc, Generics [UK] Limited (trading as Mylan) and Hexal AG and on April 14, 2016 Shire prevailed in the appeal. The decision by the appeals board of the European Patent Office is final and cannot be further appealed. LIALDA In May 2010, Shire was notified that Zydus Pharmaceuticals USA, Inc. (“Zydus”) had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the District of Delaware against Zydus and Cadila Healthcare Limited, doing business as Zydus Cadila. A Markman hearing took place on January 29, 2015 and a Markman ruling was issued on July 28, 2015. A trial took place between March 28, 2016 and April 1, 2016. On September 16, 2016 the court issued its ruling finding that the proposed generic product would not infringe the asserted claims. Shire has appealed the ruling to the CAFC. In February 2012, Shire was notified that Osmotica Pharmaceutical Corporation (“Osmotica”) had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Northern District of Georgia against Osmotica. A Markman hearing took place on August 22, 2013 and a Markman ruling was issued on September 25, 2014. The court issued an Order on February 27, 2015 in which all dates in the scheduling order have been stayed. In March 2012, Shire was notified that Watson Laboratories Inc.-Florida had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Southern District of Florida against Watson Laboratories Inc.-Florida and Watson Pharmaceuticals, Inc., Watson Pharma, Inc. and Watson Laboratories, Inc. (collectively, “Watson”) were subsequently added as defendants. A trial took place in April 2013 and on May 9, 2013 the trial court issued a decision finding that the proposed generic product infringes the patent-in-suit and that the patent is not invalid. Watson appealed the trial court’s ruling to the CAFC and a hearing took place on December 2, 2013. The ruling of the CAFC was issued on March 28, 2014 overruling the trial court on the interpretation of two claim terms and remanding the case for further proceedings. Shire petitioned the Supreme Court for a writ of certiorari which was granted on January 26, 2015. The Supreme Court also vacated the CAFC decision and remanded the case to the CAFC for further consideration in light of the Supreme Court’s recent decision in Teva v. Sandoz. On June 3, 2015, the CAFC reaffirmed their previous decision to reverse the District Court’s claims construction and remanded the case to the U.S. District Court for the Southern District of Florida. A trial was held on January 25-27, 2016. A ruling was issued on March 28, 2016 upholding the validity of the patent and finding that Watson’s proposed ANDA product infringes the patent-in-suit. Watson appealed the ruling to the CAFC and oral argument took place on October 5, 2016. In April 2012, Shire was notified that Mylan had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45-day period, Shire filed a lawsuit in the U.S. District Court for the Middle District of Florida against Mylan. A Markman hearing took place on December 22, 2014. A Markman ruling was issued on March 23, 2015. A trial took place from September 26, 2016 through September 30, 2016. In March 2015, Shire was notified that Amneal had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the U.S. District Court for the District of New Jersey against Amneal, Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals Co. India Pvt. Ltd. A Markman hearing took place on July 25, 2016. A Markman ruling was issued on August 2, 2016. No trial date has been set. In September 2015, Shire was notified that Lupin Ltd. had submitted an ANDA under the Hatch-Waxman Act seeking permission to market a generic version of LIALDA. Within the requisite 45 day period, Shire filed a lawsuit in the U.S. District Court for the District of Maryland against Lupin Ltd., Lupin Pharmaceuticals Inc., Lupin Inc. and Lupin Atlantis Holdings SA. No trial date has been set. A Markman hearing is scheduled to take place on November 10, 2016. On October 7, 2015 the Patent Trial and Appeals Board (“PTAB”) of the United States Patent Office instituted an inter partes review (“IPR”) of U.S. Patent 6,773,720 which is the patent-in-suit in the litigations referred to above. The IPR process is designed to re-assess the patentability of the claims of the patent. A decision from the PTAB was issued on October 5, 2016 upholding the validity of the patent in view of the challenges put forward in the IPR. Investigation related to DERMAGRAFT The Department of Justice, including the U.S. Attorney’s Office for the Middle District of Florida, Tampa Division and the U.S. Attorney’s Office for Washington, DC, is conducting civil and criminal investigations into the sales and marketing practices of Advanced BioHealing Inc. (“ABH”) relating to DERMAGRAFT, which Shire acquired in June 2011. Following the disposal of the DERMAGRAFT business in January 2014, Shire retained certain legacy liabilities including any liability that may arise from this investigation. Over the last several years, Shire has been cooperating fully with these investigations. As part of its efforts to cooperate, Shire has engaged in discussions with the Department of Justice about a possible resolution. Following those discussions, Shire reached an agreement on a proposal for a civil settlement in the amount of $350.0 million plus interest, subject to negotiating a final settlement agreement and obtaining final approvals. An accrual has been recorded related to the settlement. Assuming the agreement is finalized, it will resolve the civil investigations conducted by the Department of Justice, including multiple U.S. Attorney’s Offices and relevant federal and state agencies. The tentative settlement proposal would settle the federal government’s claims under the federal False Claims Act and the DERMAGRAFT Medicaid-related claims for states that opt into the settlement. Some states with DERMAGRAFT Medicaid-related claims might elect to opt out of any final settlement, and those states’ claims would remain unresolved. Material issues remain open and subject to further negotiation and approval by Shire, the Department of Justice and other relevant federal and state agencies before the tentative settlement can be finalized. Civil Investigative Demand relating to VANCOCIN On April 6, 2012, ViroPharma Incorporated (“ViroPharma”) received a notification that the United States Federal Trade Commission (“FTC”) is conducting an investigation into whether ViroPharma had engaged in unfair methods of competition with respect to VANCOCIN. On August 3, 2012, and September 8, 2014, ViroPharma and Shire respectively received Civil Investigative Demands from the FTC requesting additional information related to this matter. Shire has fully cooperated with the FTC’s investigation. At this time, Shire is unable to predict the outcome or duration of this investigation. Lawsuit related to supply of ELAPRASE to certain patients in Brazil On September 24, 2014 Shire’s Brazilian affiliate, Shire Farmaceutica Brasil Ltda, was served with a lawsuit brought by the State of Sao Paulo and in which the Brazilian Public Attorney’s office has intervened alleging that Shire is obligated to provide certain medical care including ELAPRASE for an indefinite period at no cost to patients who participated in ELAPRASE clinical trials in Brazil, and seeking recoupment to the Brazilian government for amounts paid on behalf of these patients to date, and moral damages associated with these claims. On May 6, 2016, the trial court judge ruled on the case and dismissed all the claims under the class action, which decision has been appealed. A final decision is expected within the next 18 months.

Share-based Compensation Plans

Share-based Compensation Plans	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based compensation plans	Share-based compensation plans Total share-based compensation recorded by the Company during the three and nine months ended September 30, 2016 and September 30, 2015 by line item is as follows: Three Months Ended Nine Months Ended (in millions) 2016 2015 2016 2015 Cost of sales $ 7.9 $ 6.0 $ 15.5 $ 6.0 Research and development 14.4 9.4 33.4 21.0 Selling, general and administrative 24.9 4.6 49.1 28.5 Integration and acquisition costs 26.7 — 170.7 — Reorganization costs — 6.7 — 15.3 Total 73.9 26.7 268.7 70.8 Less tax (26.9 ) (7.5 ) (73.2 ) (19.5 ) $ 47.0 $ 19.2 $ 195.5 $ 51.3 The table above includes pre-tax expense during the three and nine months ended September 30, 2016 of $45.4 million and $ 191.7 million , respectively, related to replacement and other awards held by Baxalta employees as further described below. This includes integration related expense during the three and nine months ended September 30, 2016 of $22.1 million and $ 160.5 million , respectively, from the acceleration of unrecognized expense associated with certain employee terminations. Share-based compensation plans that existed as of December 31, 2015 Prior to February 28, 2015 the Company granted stock-settled share appreciation rights (“SARs”) and performance share awards (“PSAs”) over ordinary shares and ADSs to Executive Directors and employees under the Shire Portfolio Share Plan (“PSP”) (Parts A and B). Since February 28, 2015 the Company has granted awards under the Shire Long Term Incentive Plan 2015 (“LTIP”). Under the LTIP the Company grants stock-settled SARs, restricted stock units (“RSUs”) and performance share units (“PSUs”) over ordinary shares and ADSs to Executive Directors and employees. These plans and the underlying share-based award grants pursuant to the plans as of December 31, 2015 are further discussed in the Shire 2015 Form 10-K. Replacement Awards Issued to Baxalta Employees In connection with the acquisition of Baxalta and pursuant to the merger agreement associated with the acquisition, outstanding Baxalta equity awards held by Baxalta employees or employees of Baxter were cancelled and exchanged for Shire equity awards. The replacement Shire awards generally have the same terms and conditions (including vesting) as the former Baxalta awards for which they were exchanged. The value of the replacement share-based awards granted was designed to generally preserve the intrinsic value and the fair value of the award immediately prior to the acquisition. Total replacement awards issued to Baxalta and Baxter employees on June 3, 2016 pursuant to the merger agreement were 22.2 million options and 3.9 million RSUs. The following table presents additional information regarding the replacement options issued as of June 3, 2016: (options and aggregate intrinsic values in thousands) Options* Weighted-average exercise price Weighted-average contractual term (in years) Aggregate intrinsic value Issued and outstanding 13,290 $ 43.12 7.69 $ 242,467 Vested and exercisable 5,691 $ 40.72 6.12 $ 117,453 *Number of awards are stated in terms of ordinary share equivalents (number of RSUs in thousands) RSUs* Weighted average grant date fair value** Issued and Outstanding 3,285 $ 49.55 *Number of awards are stated in terms of ordinary share equivalents **Reflects the pro rata portion representing future compensation as of June 3, 2016 Following the acquisition, the Company records share-based compensation expense associated with the acquisition-date fair value of acquired Baxalta employees’ replacement options and RSUs that is attributable to post-acquisition service requirements, as well as share-based compensation expense for post-acquisition service requirements associated with certain remaining unvested Baxter share-based awards held by the acquired Baxalta employees. The portions of the acquisition-date fair values of the awards that are attributable to post-combination service are recognized over the remaining service period of the awards. The weighted-average acquisition-date fair value and Black-Scholes assumptions related to replacement options issued to acquired Baxalta employees was as follows: As of June 3, 2016 Risk-free interest rate 1.20 % Expected dividend yield 0.35 % Expected life 3.9 years Volatility 29.1 % Fair value per Option* $ 79.31 *Pro rata portion of the fair value recognized as expense related to post combination service period Total unrecognized expense related to the replacement options issued to acquired Baxalta employees as of September 30, 2016 of $46.7 million is expected to be recognized over a weighted-average period of 1.3 years . Total unrecognized expense related to the replacement RSUs issued to acquired Baxalta employees as of September 30, 2016 of $72.0 million is expected to be recognized over a weighted-average period of 1.9 years .

Agreements and Transactions

Agreements and Transactions	9 Months Ended
	Sep. 30, 2016
Agreements and Transactions [Abstract]
Agreements and Transactions with Baxter	Agreements and Transactions with Baxter In connection with Baxalta’s separation from Baxter on July 1, 2015, Baxalta and Baxter entered into several separation-related agreements that provided a framework for Baxalta’s relationship with Baxter after the separation. As a result of the acquisition of Baxalta, the Company became party to the separation-related agreements with Baxter. These agreements, among others, included a manufacturing and supply agreement, a transition services agreement, an international commercial operations agreement and tax matters agreement. Under the terms of the manufacturing and supply agreement, the Company manufactures certain products and materials and sells them to Baxter at an agreed-upon price reflecting the Company’s cost plus a mark-up for certain products and materials. The Company reported revenues associated with the manufacturing and supply agreement with Baxter of approximately $47 million from the June 3, 2016 acquisition date through September 30, 2016 and approximately $31 million during the three months ended September 30, 2016 . Under the terms of the transition services agreement, the Company and Baxter provide various services to each other on an interim, transitional basis. The services provided by Baxter to the Company include certain finance, information technology, human resources, quality, supply chain and other administrative services and functions, and are generally provided on a cost-plus basis. The services generally extend for approximately 2 years following the July 1, 2015 separation except for certain information technology services that may extend for 3 years following the July 1, 2015 separation. The Company reported SG&A expenses associated with the transition services agreement with Baxter of approximately $32 million from the June 3, 2016 acquisition date through September 30, 2016 and approximately $24 million during the three months ended September 30, 2016 . For a certain portion of Baxalta’s non U.S. operations, the legal transfer of net assets from Baxter had not occurred by the June 3, 2016 acquisition date due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the international commercial operations agreement with Baxter, the Company is responsible for the business activities conducted by Baxter on its behalf, and is subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations are reported in the Company’s consolidated financial statements following the acquisition of Baxalta. The Company reported net sales related to these operations of $60 million from the June 3, 2016 acquisition date through September 30, 2016 and approximately $38 million during the three months ended September 30, 2016 . As of September 30, 2016 , the assets and liabilities of these operations consisted of inventories of $43 million , which are reported in inventories on the consolidated balance sheet, other assets of $47 million , which are reported as prepaid expenses and other current assets, and liabilities of $3 million , which are reported in other current liabilities. The majority of these operations are expected to be transferred to the Company by the end of 2016. The tax matters agreement governs Baxter and Baxalta’s and now the Company’s respective rights, responsibilities and obligations after the distribution with respect to taxes for any tax period ending on or before the distribution date, as well as tax periods beginning before and ending after the distribution date. In addition, the tax matters agreement addresses the allocation of liability for taxes that were incurred as a result of restructuring activities undertaken to effectuate the distribution and provides for Baxalta to indemnify Baxter against any tax liabilities resulting from Baxalta’s action or inaction that causes the merger-related transactions to be taxable. Net tax-related indemnification liabilities reported by the Company as of September 30, 2016 are further discussed in Note 20, Commitments and Contingencies, of these Unaudited Consolidated Financial Statements. As of September 30, 2016 , the Company had total amounts due from or to Baxter of $191 million reported in prepaid expenses and other current assets, $34 million reported in other noncurrent assets, $124 million reported in other current liabilities and $86 million reported in other noncurrent liabilities. These balances include the net tax-related indemnification liabilities and assets and liabilities of certain operations that have not transferred to the Company.

Guarantor Financial Information

Guarantor Financial Information	9 Months Ended
	Sep. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information On June 3, 2016, Shire plc provided full and unconditional, joint and several guarantees of the floating rate senior notes due 2018, 2.0% senior notes due 2018, 2.875% senior notes due 2020, 3.6% senior notes due 2022, 4.0% senior notes due 2025, and 5.25% senior notes due 2045 (collectively, “Baxalta Notes”), of Baxalta, a 100% owned subsidiary of the Company. Amounts related to Baxalta and its subsidiaries are included in the condensed consolidating financial information for periods subsequent to June 3, 2016, the date of the Baxalta acquisition. On September 23, 2016, Shire plc provided full and unconditional, joint and several guarantees of the SAIIDAC notes, consisting of; 1.90% senior notes due 2019, 2.40% senior notes due 2021, 2.875% senior notes due 2023 and 3.20% senior notes due 2026, of SAIIDAC, a 100% owned subsidiary of the Company. In accordance with the requirements of SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered”, the following tables present unaudited condensed consolidating financial statements of the two separate guarantee structures of the Baxalta Notes and SAIIDAC Notes, for: • Shire plc - Parent Guarantor; • SAIIDAC Subsidiary Issuer - issuer subsidiary of the SAIIDAC Notes; (a) • Baxalta Subsidiary Issuer - issuer subsidiary of the Baxalta Notes; (b) • Non-Guarantor Non-Issuer Subsidiaries - presents all other subsidiaries of Parent Guarantor on a combined basis, none of which guarantee the Baxalta Notes or SAIIDAC Notes; (c) • Non-Guarantor Subsidiaries of SAIIDAC Notes - presents combined Non-Guarantor Non-Issuer Subsidiaries, including Baxalta, under the guarantee structure where SAIIDAC is the subsidiary issuer; (b+c) • Non-Guarantor Subsidiaries of Baxalta Notes - presents combined Non-Guarantor Non-Issuer Subsidiaries, including SAIIDAC, under the guarantee structure where Baxalta is the subsidiary issuer (a+c); and • Eliminations - primarily relate to eliminations of investments in subsidiaries and intercompany balances and transactions. The Unaudited Condensed Consolidating Financial Statements present investments in subsidiaries using the equity method of accounting. Condensed Consolidating Balance Sheet (As of September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) ASSETS Current assets: Cash and cash equivalents $ — $ — $ 308.6 $ 420.0 $ 728.6 $ 420.0 $ — $ 728.6 Restricted cash — — — 20.1 20.1 20.1 — 20.1 Accounts receivable, net — — — 2,633.4 2,633.4 2,633.4 — 2,633.4 Inventories — — — 4,857.1 4,857.1 4,857.1 — 4,857.1 Prepaid expenses and other current assets 1.8 0.7 12.7 650.1 662.8 650.8 — 665.3 Intercompany receivables — 50.2 432.6 3,742.3 4,174.9 3,792.5 (4,225.1 ) — Short term intercompany loan receivable — 1,796.3 — — — 1,796.3 (1,796.3 ) — Total current assets 1.8 1,847.2 753.9 12,323.0 13,076.9 14,170.2 (6,021.4 ) 8,904.5 Investments 36,448.3 — 35,740.2 12,563.2 48,303.4 12,563.2 (84,559.9 ) 191.8 Property, plant and equipment, net — — 25.9 6,501.8 6,527.7 6,501.8 — 6,527.7 Goodwill — — — 14,850.6 14,850.6 14,850.6 — 14,850.6 Intangible assets, net — — — 38,871.5 38,871.5 38,871.5 — 38,871.5 Long term intercompany loan receivable — 15,825.3 — — — 15,825.3 (15,825.3 ) — Other non-current assets 4.2 — 437.3 180.7 618.0 180.7 (217.0 ) 405.2 Total assets $ 36,454.3 $ 17,672.5 $ 36,957.3 $ 85,290.8 $ 122,248.1 $ 102,963.3 $ (106,623.6 ) $ 69,751.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 4.7 $ 18.4 $ 101.5 $ 3,897.1 $ 3,998.6 $ 3,915.5 $ — $ 4,021.7 Short term borrowings 920.0 1,796.3 — 20.8 20.8 1,817.1 — 2,737.1 Intercompany payables 4,225.1 — — — — — (4,225.1 ) — Short term intercompany loan payable — — — 1,796.3 1,796.3 1,796.3 (1,796.3 ) — Other current liabilities — 1.1 48.4 302.6 351.0 303.7 352.1 Total current liabilities 5,149.8 1,815.8 149.9 6,016.8 6,166.7 7,832.6 (6,021.4 ) 7,110.9 Long term borrowings — 15,825.3 5,104.8 58.8 5,163.6 15,884.1 — 20,988.9 Deferred tax liability — — — 9,543.5 9,543.5 9,543.5 (217.0 ) 9,326.5 Long term intercompany loan payable 1,110.3 — — 14,715.0 14,715.0 14,715.0 (15,825.3 ) — Other non-current liabilities 408.5 2.0 64.0 2,064.8 2,128.8 2,066.8 — 2,539.3 Total liabilities 6,668.6 17,643.1 5,318.7 32,398.9 37,717.6 50,042.0 (22,063.7 ) 39,965.6 Total equity 29,785.7 29.4 31,638.6 52,891.9 84,530.5 52,921.3 (84,559.9 ) 29,785.7 Total liabilities and equity $ 36,454.3 $ 17,672.5 $ 36,957.3 $ 85,290.8 $ 122,248.1 $ 102,963.3 $ (106,623.6 ) $ 69,751.3 Condensed Consolidating Balance Sheet (As of December 31, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) ASSETS Current assets: Cash and cash equivalents $ — $ — $ — $ 135.5 $ 135.5 $ 135.5 $ — $ 135.5 Restricted cash — — — 86.0 86.0 86.0 — 86.0 Accounts receivable, net — — — 1,201.2 1,201.2 1,201.2 — 1,201.2 Inventories — — — 635.4 635.4 635.4 — 635.4 Prepaid expenses and other current assets 1.9 9.6 — 185.9 185.9 195.5 — 197.4 Intercompany receivables — — — 3,164.9 3,164.9 3,164.9 (3,164.9 ) — Total current assets 1.9 9.6 — 5,408.9 5,408.9 5,418.5 (3,164.9 ) 2,255.5 Investments 14,477.2 — — 50.8 50.8 50.8 (14,477.2 ) 50.8 Property, plant and equipment, net — — — 828.1 828.1 828.1 — 828.1 Goodwill — — — 4,147.8 4,147.8 4,147.8 — 4,147.8 Intangible assets, net — — — 9,173.3 9,173.3 9,173.3 — 9,173.3 Other non-current assets 5.3 8.3 — 140.7 140.7 149.0 — 154.3 Total assets $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 10.0 $ — $ — $ 2,040.6 $ 2,040.6 $ 2,040.6 $ — $ 2,050.6 Short term borrowings 1,500.0 — — 11.5 11.5 11.5 — 1,511.5 Intercompany payables 3,145.3 19.6 — — — 19.6 (3,164.9 ) — Other current liabilities — — — 144.0 144.0 144.0 — 144.0 Total current liabilities 4,655.3 19.6 — 2,196.1 2,196.1 2,215.7 (3,164.9 ) 3,706.1 Long term borrowings — — — 69.9 69.9 69.9 — 69.9 Deferred tax liability — — — 2,205.9 2,205.9 2,205.9 — 2,205.9 Other non-current liabilities — — — 798.8 798.8 798.8 — 798.8 Total liabilities 4,655.3 19.6 — 5,270.7 5,270.7 5,290.3 (3,164.9 ) 6,780.7 Total equity 9,829.1 (1.7 ) — 14,478.9 14,478.9 14,477.2 (14,477.2 ) 9,829.1 Total liabilities and equity $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 Condensed Consolidating Statements of Operations (for the three months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 3,315.4 $ 3,315.4 $ 3,315.4 $ — $ 3,315.4 Royalties & other revenues — — — 136.7 136.7 136.7 — 136.7 Total revenues — — — 3,452.1 3,452.1 3,452.1 — 3,452.1 Costs and expenses: Cost of sales — — — 1,736.2 1,736.2 1,736.2 — 1,736.2 Research and development — — — 511.1 511.1 511.1 — 511.1 Selling, general and administrative (2.5 ) — 10.8 867.3 878.1 867.3 — 875.6 Amortization of acquired intangible assets — — — 354.9 354.9 354.9 — 354.9 Integration and acquisition costs — — 50.0 234.5 284.5 234.5 — 284.5 Reorganization costs — — — 101.4 101.4 101.4 — 101.4 Gain on sale of product rights — — — (5.7 ) (5.7 ) (5.7 ) — (5.7 ) Total operating expenses (2.5 ) — 60.8 3,799.7 3,860.5 3,799.7 — 3,858.0 Operating income/(loss) from continuing operations 2.5 — (60.8 ) (347.6 ) (408.4 ) (347.6 ) — (405.9 ) Interest income/(expense), net (23.2 ) 61.7 (26.1 ) (190.0 ) (216.1 ) (128.3 ) — (177.6 ) Other expense, net (0.1 ) — (0.1 ) (13.5 ) (13.6 ) (13.5 ) — (13.7 ) Total other income/(expense), net (23.3 ) 61.7 (26.2 ) (203.5 ) (229.7 ) (141.8 ) — (191.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (20.8 ) 61.7 (87.0 ) (551.1 ) (638.1 ) (489.4 ) — (597.2 ) Income tax benefit/(expense) — (15.4 ) 18.9 226.1 245.0 210.7 — 229.6 Equity in income/(losses) of equity method investees, net of taxes (366.0 ) — (505.0 ) (0.9 ) (505.9 ) (0.9 ) 871.0 (0.9 ) Income/(loss) from continuing operations, net of taxes (386.8 ) 46.3 (573.1 ) (325.9 ) (899.0 ) (279.6 ) 871.0 (368.5 ) Loss from discontinued operations, net of taxes — — — (18.3 ) (18.3 ) (18.3 ) — (18.3 ) Net income/(loss) (386.8 ) 46.3 (573.1 ) (344.2 ) (917.3 ) (297.9 ) 871.0 (386.8 ) Comprehensive income/(loss) $ (135.2 ) $ 46.3 $ (333.4 ) $ (583.9 ) $ (917.3 ) $ (537.6 ) $ 871.0 $ (135.2 ) Condensed Consolidating Statements of Operations (for the nine months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 7,264.8 $ 7,264.8 $ 7,264.8 $ — $ 7,264.8 Royalties & other revenues — — — 325.7 325.7 325.7 — 325.7 Total revenues — — — 7,590.5 7,590.5 7,590.5 — 7,590.5 Costs and expenses: Cost of sales — — — 2,762.9 2,762.9 2,762.9 — 2,762.9 Research and development — — 0.4 1,022.6 1,023.0 1,022.6 — 1,023.0 Selling, general and administrative 33.3 — 19.4 1,973.1 1,992.5 1,973.1 — 2,025.8 Amortization of acquired intangible assets — — — 702.5 702.5 702.5 — 702.5 Integration and acquisition costs — — 259.7 478.9 738.6 478.9 — 738.6 Reorganization costs — — — 115.7 115.7 115.7 — 115.7 Gain on sale of product rights — — — (12.2 ) (12.2 ) (12.2 ) — (12.2 ) Total operating expenses 33.3 — 279.5 7,043.5 7,323.0 7,043.5 — 7,356.3 Operating income (loss) from continuing operations (33.3 ) — (279.5 ) 547.0 267.5 547.0 — 234.2 Interest income/(expense), net (67.7 ) 41.5 (32.4 ) (248.3 ) (280.7 ) (206.8 ) — (306.9 ) Other income/(expense), net 0.8 — 7.6 (24.6 ) (17.0 ) (24.6 ) — (16.2 ) Total other income/(expense), net (66.9 ) 41.5 (24.8 ) (272.9 ) (297.7 ) (231.4 ) — (323.1 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (100.2 ) 41.5 (304.3 ) 274.1 (30.2 ) 315.6 — (88.9 ) Income tax benefit/(expense) 1.9 (10.3 ) 77.7 149.1 226.8 138.8 — 218.4 Equity in income/(losses) of equity method investees, net of taxes (31.6 ) — (635.9 ) (1.9 ) (637.8 ) (1.9 ) 667.5 (1.9 ) Income/(loss) from continuing operations, net of taxes (129.9 ) 31.2 (862.5 ) 421.3 (441.2 ) 452.5 667.5 127.6 Loss from discontinued operations, net of taxes — — — (257.5 ) (257.5 ) (257.5 ) — (257.5 ) Net income/(loss) (129.9 ) 31.2 (862.5 ) 163.8 (698.7 ) 195.0 667.5 (129.9 ) Comprehensive income/(loss) $ (80.3 ) $ 31.2 $ (809.0 ) $ (278.0 ) $ (1,087.0 ) $ (246.8 ) $ 1,055.8 $ (80.3 ) Condensed Consolidating Statements of Operations (for the three months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 1,576.8 $ 1,576.8 $ 1,576.8 $ — $ 1,576.8 Royalties & other revenues — — — 78.2 78.2 78.2 — 78.2 Total revenues — — — 1,655.0 1,655.0 1,655.0 — 1,655.0 Costs and expenses: Cost of sales — — — 262.7 262.7 262.7 — 262.7 Research and development — — — 241.2 241.2 241.2 — 241.2 Selling, general and administrative 9.0 — — 433.3 433.3 433.3 — 442.3 Amortization of acquired intangible assets — — — 132.7 132.7 132.7 — 132.7 Integration and acquisition costs — — — 89.9 89.9 89.9 — 89.9 Reorganization costs — — — 31.1 31.1 31.1 — 31.1 Other operating expenses — — — (0.7 ) (0.7 ) (0.7 ) — (0.7 ) Total operating expenses 9.0 — — 1,190.2 1,190.2 1,190.2 — 1,199.2 Operating income (loss) from continuing operations (9.0 ) — — 464.8 464.8 464.8 — 455.8 Interest income/(expense), net (16.5 ) — — 6.6 6.6 6.6 — (9.9 ) Other income, net 0.1 — — 9.5 9.5 9.5 — 9.6 Total other income/(expense), net (16.4 ) — — 16.1 16.1 16.1 — (0.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (25.4 ) — — 480.9 480.9 480.9 — 455.5 Income tax benefit 0.4 — — 21.9 21.9 21.9 — 22.3 Equity in income/(losses) of equity method investees, net of taxes 477.8 — — (0.7 ) (0.7 ) (0.7 ) (477.8 ) (0.7 ) Income/(loss) from continuing operations, net of taxes 452.8 — — 502.1 502.1 502.1 (477.8 ) 477.1 Loss from discontinued operations, net of taxes — — — (24.3 ) (24.3 ) (24.3 ) — (24.3 ) Net income/(loss) 452.8 — — 477.8 477.8 477.8 (477.8 ) 452.8 Comprehensive income/(loss) $ 409.2 $ — $ — $ 434.2 $ 434.2 $ 434.2 $ (434.2 ) $ 409.2 Condensed Consolidating Statements of Operations (for the nine months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 4,476.2 $ 4,476.2 $ 4,476.2 $ — $ 4,476.2 Royalties & other revenues — — — 224.8 224.8 224.8 — 224.8 Total revenues — — — 4,701.0 4,701.0 4,701.0 — 4,701.0 Costs and expenses: Cost of sales — — — 718.5 718.5 718.5 — 718.5 Research and development — — — 1,210.8 1,210.8 1,210.8 — 1,210.8 Selling, general and administrative 22.5 — — 1,334.1 1,334.1 1,334.1 — 1,356.6 Amortization of acquired intangible assets — — — 352.3 352.3 352.3 — 352.3 Integration and acquisition costs — — — (46.8 ) (46.8 ) (46.8 ) — (46.8 ) Reorganization costs — — — 59.6 59.6 59.6 — 59.6 Other operating expenses — — — (13.0 ) (13.0 ) (13.0 ) — (13.0 ) Total operating expenses 22.5 — — 3,615.5 3,615.5 3,615.5 — 3,638.0 Operating income (loss) from continuing operations (22.5 ) — — 1,085.5 1,085.5 1,085.5 — 1,063.0 Interest income/(expense), net (46.9 ) — — 18.7 18.7 18.7 — (28.2 ) Other income, net 1.3 — — 10.6 10.6 10.6 — 11.9 Total other income/(expense), net (45.6 ) — — 29.3 29.3 29.3 — (16.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (68.1 ) — — 1,114.8 1,114.8 1,114.8 — 1,046.7 Income tax benefit 1.7 — — 7.3 7.3 7.3 — 9.0 Equity in income/(losses) of equity method investees, net of taxes 1,089.2 — — (1.6 ) (1.6 ) (1.6 ) (1,089.2 ) (1.6 ) Income/(loss) from continuing operations, net of taxes 1,022.8 — — 1,120.5 1,120.5 1,120.5 (1,089.2 ) 1,054.1 Loss from discontinued operations, net of taxes — — — (31.3 ) (31.3 ) (31.3 ) — (31.3 ) Net income/(loss) 1,022.8 — — 1,089.2 1,089.2 1,089.2 (1,089.2 ) 1,022.8 Comprehensive income/(loss) $ 899.2 $ — $ — $ 965.6 $ 965.6 $ 965.6 $ (965.6 ) $ 899.2 Condensed Consolidating Statement of Cash Flows (For the nine months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided (used in) operating activities $ (79.8 ) $ 182.3 $ (51.8 ) $ 1,455.3 $ 1,403.5 $ 1,637.6 $ — $ 1,506.0 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (2,390.0 ) (18,172.0 ) — (2,863.7 ) (2,863.7 ) (21,035.7 ) 23,425.7 — Movements in restricted cash — — — 68.3 68.3 68.3 — 68.3 Purchases of businesses, net of cash acquired — — — (17,476.2 ) (17,476.2 ) (17,476.2 ) — (17,476.2 ) Purchases of PP&E and non-current investments — — (6.0 ) (396.5 ) (402.5 ) (396.5 ) — (402.5 ) Proceeds from sale of product rights — — — 7.8 7.8 7.8 — 7.8 Proceeds from disposal of non-current investments and PP&E — — — 0.6 0.6 0.6 — 0.6 Other, net — — — (9.3 ) (9.3 ) (9.3 ) — (9.3 ) Net cash provided by (used in) investing activities (2,390.0 ) (18,172.0 ) (6.0 ) (20,669.0 ) (20,675.0 ) (38,841.0 ) 23,425.7 (17,811.3 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 1,655.0 30,079.9 — 7.4 7.4 30,087.3 — 31,742.3 Repayment of revolving line of credit, long term and short term borrowings (2,215.8 ) (12,409.2 ) — (7.9 ) (7.9 ) (12,417.1 ) — (14,632.9 ) Proceeds from intercompany borrowings 3,045.3 490.0 308.4 19,582.0 19,890.4 20,072.0 (23,425.7 ) — Payment of dividend (15.0 ) — — (115.2 ) (115.2 ) (115.2 ) — (130.2 ) Debt issuance costs — (171.0 ) — — — (171.0 ) — (171.0 ) Proceeds from exercise of options 0.3 — 87.9 10.7 98.6 10.7 — 98.9 Other, net — — (29.9 ) 23.4 (6.5 ) 23.4 — (6.5 ) Net cash provided by (used in) financing activities 2,469.8 17,989.7 366.4 19,500.4 19,866.8 37,490.1 (23,425.7 ) 16,900.6 Effect of foreign exchange rate changes on cash and cash equivalents — — — (2.2 ) (2.2 ) (2.2 ) — (2.2 ) Net increase in cash and cash equivalents — — 308.6 284.5 593.1 284.5 — 593.1 Cash and cash equivalents at beginning of period — — — 135.5 135.5 135.5 — 135.5 Cash and cash equivalents at end of period $ — $ — $ 308.6 $ 420.0 $ 728.6 $ 420.0 $ — $ 728.6 Condensed Consolidating Statement of Cash Flows (For the nine months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided (used in) operating activities $ (107.2 ) $ — $ — $ 1,682.4 $ 1,682.4 $ 1,682.4 $ — $ 1,575.2 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (3,570.0 ) — — (2,543.3 ) (2,543.3 ) (2,543.3 ) 6,113.3 — Movements in restricted cash (1.1 ) — — (46.9 ) (46.9 ) (46.9 ) — (48.0 ) Purchases of businesses, net of cash acquired — — — (5,553.4 ) (5,553.4 ) (5,553.4 ) — (5,553.4 ) Purchases of PP&E and non-current investments — — — (67.3 ) (67.3 ) (67.3 ) — (67.3 ) Proceeds from short-term investments — — — 67.0 67.0 67.0 — 67.0 Proceeds from sale of product rights — — — 14.5 14.5 14.5 — 14.5 Proceeds from disposal of non-current investments — — — 18.5 18.5 18.5 — 18.5 Other, net — — — 2.7 2.7 2.7 — 2.7 Net cash provided by (used in) investing activities (3,571.1 ) — — (8,108.2 ) (8,108.2 ) (8,108.2 ) 6,113.3 (5,566.0 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 3,631.1 — — 19.7 19.7 19.7 — 3,650.8 Repayment of revolving line of credit, long term and short term borrowings (2,486.1 ) — — — — — — (2,486.1 ) Proceeds from intercompany borrowings 2,543.3 — — 3,570.0 3,570.0 3,570.0 (6,113.3 ) — Payment of dividend (5.6 ) — — (104.6 ) (104.6 ) (104.6 ) — (110.2 ) Debt issuance costs (3.3 ) — — — — — — (3.3 ) Other, net (1.1 ) — — 4.8 4.8 4.8 — 3.7 Net cash provided by (used in) financing activities 3,678.3 — — 3,489.9 3,489.9 3,489.9 (6,113.3 ) 1,054.9 Effect of foreign exchange rate changes on cash and cash equivalents — — — (1.6 ) (1.6 ) (1.6 ) — (1.6 ) Net decrease in cash and cash equivalents — — — (2,937.5 ) (2,937.5 ) (2,937.5 ) — (2,937.5 ) Cash and cash equivalents at beginning of period — — — 2,982.4 2,982.4 2,982.4 — 2,982.4 Cash and cash equivalents at end of period $ — $ — $ — $ 44.9 $ 44.9 $ 44.9 $ — $ 44.9

Summary of Significant Accoun33

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation These interim financial statements of Shire plc and its subsidiaries (collectively “Shire” or the “Company”) are unaudited. They have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). The balance sheet as of December 31, 2015 was derived from audited financial statements. These interim Unaudited Consolidated Financial Statements should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, as filed with the SEC on February 23, 2016, and as updated by a Current Report on Form 8-K filed with the SEC on September 2, 2016 (the “Shire 2015 Form 10-K”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted from these interim financial statements. However, these interim financial statements include all adjustments, consisting of normal recurring adjustments, which are, in the opinion of management, necessary to fairly state the results of the interim period and the Company believes that the disclosures are adequate to make the information presented not misleading. Interim results are not necessarily indicative of results to be expected for the full year. On June 3, 2016, the Company completed its acquisition of Baxalta for $32.4 billion , representing the preliminary fair value of purchase consideration. The Company’s Unaudited Consolidated Financial Statements include the results of Baxalta from the date of acquisition. For further details regarding the acquisition, please refer to Note 2, Business Combinations, of these Unaudited Consolidated Financial Statements. During the second quarter of 2016, due to the Baxalta acquisition, the Company concluded that it was appropriate to reclassify the Amortization of Acquired Intangibles from Selling, General and Administrative on the Unaudited Consolidated Statements of Operations. Accordingly, the Company reclassified the Amortization of Acquired Intangibles from Selling, General and Administrative in comparative periods to conform to the current classification.
Use of Estimates	Use of Estimates The preparation of financial statements, in conformity with U.S. GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosure of contingent assets and liabilities. Estimates and assumptions are primarily made in relation to the valuation of intangible assets, sales deductions, income taxes (including provisions for uncertain tax positions and the realization of deferred tax assets), provisions for litigation and legal proceedings, measurement of pension and other post-employment plan obligations and net periodic benefit cost, contingent consideration receivable from product divestments and contingent consideration payable in respect of business combinations and asset purchases and valuation of other assets and liabilities acquired in business combinations. On an on-going basis the Company evaluates its estimates, judgments and methodologies. Actual results may differ from these estimates under different assumptions or conditions.
Financial instruments - derivatives	Financial instruments - derivatives The Company uses derivative financial instruments to manage its exposure to foreign exchange risk to earnings relating to forecasted transactions and recognized assets and liabilities. The Company has assumed derivatives related to the Baxalta acquisition and has elected to apply hedge accounting for certain derivatives. For each derivative instrument that is designated and effective as a cash flow hedge, the gain or loss on the derivative is recorded in Accumulated Other Comprehensive Income (“AOCI”) and then recognized in earnings consistent with the underlying hedged item. Cash flow hedges are classified in revenues and cost of sales and primarily relate to forecasted third-party sales denominated in foreign currencies and forecasted intercompany sales denominated in foreign currencies, respectively. For each derivative instrument that is designated and effective as a fair value hedge, the gain or loss on the derivative is recognized immediately to earnings, and offsets the loss or gain on the underlying hedged item. Fair value hedges are classified in interest income and interest expense, as they hedge the interest rate risk associated with certain of the Company’s fixed-rate debt. In its application of hedge accounting, the Company assesses, both at inception and on a prospective basis, whether the derivatives that are used in hedging transactions are highly effective in offsetting the changes in cash flows or fair values of the hedged items. The Company also assesses hedge effectiveness on a retrospective basis every quarter with any hedge ineffectiveness recorded to the Consolidated Statement of Operations. The Company uses forward contracts to hedge earnings from the effects of foreign exchange relating to certain of the Company’s intercompany and third-party receivables and payables denominated in a foreign currency. These derivative instruments generally are not formally designated as hedges and the terms of these instruments generally do not exceed three months. The fair values of these instruments are included on the balance sheet in current assets/liabilities, with changes in the fair value recognized in the Consolidated Statements of Operations. The cash flows relating to these instruments are presented within net cash provided by operating activities in the Consolidated Statement of Cash Flows, unless the derivative instruments are economically hedging specific investing or financing activities.
New Accounting Pronouncements	New Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies that the Company adopts as of the specified effective date. Unless otherwise discussed below, the Company does not believe that the impact of recently issued standards that are not yet effective will have a material impact on the Company’s financial position or results of operations upon adoption. Adopted during the current period Reporting requirements for development stage entities In June 2014, the FASB simplified the existing guidance for development stage entities by removing all incremental financial reporting requirements and the exception available for development stage entities when determining whether the development stage entity is a variable interest entity. The elimination of the exception may change the consolidation analysis, consolidation decision, and disclosure requirements for a reporting entity that has an interest in an entity in the development stage. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Debt Issuance Costs In April 2015, the FASB issued a new standard that requires debt issuance costs related to a recognized debt liability to be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. In August 2015, the FASB issued additional guidance which clarified that debt issuance costs related to line-of-credit arrangements can be presented in the balance sheet as an asset and amortized over the term of the line-of-credit arrangement. The recognition and measurement guidance for debt issuance costs were not affected by these amendments. Shire adopted this guidance as of January 1, 2016 with retroactive application. The Short-term borrowings and Long-term borrowings line items in the Consolidated Balance Sheets and related footnote disclosures for all periods presented have been adjusted. The adoption of this guidance did not impact the Company’s results of operations or cash flows. Cloud Computing Arrangement In April 2015, the FASB issued guidance to simplify the accounting for fees paid in a cloud computing arrangement. Under the standard, if a cloud computing arrangement includes a software license, then the software license element of the arrangement should be accounted for consistent with the acquisition of other software licenses. If a cloud computing arrangement does not include a software license, the arrangement should be accounted for as a service contract. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance did not impact the Company’s consolidated financial position, results of operations or cash flows. Measurement-Period Adjustments In September 2015, the FASB issued guidance to simplify the accounting for adjustments related to business combinations arising within one year of the acquisition. The new standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined and record the effect on earnings of those changes as if the accounting had been completed at the acquisition date, and sets forth new disclosure requirements related to the adjustments. Shire adopted this guidance as of January 1, 2016 with prospective application. The adoption of this guidance impacted the recognition and disclosure of measurement period adjustments identified during the three months ended September 30, 2016 related to the Baxalta acquisition. Refer to Note 2, Business Combinations, of these Unaudited Consolidated Financial Statements for further information. Financial Instrument Accounting In March 2016, the FASB issued new guidance that clarifies the requirements for assessing whether contingent call and put options that can accelerate the payment of principal of debt instruments are clearly and closely related to their debt host. This guidance will be effective beginning on January 1, 2017, and modified retrospective application is required. Early adoption is permitted. This guidance was adopted in the third quarter of 2016 and had no impact on the Company's financial position or results of operations. Pension Plans In May 2015, the FASB issued new guidance which removes the disclosure requirement to categorize within the fair value hierarchy all investments that measure fair value using the net asset value per share as a practical expedient and certain disclosures associated with these types of investments. This guidance became effective beginning on January 1, 2016, and retrospective application is required. This guidance was adopted during the current period and impacted the disclosure of certain acquired pension plan assets in the fair value hierarchy in Note 15, Retirement and Other Benefit Programs, but did not impact the Company's financial position or results of operations. To be adopted in future periods Revenue from Contracts with Customers In May 2014, the FASB issued new accounting guidance for recognizing revenue from contracts with customers. This new standard supersedes all existing revenue recognition requirements, including most industry-specific guidance. The new standard requires a company to recognize revenue when it transfers goods or services to customers in an amount that reflects the consideration that the company expects to receive for those goods or services. The new standard also requires additional qualitative and quantitative disclosures. In August 2015, the FASB issued additional guidance that delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued additional guidance on when and how much revenue to recognize when another party (an agent), along with the entity, is involved in providing a good or a service to a customer. In April 2016, the FASB issued additional guidance on accounting for licenses of intellectual property and identifying performance obligations. In May 2016, the FASB issued additional guidance on assessing collectability, presentation of sales taxes, noncash consideration, and completed contracts and contract modifications. In May 2016, the FASB rescinded several SEC Staff Announcements that are codified in ASC 605, including, among other items, guidance relating to accounting for shipping and handling fees and freight services. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Inventory In July 2015, the FASB issued new guidance which requires an entity to measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This standard is effective for the Company as of January 1, 2017. Early adoption is permitted. The Company does not believe the adoption of this guidance will have a material impact on its financial position or results of operations. Financial Instrument Accounting In January 2016, the FASB issued a new standard that amends certain aspects of accounting and disclosure requirements of financial instruments, including the requirement that equity investments with readily determinable fair values be measured at fair value with changes in fair value recognized in our results of operations. The new standard does not apply to investments accounted for under the equity method of accounting or those that result in consolidation of the investee. Equity investments that do not have readily determinable fair values may be measured at fair value or at cost minus impairment adjusted for changes in observable prices. A financial liability that is measured at fair value in accordance with the fair value option is required to be presented separately in Other Comprehensive Income for the portion of the total change in the fair value resulting from change in the instrument-specific credit risk. In addition, a valuation allowance should be evaluated on deferred tax assets related to available-for-sale debt securities in combination with other deferred tax assets. The new standard will be effective for the Company as of January 1, 2018. The Company is currently evaluating the method of adoption and the potential impact on its financial position and results of operations of adopting this guidance. Leases In February 2016, the FASB issued new accounting guidance that will require the recognition of all lease assets and lease liabilities by lessees and sets forth new disclosure requirements for those lease assets and liabilities. The standard requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements. This standard is effective for the Company as of January 1, 2019. Early adoption is permitted. The Company is currently evaluating the potential impact on its financial position and results of operations of adopting this guidance. Share-Based Payment Accounting In March 2016, the FASB issued a new standard that requires recognition of the income tax effects of vested or settled awards in the income statement and involves several other aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. The new standard will be effective for us on January 1, 2017. The Company is currently evaluating the method of adoption and potential impact on its financial position, results of operations and statement of cash flow of adopting this guidance. Statement of Cash Flows In August 2016, the FASB issued new accounting guidance to reduce diversity in practice regarding how certain transactions are classified in the statement of cash flows. This amendment is effective for the Company as of January 1, 2018. Early adoption is permitted. The adoption of this guidance is not expected to have a significant impact on the Company's Consolidated Statement of Cash Flows.

Business Combinations (Tables)

Business Combinations (Tables)	9 Months Ended
	Sep. 30, 2016
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The preliminary fair value of the purchase price consideration consisted of the following: (in millions) Estimated fair value Cash paid to shareholders $ 12,366.7 Fair value of stock issued to shareholders 19,353.2 Fair value of partially vested stock options and RSUs assumed 497.6 Contingent consideration payable 161.0 Total Purchase Consideration $ 32,378.5
Baxalta
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The Company's preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date, including measurement period adjustments identified during the three months ended September 30, 2016, is outlined below. (in millions) Preliminary values as of June 30, 2016 Measurement period adjustments Preliminary values as of September 30, 2016 ASSETS Current assets: Cash and cash equivalents $ 583.2 $ — $ 583.2 Accounts receivable, net 1,382.8 17.0 1,399.8 Inventories 5,341.1 (276.4 ) 5,064.7 Other current assets 362.2 — 362.2 Total current assets 7,669.3 (259.4 ) 7,409.9 Property, plant and equipment, net 5,687.7 (118.4 ) 5,569.3 Investments 128.2 — 128.2 Goodwill 6,106.4 1,894.6 8,001.0 Other intangible assets, net Currently marketed products 24,550.0 (400.0 ) 24,150.0 In-Process Research and Development ("IPR&D") 2,940.0 (1,460.0 ) 1,480.0 Contract based arrangements 72.2 10.0 82.2 Other non-current assets 103.3 — 103.3 Total assets $ 47,257.1 $ (333.2 ) $ 46,923.9 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 1,509.5 $ 27.5 $ 1,537.0 Other current liabilities 15.4 77.5 92.9 Long-term borrowings 5,424.9 — 5,424.9 Deferred tax liability 6,831.7 (446.4 ) 6,385.3 Other non-current liabilities 1,092.1 13.2 1,105.3 Total liabilities 14,873.6 (328.2 ) 14,545.4 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 32,383.5 $ (5.0 ) $ 32,378.5 Consideration Preliminary fair value of purchase consideration $ 32,383.5 $ (5.0 ) $ 32,378.5
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and Baxalta as if the acquisition of Baxalta had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2015. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2016 2015 Revenues $ 3,250.0 $ 10,193.5 $ 9,086.0 Net (loss)/income from continuing operations (52.0 ) 1,406.6 (1,152.1 ) Per share amounts: Net (loss)/income from continuing operations per share - basic $ (0.06 ) $ 1.94 $ (1.29 ) Net (loss)/income from continuing operations per share - diluted $ (0.06 ) $ 1.92 $ (1.29 )
Dyax
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The revised preliminary allocation of the total purchase price is as follows: (in millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 241.2 Accounts receivable, net 22.5 Inventories 20.2 Other current assets 8.1 Total current assets 292.0 Property, plant and equipment, net 5.8 Goodwill 2,688.8 Other intangible assets, net Currently marketed projects 135.0 IPR&D 4,100.0 Contract based royalty arrangements 425.0 Other non-current assets 28.6 Total assets $ 7,675.2 LIABILITIES Current liabilities: Accounts payable and accrued expenses $ 30.0 Other current liabilities 1.7 Deferred tax liability 1,312.1 Other non-current liabilities 1.4 Total liabilities 1,345.2 Preliminary fair value of identifiable assets acquired and liabilities assumed $ 6,330.0 Consideration Preliminary fair value of purchase consideration $ 6,330.0
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and Dyax as if the acquisitions of Dyax had occurred as of January 1, 2015. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed at the date indicated. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2016 2015 Revenues $ 1,679.7 $ 7,596.4 $ 4,772.5 Net income from continuing operations 438.0 25.9 837.1 Per share amounts: Net income from continuing operations per share - basic $ 0.74 $ 0.04 $ 1.42 Net income from continuing operations per share - diluted $ 0.74 $ 0.04 $ 1.41
NPS Pharma
Business Acquisition [Line Items]
Schedule of Purchase Price Allocation	The Company’s allocation of the purchase price to the fair value of assets acquired and liabilities assumed is outlined below: (in millions) Fair value ASSETS Current assets: Cash and cash equivalents $ 41.6 Short-term investments 67.0 Accounts receivable 33.4 Inventories 89.4 Other current assets 11.1 Total current assets 242.5 Property, plant and equipment, net 4.8 Goodwill 1,551.0 Other intangible assets Currently marketed products 4,640.0 Royalty rights (categorized as "Other amortized intangible assets") 353.0 Total assets $ 6,791.3 LIABILITIES Current liabilities: Accounts payable and other current liabilities $ 75.7 Short-term debt 27.4 Long-term debt, less current portion 78.9 Deferred tax liabilities 1,385.2 Other non-current liabilities 4.5 Total liabilities 1,571.7 Fair value of identifiable assets acquired and liabilities assumed $ 5,219.6 Consideration Cash consideration paid $ 5,219.6
Business Acquisition, Pro Forma Information	The following unaudited pro forma financial information presents the combined results of the operations of Shire and NPS as if the acquisitions of NPS had occurred as of January 1, 2014. The unaudited pro forma financial information is not necessarily indicative of what the consolidated results of operations actually would have been had the respective acquisitions been completed on January 1, 2014. In addition, the unaudited pro forma financial information does not purport to project the future results of operations of the combined Company. Three Months Ended Nine Months Ended (in millions) 2015 2015 Revenues $ 1,655.0 $ 4,730.9 Net income from continuing operations 479.1 1,005.6 Per share amounts: Net income from continuing operations per share - basic $ 0.81 $ 1.70 Net income from continuing operations per share - diluted $ 0.81 $ 1.69

Integration and Acquisition C35

Integration and Acquisition Costs (Tables)	9 Months Ended
	Sep. 30, 2016
Business Combinations [Abstract]
Summary of Employee Termination Related Reserve	The following table summarizes the employee termination related reserve as of September 30, 2016 : (in millions) Severance and Employee Benefits As of January 1, 2016 $ — Amount charged to integration costs 202.3 Paid/utilized (128.1 ) As of September 30, 2016 $ 74.2

Accounts Receivable (Tables)

Accounts Receivable (Tables)	9 Months Ended
	Sep. 30, 2016
Receivables [Abstract]
Provision for discounts and doubtful accounts	Reserve for discounts and allowances: (in millions) 2016 2015 As of January 1, $ 55.8 $ 48.5 Provision charged to operations 569.9 293.8 Payments/credits related to sales (498.3 ) (286.6 ) As of September 30, $ 127.4 $ 55.7

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventories comprise: (in millions) September 30, 2016 December 31, 2015 Finished goods $ 1,597.6 $ 184.9 Work-in-progress 2,431.3 302.0 Raw materials 828.2 148.5 $ 4,857.1 $ 635.4 For a more detailed description of the inventories acquired with Baxalta and Dyax, please see Note 2, Business Combinations, to these Unaudited Consolidated Financial Statements.

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Components of property, plant and equipment, net are summarized as follows: (in millions) September 30, 2016 December 31, 2015 Land $ 356.3 $ 96.7 Buildings and leasehold improvements 1,999.5 606.4 Machinery, equipment and other 2,440.5 827.4 Assets under construction 2,647.0 93.7 7,443.3 1,624.2 Less: Accumulated depreciation (915.6 ) (796.1 ) $ 6,527.7 $ 828.1

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Other Intangible Assets	The following table summarizes the Company's intangible assets: (in millions) Currently marketed products IPR&D Other intangible assets Total September 30, 2016 Gross acquired intangible assets $ 34,104.6 $ 6,522.8 $ 882.2 $ 41,509.6 Accumulated amortization (2,467.7 ) — (170.4 ) (2,638.1 ) Other intangible assets, net $ 31,636.9 $ 6,522.8 $ 711.8 $ 38,871.5 December 31, 2015 Gross acquired intangible assets $ 9,371.9 $ 1,362.0 $ 375.0 $ 11,108.9 Accumulated amortization (1,852.1 ) — (83.5 ) (1,935.6 ) Other intangible assets, net $ 7,519.8 $ 1,362.0 $ 291.5 $ 9,173.3
Intangible Assets (Excluding Goodwill) Roll Forward	The change in the net book value of intangible assets for the nine months ended September 30, 2016 and 2015 is shown in the table below: (in millions) 2016 2015 As of January 1, $ 9,173.3 $ 4,934.4 Acquisitions 30,377.7 5,473.7 Amortization charged (702.5 ) (352.3 ) Impairment charges (8.9 ) (523.3 ) Foreign currency translation 31.9 (81.9 ) As of September 30, $ 38,871.5 $ 9,450.6
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization of acquired intangible assets for the next five years is expected to be as follows: (in millions) Anticipated future amortization 2016 (remaining three months) $ 358.1 2017 1,429.9 2018 1,424.2 2019 1,344.8 2020 1,340.9 2021 1,336.5

Goodwill (Tables)

Goodwill (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The following table provides a roll-forward of the goodwill balance: (in millions) 2016 2015 As of January 1, $ 4,147.8 $ 2,474.9 Acquisitions 10,689.8 1,837.0 Foreign currency translation 13.0 (22.3 ) As of September 30, $ 14,850.6 $ 4,289.6

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	(in millions) Total Level 1 Level 2 Level 3 At December 31, 2015 Financial assets: Marketable equity securities $ 17.2 $ 17.2 $ — $ — Contingent consideration receivable 13.8 — — 13.8 Derivative contracts 1.9 — 1.9 — Total assets 32.9 17.2 1.9 13.8 Financial liabilities: Derivative contracts 11.5 — 11.5 — Contingent consideration payable 475.9 — — 475.9 Total liabilities $ 487.4 $ — $ 11.5 $ 475.9 As of September 30, 2016 and December 31, 2015, the following financial assets and liabilities are measured at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). Fair value (in millions) Total Level 1 Level 2 Level 3 At September 30, 2016 Financial assets: Marketable equity securities $ 69.7 $ 69.7 $ — $ — Marketable debt securities 16.5 3.7 12.8 — Contingent consideration receivable 15.7 — — 15.7 Derivative instruments 50.6 — 50.6 — Total assets 152.5 73.4 63.4 15.7 Financial liabilities: Derivative instruments 13.3 — 13.3 — Contingent consideration payable 996.7 — — 996.7 Total liabilities $ 1,010.0 $ — $ 13.3 $ 996.7
Assets Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)	The following table provides a roll forward of the fair values of our contingent consideration receivable and payables which include Level 3 measurements: Contingent consideration receivable (in millions) 2016 2015 Balance at January 1, $ 13.8 $ 15.9 Change in fair value included in earnings 3.6 9.8 Other (1.7 ) (10.8 ) Balance at September 30, $ 15.7 $ 14.9
Liabilities Measured at Fair Value on a Recurring Basis Using Significant Unobservable Inputs (Level 3)	Contingent consideration payable (in millions) 2016 2015 Balance at January 1, $ 475.9 $ 629.9 Additions 557.0 92.8 Change in fair value included in earnings (34.8 ) (196.5 ) Other (1.4 ) (5.6 ) Balance at September 30, $ 996.7 $ 520.6
Fair Value Inputs, Assets Quantitative Information Table	Quantitative information about the Company’s recurring Level 3 fair value measurements is as follows: Financial assets: Fair Value at the Measurement Date At September 30, 2016 (in millions, except percentages) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration receivable $ 15.7 Income approach (probability weighted discounted cash flow) • Probability weightings applied to different sales scenarios • 10 to 90% • Future forecast consideration receivable based on contractual terms with purchaser • $0 to $23 • Assumed market participant discount rate • 8.4%
Fair Value Inputs, Liabilities Quantitative Information Table	Financial liabilities: Fair Value at the Measurement Date At September 30, 2016 (in millions, except percentages) Fair value Valuation technique Significant unobservable inputs Range Contingent consideration payable $ 996.7 Income approach (probability weighted discounted cash flow) • Cumulative probability of milestones being achieved • 4 to 90% • Assumed market participant discount rate • 1.2 to 10.5% • Periods in which milestones are expected to be achieved • 2016 to 2030 • Forecast quarterly royalties payable on net sales of relevant products • $3.5 to $7.1
Schedule of Fair Value, Assets and Liabilities Not Measured at Fair Value on Recurring Basis	The carrying amounts and estimated fair values as of September 30, 2016 and December 31, 2015 of the Company’s financial assets and liabilities that are not measured at fair value on a recurring basis are as follows: September 30, 2016 December 31, 2015 (in millions) Carrying amount Fair value Carrying amount Fair value Financial liabilities: Senior notes $ 12,037.0 $ 12,080.9 $ — $ — Baxalta notes 5,104.4 5,467.7 — — Capital lease obligation 348.6 348.6 13.4 13.4

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2016
Derivative Instrument Detail [Abstract]
Schedule of Foreign Exchange Contracts and Other Derivative Instruments, Statement of Financial Position	(in millions) Location of gain (loss) in Income Statement Gain (loss) recognized in income Nine months ended September 30, 2016 2015 Fair value hedges Interest rate contracts Interest expense $ 2.1 $ — Undesignated Derivative Instruments Foreign exchange contracts Other (expense)/income, net (50.0 ) 12.0 Interest rate swap contracts Interest expense (1.1 ) — (in millions) Gain (loss) recognized in OCI Income Statement location Gain (loss) reclassified from AOCI into income Nine months ended September 30, 2016 2015 2016 2015 Designated Derivative Instruments Cash flow hedges Foreign exchange contracts $ (0.1 ) $ — Cost of sales $ — $ —
Classification and Estimated Fair Value Amounts of Derivative Instruments	The following table presents the classification and estimated fair value of the Company’s derivative instruments as of September 30, 2016 : Derivatives in asset positions Derivatives in liability positions (in millions) Balance Sheet location Fair Value Balance Sheet location Fair Value Designated Derivative Instruments Foreign exchange contracts Prepaid expenses and other current assets $ 2.8 Accounts payable and accrued expenses $ 6.1 Interest rate contracts Long term borrowings 43.7 — $ 46.5 $ 6.1 Undesignated Derivative Instruments Foreign exchange forward contracts Prepaid expenses and other current assets $ 4.1 Accounts payable and accrued expenses $ 6.1 Interest rate swap contracts Prepaid expenses and other current assets — Accounts payable and accrued expenses 1.1 $ 50.6 $ 13.3

Borrowings and Capital Lease 43

Borrowings and Capital Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Borrowings	(in millions) September 30, 2016 December 31, 2015 Short term borrowings: Borrowings under the Revolving Credit Facilities Agreement $ 920.0 $ 750.0 Borrowings under the November 2015 Facilities Agreement 1,796.3 — Borrowings under the January 2015 Facilities Agreement — 750.0 Other borrowings 20.8 11.5 $ 2,737.1 $ 1,511.5 Long term borrowings: Senior notes $ 12,037.0 $ — Baxalta notes 5,104.4 — Borrowings under the November 2015 Facilities Agreement 3,788.3 — Other borrowings 59.2 69.9 Capital lease obligations (long term portion) 348.6 — $ 24,074.6 $ 1,581.4 Below is a summary of the Baxalta Notes as of September 30, 2016 : (in millions, except for percentage information) Aggregate Principal Coupon Rate Effective interest rate in 2016 Carrying amount at September 30, 2016 Variable-rate notes due 2018 $ 375.0 LIBOR plus 0.78% 1.65 % $ 370.9 Fixed-rate notes due 2018 375.0 2.000 % 2.20 % 374.8 Fixed-rate notes due 2020 1,000.0 2.875 % 2.80 % 1,014.8 Fixed-rate notes due 2022 500.0 3.600 % 3.30 % 508.8 Fixed-rate notes due 2025 1,750.0 4.000 % 3.90 % 1,803.0 Fixed-rate notes due 2045 1,000.0 5.250 % 5.20 % 1,032.1 Total assumed Senior Notes $ 5,000.0 $ 5,104.4 Below is a summary of the SAIIDAC Notes as of September 30, 2016: (in millions, except for percentage information) Aggregate Amount Coupon Rate Effective interest rate in 2016 Carrying amount at September 30, 2016 Fixed-rate notes due 2019 $ 3,300.0 1.900 % 2.05 % 3,286.5 Fixed-rate notes due 2021 3,300.0 2.400 % 2.53 % 3,282.4 Fixed-rate notes due 2023 2,500.0 2.875 % 2.97 % 2,487.8 Fixed-rate notes due 2026 3,000.0 3.200 % 3.30 % 2,980.3 $ 12,100.0 $ 12,037.0
Debt maturities and future payments on capital lease obligations	The future payments on debt maturities and capital lease obligations as of September 30, 2016 are as follows: (in millions) 2016 (remaining three months) $ 605.7 2017 2,626.7 2018 3,184.1 2019 3,344.1 2020 1,960.1 2021 3,318.7 Thereafter 9,110.7 Total obligations 24,150.1 Fair value hedges, unamortized bond premium and deferred financing costs (75.5 ) Total debt and capital lease obligations $ 24,074.6

Retirement and Other Benefit 44

Retirement and Other Benefit Programs (Tables)	9 Months Ended
	Sep. 30, 2016
Compensation and Retirement Disclosure [Abstract]
Summary of Fair Value of the Pension and OPEB-Related Balances	The following is a summary of the fair value of the pension and OPEB-related balances assumed as of June 3, 2016, the acquisition date. (in millions) U.S. pensions International pensions OPEB Projected Benefit Obligation and Plan Assets Assumed Projected benefit obligation $ 441.6 $ 503.8 $ 23.5 Plan assets 218.0 140.5 — Funded status as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 ) Amounts Recognized in the Consolidated Balance Sheet Other current liabilities $ (0.2 ) $ (3.1 ) $ — Other non-current liabilities (223.4 ) (360.2 ) (23.5 ) Net liability recognized as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 )
Schedule of Amounts Recognized in Balance Sheet	The following is a summary of the fair value of the pension and OPEB-related balances assumed as of June 3, 2016, the acquisition date. (in millions) U.S. pensions International pensions OPEB Projected Benefit Obligation and Plan Assets Assumed Projected benefit obligation $ 441.6 $ 503.8 $ 23.5 Plan assets 218.0 140.5 — Funded status as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 ) Amounts Recognized in the Consolidated Balance Sheet Other current liabilities $ (0.2 ) $ (3.1 ) $ — Other non-current liabilities (223.4 ) (360.2 ) (23.5 ) Net liability recognized as of June 3, 2016 $ (223.6 ) $ (363.3 ) $ (23.5 )
Information Relating to Individual Plans in Funded Status that have ABO in Excess of Plan Assets	The following is information relating to the individual plans as of June 3, 2016 in the funded status table above that have an ABO in excess of plan assets. (in millions) June 3, 2016 U.S. ABO $ 369.2 Fair value of plan assets 218.0 International ABO 364.9 Fair value of plan assets 118.2
Expected Net Pension and OPEB Plan Payments for Next 10 Years	Expected Net Pension and OPEB Plan Payments for the Next 10 Years (in millions) U.S. pensions International pensions OPEB 2016 (after June 3, 2016) $ 0.9 $ 7.3 $ — 2017 3.6 14.7 0.2 2018 5.4 14.6 0.3 2019 7.3 16.2 0.4 2020 9.3 16.7 0.5 2021 through 2025 75.6 104.8 3.5 Total expected benefit payments for next 10 years $ 102.1 $ 174.3 $ 4.9
Net Periodic Benefit Cost	The net periodic benefit cost presented below is from the June 3, 2016 through September 30, 2016. June 3, 2016 through September 30, 2016 (in millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 7.4 $ 10.5 $ 0.5 Interest cost 6.4 1.8 0.3 Expected return on plan assets (5.1 ) (2.2 ) — Net periodic benefit cost $ 8.7 $ 10.1 $ 0.8 The net periodic benefit cost presented below is for the three months ended September 30, 2016. Three months ended September 30, 2016 (in millions) U.S. pensions International pensions OPEB Net periodic benefit cost Service cost $ 5.5 $ 7.9 $ 0.4 Interest cost 4.8 1.4 0.2 Expected return on plan assets (3.8 ) (1.7 ) — Net periodic benefit cost $ 6.5 $ 7.6 $ 0.6
Weighted Average Assumptions, Net Benefit Plan Obligations and Future Net Period Benefit Cost	The expected net benefit payments above reflected the Company’s share of the total net benefits expected to be paid from the
Schedule of Allocation and Fair Value of Plan Assets	The following pension assets are recorded at fair value on a recurring basis using quoted prices in active markets for identical assets (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3). U.S. pension plan assets (in millions) Balance at June 3, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash equivalents* $ 4.4 $ — $ — $ — Collective trust funds* 42.7 — — — Mutual fund* 10.7 — — — Equity Collective trust funds* 96.5 — — — Mutual fund* 53.0 17.0 — — Hedge funds* 10.7 — — — Fair value of pension plan assets $ 218.0 $ 17.0 $ — $ — *Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not required to be classified in the fair value hierarchy. The following tables summarize the bases used to measure the pension plan assets and liabilities that are carried at fair value on a recurring basis for the international funded plans. International pension plan assets (in millions) Balance at June 3, 2016 Level 1 Level 2 Level 3 Assets Fixed income Cash and cash equivalents $ 9.7 $ 9.7 $ — $ — Government agency issues 1.5 1.5 — — Corporate bonds 30.1 30.1 — — Mutual funds 40.5 40.5 — — Equity Common stock: Large cap 15.7 15.7 — — Mid cap 1.6 1.6 — — Total common stock 17.3 17.3 — — Mutual funds 21.5 21.5 — — Real estate funds* 10.2 8.4 — — Other holdings 9.7 0.1 9.6 — Fair value of pension plan assets $ 140.5 $ 129.1 $ 9.6 $ — *Investments that are measured at fair value using the net asset value per share or its equivalent as a practical expedient are not required to be classified in the fair value hierarchy.
Valuation Methodologies in Calculation Pension Plans	The assets and liabilities of the Company’s pension plans are valued using the following valuation methods: Investment category Valuation methodology Cash and cash equivalents These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value Government agency issues Values are based on quoted prices in an active market Corporate bonds Values are based on the valuation date in an active market Common stock Values are based on the closing prices on the valuation date in an active market on national and international stock exchanges Mutual funds Values are based on the net asset value of the units held in the respective fund which are obtained from national and international exchanges or as reported by the fund managers Collective trust funds and hedge funds Values are based on the net asset value of the units held at year end Real estate funds The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from national and international exchanges or based on the net asset value of the underlying assets of the fund provided by the fund manager Other holdings The value of these assets vary by investment type and are primarily based on reputable pricing vendors that typically use pricing matrices or models
Funded Status Percentage Of Company's Pension Plans	The table below details the funded status percentage of the Company’s assumed pension plans from Baxalta as of the acquisition date, including certain plans that are unfunded in accordance with the guidelines of the Company’s funding policy outlined above. United States International (in millions, except percentages) Qualified plans Nonqualified plans Funded plans Unfunded plans Total Fair value of plan assets $ 218.0 n/a $ 140.5 n/a $ 358.5 PBO 410.9 30.7 324.0 179.8 945.4 Funded status percentage 53 % n/a 43 % n/a 38 %

Accumulated Other Comprehensi45

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Changes in Accumulated Other Comprehensive Income, Net of Tax	The changes in accumulated other comprehensive loss, net of their related tax effects, for the nine months ended September 30, 2016 and 2015 are included below: (in millions) Foreign currency translation adjustment Unrealized holding (loss)/gain on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2016 $ (182.1 ) $ (1.7 ) $ — $ (183.8 ) Net current period other comprehensive income 38.8 10.4 0.4 49.6 As of September 30, 2016 $ (143.3 ) $ 8.7 $ 0.4 $ (134.2 ) (in millions) Foreign currency translation adjustment Unrealized holding (loss)/gain on available-for-sale securities Hedging activities Accumulated other comprehensive loss As of January 1, 2015 $ (25.7 ) $ (5.8 ) $ — $ (31.5 ) Net current period other comprehensive (loss)/income (124.9 ) 1.3 — (123.6 ) As of September 30, 2015 $ (150.6 ) $ (4.5 ) — $ (155.1 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table reconciles net income and loss and the weighted average ordinary shares outstanding for basic and diluted earnings per share for the periods presented: Three Months Ended Nine Months Ended (in millions) 2016 2015 2016 2015 (Loss)/Income from continuing operations, net of taxes $ (368.5 ) $ 477.1 $ 127.6 $ 1,054.1 Loss from discontinued operations (18.3 ) (24.3 ) (257.5 ) (31.3 ) Numerator for basic and diluted (loss)/earnings per share $ (386.8 ) $ 452.8 $ (129.9 ) $ 1,022.8 Weighted average number of shares: Basic 900.2 590.9 725.5 590.2 Effect of dilutive shares: Share-based awards to employees — 2.5 — 3.0 Diluted 900.2 593.4 725.5 593.2
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below: Three Months Ended Nine Months Ended (in millions) 2016 No. of shares 2015 No. of shares 2016 No. of shares 2015 No. of shares Share-based awards to employees 14.6 3.9 9.7 3.3

Segment Reporting (Tables)

Segment Reporting (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
Segment Reporting	In the periods set out below, revenues by major product were as follows: Nine Months Ended (in millions) 2016 2015 Product sales: HEMOPHILIA $ 978.0 $ — INHIBITOR THERAPIES 255.7 — Hematology total 1,233.7 — CINRYZE 502.6 474.4 ELAPRASE 424.3 405.5 FIRAZYR 411.3 319.8 REPLAGAL 340.5 325.5 VPRIV 259.3 256.2 KALBITOR 39.2 — Genetic Diseases total 1,977.2 1,781.4 VYVANSE 1,539.5 1,268.9 ADDERALL XR 281.1 259.7 Other Neuroscience 81.2 81.9 Neuroscience total 1,901.8 1,610.5 IMMUNOGLOBULIN THERAPIES 610.7 — BIO THERAPEUTICS 185.3 — Immunology total 796.0 — LIALDA/MEZAVANT 570.3 483.0 PENTASA 222.3 232.7 GATTEX/REVESTIVE 154.3 95.2 NATPARA 58.8 12.8 Other Internal Medicine 260.6 260.6 Internal Medicine total 1,266.3 1,084.3 Oncology total 75.7 — Opthalmology Total 14.1 — Total product sales 7,264.8 4,476.2 Royalties and Other Revenues: SENSIPAR Royalties 112.2 80.0 3TC and ZEFFIX Royalties 43.3 29.9 FOSRENOL Royalties 34.3 32.4 ADDERALL XR Royalties 15.7 22.2 Other Royalties and Revenues 120.2 60.3 Total Royalties and Other Revenues 325.7 224.8 Total Revenues $ 7,590.5 $ 4,701.0 `

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Lease Payments under Operating Leases	Future minimum lease payments under operating leases as of September 30, 2016 are presented below: (in millions) Operating leases 2016 (remaining three months) $ 42.6 2017 118.9 2018 94.8 2019 84.5 2020 80.1 2021 74.6 Thereafter 333.7 $ 829.2

Share-based Compensation Plans

Share-based Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation Expense	Total share-based compensation recorded by the Company during the three and nine months ended September 30, 2016 and September 30, 2015 by line item is as follows: Three Months Ended Nine Months Ended (in millions) 2016 2015 2016 2015 Cost of sales $ 7.9 $ 6.0 $ 15.5 $ 6.0 Research and development 14.4 9.4 33.4 21.0 Selling, general and administrative 24.9 4.6 49.1 28.5 Integration and acquisition costs 26.7 — 170.7 — Reorganization costs — 6.7 — 15.3 Total 73.9 26.7 268.7 70.8 Less tax (26.9 ) (7.5 ) (73.2 ) (19.5 ) $ 47.0 $ 19.2 $ 195.5 $ 51.3
Schedule of Replacement Awards	The following table presents additional information regarding the replacement options issued as of June 3, 2016: (options and aggregate intrinsic values in thousands) Options* Weighted-average exercise price Weighted-average contractual term (in years) Aggregate intrinsic value Issued and outstanding 13,290 $ 43.12 7.69 $ 242,467 Vested and exercisable 5,691 $ 40.72 6.12 $ 117,453 *Number of awards are stated in terms of ordinary share equivalents (number of RSUs in thousands) RSUs* Weighted average grant date fair value** Issued and Outstanding 3,285 $ 49.55 *Number of awards are stated in terms of ordinary share equivalents **Reflects the pro rata portion representing future compensation as of June 3, 2016
Schedule of Share-based Payment Award, Valuation Assumptions	The weighted-average acquisition-date fair value and Black-Scholes assumptions related to replacement options issued to acquired Baxalta employees was as follows: As of June 3, 2016 Risk-free interest rate 1.20 % Expected dividend yield 0.35 % Expected life 3.9 years Volatility 29.1 % Fair value per Option* $ 79.31 *Pro rata portion of the fair value recognized as expense related to post combination service period

Guarantor Financial Informati50

Guarantor Financial Information (Tables)	9 Months Ended
	Sep. 30, 2016
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Condensed Income Statement	Condensed Consolidating Statements of Operations (for the three months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 3,315.4 $ 3,315.4 $ 3,315.4 $ — $ 3,315.4 Royalties & other revenues — — — 136.7 136.7 136.7 — 136.7 Total revenues — — — 3,452.1 3,452.1 3,452.1 — 3,452.1 Costs and expenses: Cost of sales — — — 1,736.2 1,736.2 1,736.2 — 1,736.2 Research and development — — — 511.1 511.1 511.1 — 511.1 Selling, general and administrative (2.5 ) — 10.8 867.3 878.1 867.3 — 875.6 Amortization of acquired intangible assets — — — 354.9 354.9 354.9 — 354.9 Integration and acquisition costs — — 50.0 234.5 284.5 234.5 — 284.5 Reorganization costs — — — 101.4 101.4 101.4 — 101.4 Gain on sale of product rights — — — (5.7 ) (5.7 ) (5.7 ) — (5.7 ) Total operating expenses (2.5 ) — 60.8 3,799.7 3,860.5 3,799.7 — 3,858.0 Operating income/(loss) from continuing operations 2.5 — (60.8 ) (347.6 ) (408.4 ) (347.6 ) — (405.9 ) Interest income/(expense), net (23.2 ) 61.7 (26.1 ) (190.0 ) (216.1 ) (128.3 ) — (177.6 ) Other expense, net (0.1 ) — (0.1 ) (13.5 ) (13.6 ) (13.5 ) — (13.7 ) Total other income/(expense), net (23.3 ) 61.7 (26.2 ) (203.5 ) (229.7 ) (141.8 ) — (191.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (20.8 ) 61.7 (87.0 ) (551.1 ) (638.1 ) (489.4 ) — (597.2 ) Income tax benefit/(expense) — (15.4 ) 18.9 226.1 245.0 210.7 — 229.6 Equity in income/(losses) of equity method investees, net of taxes (366.0 ) — (505.0 ) (0.9 ) (505.9 ) (0.9 ) 871.0 (0.9 ) Income/(loss) from continuing operations, net of taxes (386.8 ) 46.3 (573.1 ) (325.9 ) (899.0 ) (279.6 ) 871.0 (368.5 ) Loss from discontinued operations, net of taxes — — — (18.3 ) (18.3 ) (18.3 ) — (18.3 ) Net income/(loss) (386.8 ) 46.3 (573.1 ) (344.2 ) (917.3 ) (297.9 ) 871.0 (386.8 ) Comprehensive income/(loss) $ (135.2 ) $ 46.3 $ (333.4 ) $ (583.9 ) $ (917.3 ) $ (537.6 ) $ 871.0 $ (135.2 ) Condensed Consolidating Statements of Operations (for the nine months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 7,264.8 $ 7,264.8 $ 7,264.8 $ — $ 7,264.8 Royalties & other revenues — — — 325.7 325.7 325.7 — 325.7 Total revenues — — — 7,590.5 7,590.5 7,590.5 — 7,590.5 Costs and expenses: Cost of sales — — — 2,762.9 2,762.9 2,762.9 — 2,762.9 Research and development — — 0.4 1,022.6 1,023.0 1,022.6 — 1,023.0 Selling, general and administrative 33.3 — 19.4 1,973.1 1,992.5 1,973.1 — 2,025.8 Amortization of acquired intangible assets — — — 702.5 702.5 702.5 — 702.5 Integration and acquisition costs — — 259.7 478.9 738.6 478.9 — 738.6 Reorganization costs — — — 115.7 115.7 115.7 — 115.7 Gain on sale of product rights — — — (12.2 ) (12.2 ) (12.2 ) — (12.2 ) Total operating expenses 33.3 — 279.5 7,043.5 7,323.0 7,043.5 — 7,356.3 Operating income (loss) from continuing operations (33.3 ) — (279.5 ) 547.0 267.5 547.0 — 234.2 Interest income/(expense), net (67.7 ) 41.5 (32.4 ) (248.3 ) (280.7 ) (206.8 ) — (306.9 ) Other income/(expense), net 0.8 — 7.6 (24.6 ) (17.0 ) (24.6 ) — (16.2 ) Total other income/(expense), net (66.9 ) 41.5 (24.8 ) (272.9 ) (297.7 ) (231.4 ) — (323.1 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (100.2 ) 41.5 (304.3 ) 274.1 (30.2 ) 315.6 — (88.9 ) Income tax benefit/(expense) 1.9 (10.3 ) 77.7 149.1 226.8 138.8 — 218.4 Equity in income/(losses) of equity method investees, net of taxes (31.6 ) — (635.9 ) (1.9 ) (637.8 ) (1.9 ) 667.5 (1.9 ) Income/(loss) from continuing operations, net of taxes (129.9 ) 31.2 (862.5 ) 421.3 (441.2 ) 452.5 667.5 127.6 Loss from discontinued operations, net of taxes — — — (257.5 ) (257.5 ) (257.5 ) — (257.5 ) Net income/(loss) (129.9 ) 31.2 (862.5 ) 163.8 (698.7 ) 195.0 667.5 (129.9 ) Comprehensive income/(loss) $ (80.3 ) $ 31.2 $ (809.0 ) $ (278.0 ) $ (1,087.0 ) $ (246.8 ) $ 1,055.8 $ (80.3 ) Condensed Consolidating Statements of Operations (for the three months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 1,576.8 $ 1,576.8 $ 1,576.8 $ — $ 1,576.8 Royalties & other revenues — — — 78.2 78.2 78.2 — 78.2 Total revenues — — — 1,655.0 1,655.0 1,655.0 — 1,655.0 Costs and expenses: Cost of sales — — — 262.7 262.7 262.7 — 262.7 Research and development — — — 241.2 241.2 241.2 — 241.2 Selling, general and administrative 9.0 — — 433.3 433.3 433.3 — 442.3 Amortization of acquired intangible assets — — — 132.7 132.7 132.7 — 132.7 Integration and acquisition costs — — — 89.9 89.9 89.9 — 89.9 Reorganization costs — — — 31.1 31.1 31.1 — 31.1 Other operating expenses — — — (0.7 ) (0.7 ) (0.7 ) — (0.7 ) Total operating expenses 9.0 — — 1,190.2 1,190.2 1,190.2 — 1,199.2 Operating income (loss) from continuing operations (9.0 ) — — 464.8 464.8 464.8 — 455.8 Interest income/(expense), net (16.5 ) — — 6.6 6.6 6.6 — (9.9 ) Other income, net 0.1 — — 9.5 9.5 9.5 — 9.6 Total other income/(expense), net (16.4 ) — — 16.1 16.1 16.1 — (0.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (25.4 ) — — 480.9 480.9 480.9 — 455.5 Income tax benefit 0.4 — — 21.9 21.9 21.9 — 22.3 Equity in income/(losses) of equity method investees, net of taxes 477.8 — — (0.7 ) (0.7 ) (0.7 ) (477.8 ) (0.7 ) Income/(loss) from continuing operations, net of taxes 452.8 — — 502.1 502.1 502.1 (477.8 ) 477.1 Loss from discontinued operations, net of taxes — — — (24.3 ) (24.3 ) (24.3 ) — (24.3 ) Net income/(loss) 452.8 — — 477.8 477.8 477.8 (477.8 ) 452.8 Comprehensive income/(loss) $ 409.2 $ — $ — $ 434.2 $ 434.2 $ 434.2 $ (434.2 ) $ 409.2 Condensed Consolidating Statements of Operations (for the nine months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) Revenues: Product sales $ — $ — $ — $ 4,476.2 $ 4,476.2 $ 4,476.2 $ — $ 4,476.2 Royalties & other revenues — — — 224.8 224.8 224.8 — 224.8 Total revenues — — — 4,701.0 4,701.0 4,701.0 — 4,701.0 Costs and expenses: Cost of sales — — — 718.5 718.5 718.5 — 718.5 Research and development — — — 1,210.8 1,210.8 1,210.8 — 1,210.8 Selling, general and administrative 22.5 — — 1,334.1 1,334.1 1,334.1 — 1,356.6 Amortization of acquired intangible assets — — — 352.3 352.3 352.3 — 352.3 Integration and acquisition costs — — — (46.8 ) (46.8 ) (46.8 ) — (46.8 ) Reorganization costs — — — 59.6 59.6 59.6 — 59.6 Other operating expenses — — — (13.0 ) (13.0 ) (13.0 ) — (13.0 ) Total operating expenses 22.5 — — 3,615.5 3,615.5 3,615.5 — 3,638.0 Operating income (loss) from continuing operations (22.5 ) — — 1,085.5 1,085.5 1,085.5 — 1,063.0 Interest income/(expense), net (46.9 ) — — 18.7 18.7 18.7 — (28.2 ) Other income, net 1.3 — — 10.6 10.6 10.6 — 11.9 Total other income/(expense), net (45.6 ) — — 29.3 29.3 29.3 — (16.3 ) Income/(loss) from continuing operations before income taxes and equity in (losses)/earnings of equity method investees (68.1 ) — — 1,114.8 1,114.8 1,114.8 — 1,046.7 Income tax benefit 1.7 — — 7.3 7.3 7.3 — 9.0 Equity in income/(losses) of equity method investees, net of taxes 1,089.2 — — (1.6 ) (1.6 ) (1.6 ) (1,089.2 ) (1.6 ) Income/(loss) from continuing operations, net of taxes 1,022.8 — — 1,120.5 1,120.5 1,120.5 (1,089.2 ) 1,054.1 Loss from discontinued operations, net of taxes — — — (31.3 ) (31.3 ) (31.3 ) — (31.3 ) Net income/(loss) 1,022.8 — — 1,089.2 1,089.2 1,089.2 (1,089.2 ) 1,022.8 Comprehensive income/(loss) $ 899.2 $ — $ — $ 965.6 $ 965.6 $ 965.6 $ (965.6 ) $ 899.2
Condensed Balance Sheet	Condensed Consolidating Balance Sheet (As of September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) ASSETS Current assets: Cash and cash equivalents $ — $ — $ 308.6 $ 420.0 $ 728.6 $ 420.0 $ — $ 728.6 Restricted cash — — — 20.1 20.1 20.1 — 20.1 Accounts receivable, net — — — 2,633.4 2,633.4 2,633.4 — 2,633.4 Inventories — — — 4,857.1 4,857.1 4,857.1 — 4,857.1 Prepaid expenses and other current assets 1.8 0.7 12.7 650.1 662.8 650.8 — 665.3 Intercompany receivables — 50.2 432.6 3,742.3 4,174.9 3,792.5 (4,225.1 ) — Short term intercompany loan receivable — 1,796.3 — — — 1,796.3 (1,796.3 ) — Total current assets 1.8 1,847.2 753.9 12,323.0 13,076.9 14,170.2 (6,021.4 ) 8,904.5 Investments 36,448.3 — 35,740.2 12,563.2 48,303.4 12,563.2 (84,559.9 ) 191.8 Property, plant and equipment, net — — 25.9 6,501.8 6,527.7 6,501.8 — 6,527.7 Goodwill — — — 14,850.6 14,850.6 14,850.6 — 14,850.6 Intangible assets, net — — — 38,871.5 38,871.5 38,871.5 — 38,871.5 Long term intercompany loan receivable — 15,825.3 — — — 15,825.3 (15,825.3 ) — Other non-current assets 4.2 — 437.3 180.7 618.0 180.7 (217.0 ) 405.2 Total assets $ 36,454.3 $ 17,672.5 $ 36,957.3 $ 85,290.8 $ 122,248.1 $ 102,963.3 $ (106,623.6 ) $ 69,751.3 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 4.7 $ 18.4 $ 101.5 $ 3,897.1 $ 3,998.6 $ 3,915.5 $ — $ 4,021.7 Short term borrowings 920.0 1,796.3 — 20.8 20.8 1,817.1 — 2,737.1 Intercompany payables 4,225.1 — — — — — (4,225.1 ) — Short term intercompany loan payable — — — 1,796.3 1,796.3 1,796.3 (1,796.3 ) — Other current liabilities — 1.1 48.4 302.6 351.0 303.7 352.1 Total current liabilities 5,149.8 1,815.8 149.9 6,016.8 6,166.7 7,832.6 (6,021.4 ) 7,110.9 Long term borrowings — 15,825.3 5,104.8 58.8 5,163.6 15,884.1 — 20,988.9 Deferred tax liability — — — 9,543.5 9,543.5 9,543.5 (217.0 ) 9,326.5 Long term intercompany loan payable 1,110.3 — — 14,715.0 14,715.0 14,715.0 (15,825.3 ) — Other non-current liabilities 408.5 2.0 64.0 2,064.8 2,128.8 2,066.8 — 2,539.3 Total liabilities 6,668.6 17,643.1 5,318.7 32,398.9 37,717.6 50,042.0 (22,063.7 ) 39,965.6 Total equity 29,785.7 29.4 31,638.6 52,891.9 84,530.5 52,921.3 (84,559.9 ) 29,785.7 Total liabilities and equity $ 36,454.3 $ 17,672.5 $ 36,957.3 $ 85,290.8 $ 122,248.1 $ 102,963.3 $ (106,623.6 ) $ 69,751.3 Condensed Consolidating Balance Sheet (As of December 31, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) ASSETS Current assets: Cash and cash equivalents $ — $ — $ — $ 135.5 $ 135.5 $ 135.5 $ — $ 135.5 Restricted cash — — — 86.0 86.0 86.0 — 86.0 Accounts receivable, net — — — 1,201.2 1,201.2 1,201.2 — 1,201.2 Inventories — — — 635.4 635.4 635.4 — 635.4 Prepaid expenses and other current assets 1.9 9.6 — 185.9 185.9 195.5 — 197.4 Intercompany receivables — — — 3,164.9 3,164.9 3,164.9 (3,164.9 ) — Total current assets 1.9 9.6 — 5,408.9 5,408.9 5,418.5 (3,164.9 ) 2,255.5 Investments 14,477.2 — — 50.8 50.8 50.8 (14,477.2 ) 50.8 Property, plant and equipment, net — — — 828.1 828.1 828.1 — 828.1 Goodwill — — — 4,147.8 4,147.8 4,147.8 — 4,147.8 Intangible assets, net — — — 9,173.3 9,173.3 9,173.3 — 9,173.3 Other non-current assets 5.3 8.3 — 140.7 140.7 149.0 — 154.3 Total assets $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8 LIABILITIES AND EQUITY Current liabilities: Accounts payable and accrued expenses $ 10.0 $ — $ — $ 2,040.6 $ 2,040.6 $ 2,040.6 $ — $ 2,050.6 Short term borrowings 1,500.0 — — 11.5 11.5 11.5 — 1,511.5 Intercompany payables 3,145.3 19.6 — — — 19.6 (3,164.9 ) — Other current liabilities — — — 144.0 144.0 144.0 — 144.0 Total current liabilities 4,655.3 19.6 — 2,196.1 2,196.1 2,215.7 (3,164.9 ) 3,706.1 Long term borrowings — — — 69.9 69.9 69.9 — 69.9 Deferred tax liability — — — 2,205.9 2,205.9 2,205.9 — 2,205.9 Other non-current liabilities — — — 798.8 798.8 798.8 — 798.8 Total liabilities 4,655.3 19.6 — 5,270.7 5,270.7 5,290.3 (3,164.9 ) 6,780.7 Total equity 9,829.1 (1.7 ) — 14,478.9 14,478.9 14,477.2 (14,477.2 ) 9,829.1 Total liabilities and equity $ 14,484.4 $ 17.9 $ — $ 19,749.6 $ 19,749.6 $ 19,767.5 $ (17,642.1 ) $ 16,609.8
Condensed Cash Flow Statement	Condensed Consolidating Statement of Cash Flows (For the nine months ended September 30, 2016) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided (used in) operating activities $ (79.8 ) $ 182.3 $ (51.8 ) $ 1,455.3 $ 1,403.5 $ 1,637.6 $ — $ 1,506.0 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (2,390.0 ) (18,172.0 ) — (2,863.7 ) (2,863.7 ) (21,035.7 ) 23,425.7 — Movements in restricted cash — — — 68.3 68.3 68.3 — 68.3 Purchases of businesses, net of cash acquired — — — (17,476.2 ) (17,476.2 ) (17,476.2 ) — (17,476.2 ) Purchases of PP&E and non-current investments — — (6.0 ) (396.5 ) (402.5 ) (396.5 ) — (402.5 ) Proceeds from sale of product rights — — — 7.8 7.8 7.8 — 7.8 Proceeds from disposal of non-current investments and PP&E — — — 0.6 0.6 0.6 — 0.6 Other, net — — — (9.3 ) (9.3 ) (9.3 ) — (9.3 ) Net cash provided by (used in) investing activities (2,390.0 ) (18,172.0 ) (6.0 ) (20,669.0 ) (20,675.0 ) (38,841.0 ) 23,425.7 (17,811.3 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 1,655.0 30,079.9 — 7.4 7.4 30,087.3 — 31,742.3 Repayment of revolving line of credit, long term and short term borrowings (2,215.8 ) (12,409.2 ) — (7.9 ) (7.9 ) (12,417.1 ) — (14,632.9 ) Proceeds from intercompany borrowings 3,045.3 490.0 308.4 19,582.0 19,890.4 20,072.0 (23,425.7 ) — Payment of dividend (15.0 ) — — (115.2 ) (115.2 ) (115.2 ) — (130.2 ) Debt issuance costs — (171.0 ) — — — (171.0 ) — (171.0 ) Proceeds from exercise of options 0.3 — 87.9 10.7 98.6 10.7 — 98.9 Other, net — — (29.9 ) 23.4 (6.5 ) 23.4 — (6.5 ) Net cash provided by (used in) financing activities 2,469.8 17,989.7 366.4 19,500.4 19,866.8 37,490.1 (23,425.7 ) 16,900.6 Effect of foreign exchange rate changes on cash and cash equivalents — — — (2.2 ) (2.2 ) (2.2 ) — (2.2 ) Net increase in cash and cash equivalents — — 308.6 284.5 593.1 284.5 — 593.1 Cash and cash equivalents at beginning of period — — — 135.5 135.5 135.5 — 135.5 Cash and cash equivalents at end of period $ — $ — $ 308.6 $ 420.0 $ 728.6 $ 420.0 $ — $ 728.6 Condensed Consolidating Statement of Cash Flows (For the nine months ended September 30, 2015) Shire plc (Parent Guarantor) SAIIDAC (Subsidiary Issuer) Baxalta Inc. (Subsidiary Issuer) Non-Guarantor Non-Issuer Subsidiaries Non-Guarantor Subsidiaries of SAIIDAC Notes Non-Guarantor Subsidiaries of Baxalta Notes Eliminations Consolidated (in millions) CASH FLOWS FROM OPERATING ACTIVITIES Net cash provided (used in) operating activities $ (107.2 ) $ — $ — $ 1,682.4 $ 1,682.4 $ 1,682.4 $ — $ 1,575.2 CASH FLOWS FROM INVESTING ACTIVITIES: Transactions with subsidiaries (3,570.0 ) — — (2,543.3 ) (2,543.3 ) (2,543.3 ) 6,113.3 — Movements in restricted cash (1.1 ) — — (46.9 ) (46.9 ) (46.9 ) — (48.0 ) Purchases of businesses, net of cash acquired — — — (5,553.4 ) (5,553.4 ) (5,553.4 ) — (5,553.4 ) Purchases of PP&E and non-current investments — — — (67.3 ) (67.3 ) (67.3 ) — (67.3 ) Proceeds from short-term investments — — — 67.0 67.0 67.0 — 67.0 Proceeds from sale of product rights — — — 14.5 14.5 14.5 — 14.5 Proceeds from disposal of non-current investments — — — 18.5 18.5 18.5 — 18.5 Other, net — — — 2.7 2.7 2.7 — 2.7 Net cash provided by (used in) investing activities (3,571.1 ) — — (8,108.2 ) (8,108.2 ) (8,108.2 ) 6,113.3 (5,566.0 ) CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from revolving line of credit, long term and short term borrowings 3,631.1 — — 19.7 19.7 19.7 — 3,650.8 Repayment of revolving line of credit, long term and short term borrowings (2,486.1 ) — — — — — — (2,486.1 ) Proceeds from intercompany borrowings 2,543.3 — — 3,570.0 3,570.0 3,570.0 (6,113.3 ) — Payment of dividend (5.6 ) — — (104.6 ) (104.6 ) (104.6 ) — (110.2 ) Debt issuance costs (3.3 ) — — — — — — (3.3 ) Other, net (1.1 ) — — 4.8 4.8 4.8 — 3.7 Net cash provided by (used in) financing activities 3,678.3 — — 3,489.9 3,489.9 3,489.9 (6,113.3 ) 1,054.9 Effect of foreign exchange rate changes on cash and cash equivalents — — — (1.6 ) (1.6 ) (1.6 ) — (1.6 ) Net decrease in cash and cash equivalents — — — (2,937.5 ) (2,937.5 ) (2,937.5 ) — (2,937.5 ) Cash and cash equivalents at beginning of period — — — 2,982.4 2,982.4 2,982.4 — 2,982.4 Cash and cash equivalents at end of period $ — $ — $ — $ 44.9 $ 44.9 $ 44.9 $ — $ 44.9

Summary of Significant Accoun51

Summary of Significant Accounting Policies (Details) $ in Millions	Jun. 03, 2016USD ($)
Baxalta
Preliminary fair value of purchase consideration	$ 32,378.5

Business Combinations (Combinat

Business Combinations (Combination with Baxalta) (Narrative) (Details) $ / shares in Units, shares in Millions, $ in Millions	Jun. 03, 2016USD ($)$ / sharesshares	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)
Business Acquisition [Line Items]
Goodwill		$ 14,850.6	$ 4,289.6	$ 14,850.6	$ 4,289.6	$ 4,147.8	$ 2,474.9
Integration and acquisition costs		284.5	$ 89.9	738.6	$ (46.8)
Baxalta
Business Acquisition [Line Items]
Purchase price paid per share of acquiree, in cash (in USD per share) | $ / shares	$ 18
Shares issued for acquisition (in shares) | shares	305.2
Post acquisition revenues included in consolidated statement of income		1,586.4		2,166.7
Goodwill	$ 8,001
Integration and acquisition costs		$ 254.1		$ 696.4
Maximum amount of contingent cash consideration	1,500
Contingent consideration payable	161
Defined benefit net liability	610.4
Fair value of plan assets	$ 358.5
Baxalta | ADS
Business Acquisition [Line Items]
Shire shares per Baxalta share	0.1482
Baxalta | Common stock
Business Acquisition [Line Items]
Shire shares per Baxalta share	0.4446
Currently marketed products | Baxalta
Business Acquisition [Line Items]
Other intangible assets, net	$ 24,150
Weighted average amortization period of acquired amortizable intangible assets	30 years
In-Process Research and Development (IPR&D) | Baxalta
Business Acquisition [Line Items]
Other intangible assets, net	$ 1,480
Discount rate used in determining fair value of acquired in process research and development, low rate	10.00%
Minimum | Currently marketed products | Baxalta
Business Acquisition [Line Items]
Estimated useful life of intangible assets	11 years
Maximum | Currently marketed products | Baxalta
Business Acquisition [Line Items]
Estimated useful life of intangible assets	38 years

Business Combinations (Baxalta

Business Combinations (Baxalta Purchase Price Consideration) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Business Acquisition [Line Items]
Cash paid to shareholders	$ 12,366.7
Fair value of stock issued to shareholders	19,353.2
Fair value of partially vested stock options and RSUs assumed	497.6
Contingent consideration payable	161
Total Purchase Consideration	$ 32,378.5

Business Combinations (Baxalt54

Business Combinations (Baxalta Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Jun. 03, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Goodwill		$ 14,850.6	$ 4,147.8	$ 4,289.6	$ 2,474.9
Baxalta
Current assets:
Cash and cash equivalents	$ 583.2
Accounts receivable, net	1,399.8
Inventories	5,064.7
Other current assets	362.2
Total current assets	7,409.9
Property, plant and equipment, net	5,569.3
Investments	128.2
Goodwill	8,001
Other non-current assets	103.3
Total assets	46,923.9
Current liabilities:
Accounts payable and accrued expenses	1,537
Other current liabilities	92.9
Long-term borrowings	5,424.9
Deferred tax liability	6,385.3
Other non-current liabilities	1,105.3
Total liabilities	14,545.4
Preliminary fair value of identifiable assets acquired and liabilities assumed	32,378.5
Preliminary fair value of purchase consideration	32,378.5
Currently marketed products | Baxalta
Current assets:
Other intangible assets, net	24,150
In-Process Research and Development (IPR&D) | Baxalta
Current assets:
Other intangible assets, net	1,480
Contract based arrangements | Baxalta
Current assets:
Other intangible assets, net	82.2
Preliminary values | Baxalta
Current assets:
Cash and cash equivalents	583.2
Accounts receivable, net	1,382.8
Inventories	5,341.1
Other current assets	362.2
Total current assets	7,669.3
Property, plant and equipment, net	5,687.7
Investments	128.2
Goodwill	6,106.4
Other non-current assets	103.3
Total assets	47,257.1
Current liabilities:
Accounts payable and accrued expenses	1,509.5
Other current liabilities	15.4
Long-term borrowings	5,424.9
Deferred tax liability	6,831.7
Other non-current liabilities	1,092.1
Total liabilities	14,873.6
Preliminary fair value of identifiable assets acquired and liabilities assumed	32,383.5
Preliminary fair value of purchase consideration	32,383.5
Preliminary values | Currently marketed products | Baxalta
Current assets:
Other intangible assets, net	24,550
Preliminary values | In-Process Research and Development (IPR&D) | Baxalta
Current assets:
Other intangible assets, net	2,940
Preliminary values | Contract based arrangements | Baxalta
Current assets:
Other intangible assets, net	72.2
Measurement period adjustments | Baxalta
Current assets:
Cash and cash equivalents	0
Accounts receivable, net	17
Inventories	(276.4)
Other current assets	0
Total current assets	(259.4)
Property, plant and equipment, net	(118.4)
Investments	0
Goodwill	1,894.6
Other non-current assets	0
Total assets	(333.2)
Current liabilities:
Accounts payable and accrued expenses	27.5
Other current liabilities	77.5
Long-term borrowings	0
Deferred tax liability	(446.4)
Other non-current liabilities	13.2
Total liabilities	(328.2)
Preliminary fair value of identifiable assets acquired and liabilities assumed	(5)
Preliminary fair value of purchase consideration	(5)
Measurement period adjustments | Currently marketed products | Baxalta
Current assets:
Other intangible assets, net	(400)
Measurement period adjustments | In-Process Research and Development (IPR&D) | Baxalta
Current assets:
Other intangible assets, net	(1,460)
Measurement period adjustments | Contract based arrangements | Baxalta
Current assets:
Other intangible assets, net	$ 10

Business Combinations (Baxalt55

Business Combinations (Baxalta Pro Forma Information) (Details) - Baxalta - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Revenues	$ 3,250	$ 10,193.5	$ 9,086
Net (loss)/income from continuing operations	$ (52)	$ 1,406.6	$ (1,152.1)
Net (loss)/income from continuing operations per share - basic (in usd per share)	$ (0.06)	$ 1.94	$ (1.29)
Net (loss)/income from continuing operations per share - diluted (in usd per share)	$ (0.06)	$ 1.92	$ (1.29)
Increase/(decrease) to net income to reflect acquisition related costs		$ 562.6	$ (562.6)
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	$ (592.5)	873.6	(1,777.5)
An adjustment to increase amortization of intangible assets	153.6	198.8	478
Decrease to net income to reflect the additional interest expense	$ (64)	$ 97.2	$ (215.1)

Business Combinations (Acquisit

Business Combinations (Acquisition of Dyax) (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	Jan. 22, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 14,850.6	$ 4,289.6	$ 14,850.6	$ 4,289.6	$ 4,147.8	$ 2,474.9
Integration and acquisition costs		284.5	$ 89.9	738.6	$ (46.8)
Dyax
Business Acquisition [Line Items]
Purchase price paid per share of acquiree, in cash (in USD per share)	$ 37.30
Contingent consideration payable (in usd per share)	$ 4
Preliminary fair value of identifiable assets acquired and liabilities assumed	$ 6,330
Cash paid on closing	5,934
Contingent consideration payable	396
Maximum amount of contingent cash consideration	646
Post acquisition revenues included in consolidated statement of income		16.7		51.3
Goodwill	2,688.8
Integration and acquisition costs		$ 11.3		$ 65
Currently marketed products | Dyax
Business Acquisition [Line Items]
Other intangible assets, net	135
In-Process Research and Development (IPR&D) | Dyax
Business Acquisition [Line Items]
Other intangible assets, net	4,100
Royalty rights | Dyax
Business Acquisition [Line Items]
Other intangible assets, net	$ 425
Weighted average amortization period of acquired amortizable intangible assets	8 years
KALBITOR | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	18 years
SHP643 | Dyax
Business Acquisition [Line Items]
Discount rate used in determining fair value of acquired in process research and development, high rate	9.00%
Minimum | Royalty rights | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	7 years
Maximum | Royalty rights | Dyax
Business Acquisition [Line Items]
Estimated useful life of intangible assets	9 years

Business Combinations (Dyax Ass

Business Combinations (Dyax Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Jan. 22, 2016	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Non-current assets:
Goodwill		$ 14,850.6	$ 4,147.8	$ 4,289.6	$ 2,474.9
Dyax
Current assets:
Cash and cash equivalents	$ 241.2
Accounts receivable, net	22.5
Inventories	20.2
Other current assets	8.1
Total current assets	292
Non-current assets:
Property, plant and equipment, net	5.8
Goodwill	2,688.8
Other non-current assets	28.6
Total assets	7,675.2
Current liabilities:
Accounts payable and accrued expenses	30
Other current liabilities	1.7
Non-current liabilities:
Deferred tax liability	1,312.1
Other non-current liabilities	1.4
Total liabilities	1,345.2
Preliminary fair value of identifiable assets acquired and liabilities assumed	6,330
Preliminary fair value of purchase consideration	6,330
Currently marketed products | Dyax
Non-current assets:
Other intangible assets, net	135
In-Process Research and Development (IPR&D) | Dyax
Non-current assets:
Other intangible assets, net	4,100
Royalty rights | Dyax
Non-current assets:
Other intangible assets, net	$ 425

Business Combinations (Dyax Pro

Business Combinations (Dyax Pro Forma Information) (Details) - Dyax - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Revenues	$ 1,679.7	$ 7,596.4	$ 4,772.5
Net income from continuing operations	$ 438	$ 25.9	$ 837.1
Net income from continuing operations per share - basic (in usd per share)	$ 0.74	$ 0.04	$ 1.42
Net income from continuing operations per share - diluted (in usd per share)	$ 0.74	$ 0.04	$ 1.41
Increase/(decrease) to net income to reflect acquisition related costs		$ 108.4	$ (108.4)
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	$ (1.6)		(3.9)
An adjustment to increase amortization of intangible assets	5.4	$ 1.3	16.2
Decrease to net income to reflect the additional interest expense	$ (20.4)		$ (61.2)

Business Combinations (Acquis59

Business Combinations (Acquisition of NPS) (Narrative) (Details) - USD ($) $ in Millions	Feb. 21, 2015	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$ 14,850.6	$ 4,147.8	$ 4,289.6	$ 2,474.9
NPS Pharma
Business Acquisition [Line Items]
Cash paid on closing	$ 5,219.6
Goodwill	1,551
Currently marketed products | NPS Pharma
Business Acquisition [Line Items]
Other intangible assets, net	4,640
Royalty rights | NPS Pharma
Business Acquisition [Line Items]
Other intangible assets, net	$ 353
Weighted average amortization period of acquired amortizable intangible assets	4 years
NATPARA/NATPAR | Currently marketed products | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	24 years
Minimum | Royalty rights | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	4 years
Maximum | Royalty rights | NPS Pharma
Business Acquisition [Line Items]
Estimated useful life of intangible assets	5 years

Business Combinations (NPS Asse

Business Combinations (NPS Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Millions	Feb. 21, 2015	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Non-current assets:
Goodwill		$ 14,850.6	$ 4,147.8	$ 4,289.6	$ 2,474.9
NPS Pharma
Current assets:
Cash and cash equivalents	$ 41.6
Short-term investments	67
Accounts receivable, net	33.4
Inventories	89.4
Other current assets	11.1
Total current assets	242.5
Non-current assets:
Property, plant and equipment, net	4.8
Goodwill	1,551
Total assets	6,791.3
Current liabilities:
Accounts payable and accrued expenses	75.7
Short-term debt	27.4
Non-current liabilities:
Long-term borrowings	78.9
Deferred tax liability	1,385.2
Other non-current liabilities	4.5
Total liabilities	1,571.7
Preliminary fair value of identifiable assets acquired and liabilities assumed	5,219.6
Cash paid to shareholders	5,219.6
Currently marketed products | NPS Pharma
Non-current assets:
Other intangible assets, net	4,640
Royalty rights (categorized as Other amortized intangible assets) | NPS Pharma
Non-current assets:
Other intangible assets, net	$ 353

Business Combinations (NPS Pro

Business Combinations (NPS Pro Forma Information) (Details) - NPS Pharma - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Revenues	$ 1,655,000,000	$ 4,730,900,000
Net income from continuing operations	$ 479,100,000	$ 1,005,600,000
Net income from continuing operations per share - basic (in usd per share)	$ 0.81	$ 1.70
Net income from continuing operations per share - diluted (in usd per share)	$ 0.81	$ 1.69
Increase/(decrease) to net income to reflect acquisition related costs	$ 2,000,000	$ 105,200,000
Increase/(decrease) to net income to reflect the fair value adjustment to acquisition date inventory.	4,200,000	13,400,000
An adjustment to increase amortization of intangible assets	$ 0	$ (21,200,000)

Collaborative and other licen62

Collaborative and other licensing arrangements (Narrative) (Details) € in Millions	1 Months Ended			3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Jul. 31, 2016USD ($)	Jun. 30, 2016	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2016EUR (€)	Sep. 30, 2015USD ($)	Sep. 30, 2016EUR (€)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Option exercise fee, for each protein | €									€ 20
Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone payments received				$ 3,000,000	$ 0	$ 3,500,000		$ 12,600,000
Development Milestone | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable	$ 17,300,000			17,300,000		17,300,000
Sales Milestone | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum milestone payment receivable	17,700,000			17,700,000		17,700,000
Other Revenues | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized				1,700,000	500,000	4,000,000		1,500,000
Product Sales | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestone revenues recognized				16,400,000	$ 13,800,000	47,700,000		$ 37,200,000
Agreement with SFJ Pharmaceuticals IX, L.P.
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Fair value of assumed contingency	288,600,000			288,600,000		288,600,000
Collaboration with Precision BioSciences | Future payments related to option fees and development, regulatory and commercial milestones | In-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Maximum conditional obligation	1,600,000,000			$ 1,600,000,000		1,600,000,000
Research Collaboration with Symphogen | Future payments related to option fees and development, regulatory and commercial milestones | In-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment | €							€ 1,200
License Agreement with Merrimack Pharmaceuticals | Future payments related to option fees and development, regulatory and commercial milestones | Out-licensing Arrangement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment						$ 678,000,000
Pfizer Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payment		$ 90,000,000
SFJ Pharmaceuticals Group [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Payments to terminate agreement	$ 288,000,000
Minimum | Pfizer Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment		75,000,000
Maximum | Pfizer Inc [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Milestones payment		$ 460,000,000
Baxalta | Option to Obtain Exclusive Licensing Rights
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Exercise period after protein is ready for Phase 2 clinical trials			90 days

Integration and Acquisition C63

Integration and Acquisition Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Business Acquisition [Line Items]
Integration and acquisition costs (credits)	$ 284.5	$ 89.9	$ 738.6	$ (46.8)
Cash paid			128.1
Baxalta
Business Acquisition [Line Items]
Integration and acquisition costs (credits)	254.1		696.4
NPS Pharma
Business Acquisition [Line Items]
Integration and acquisition costs (credits)		30.7		149.7
Lumena and Lotus Tissue Repair
Business Acquisition [Line Items]
Change in fair value of contingent consideration		59.2		$ 196.5
Cash paid		$ 90
Employee termination benefits and other reorganization costs | Baxalta
Business Acquisition [Line Items]
Integration costs	$ 120		$ 373.1

Integration and Acquisition C64

Integration and Acquisition Costs (Summary of Employee Termination Related Reserve) (Details) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Restructuring Reserve [Roll Forward]
As at January 1,	$ 0
Amount charged to integration costs	202.3
Paid/utilized	(128.1)
As at September 30,	$ 74.2

Reorganization Costs (Narrative

Reorganization Costs (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Restructuring Cost and Reserve [Line Items]
Reorganization costs	$ 101.4	$ 31.1	$ 115.7	$ 59.6
Offices
Restructuring Cost and Reserve [Line Items]
Reorganization costs	77.4		77.4
Severance and Employee Benefits
Restructuring Cost and Reserve [Line Items]
Reorganization costs	$ 18.4		$ 18.4

Discontinued Operations (Narrat

Discontinued Operations (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations, net of taxes	$ 18.3	$ 24.3	$ 257.5	$ 31.3
DERMAGRAFT [Member] | Discontinued Operations [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Loss from discontinued operations, net of taxes	18.3	24.3	257.5	31.3
Tax benefit of discontinued operations	$ 5.7	$ 14	$ 101.1	$ 18

Accounts Receivable (Narrative)

Accounts Receivable (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Receivables [Abstract]
Accounts receivable, net	$ 2,633.4	$ 1,201.2
Reserve for discounts and allowances	127.4	55.8	$ 55.7	$ 48.5
Accounts receivable related to royalty income	$ 89.9	$ 79

Accounts Receivable (Summary of

Accounts Receivable (Summary of Reserve for Discounts and Allowances) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Provision for discounts and doubtful accounts
As at January 1,	$ 55.8	$ 48.5
Provision charged to operations	569.9	293.8
Payments/credits related to sales	(498.3)	(286.6)
As at September 30,	$ 127.4	$ 55.7

Inventories (Summary of Invento

Inventories (Summary of Inventories) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Schedule of Inventory
Finished goods	$ 1,597.6	$ 184.9
Work-in-progress	2,431.3	302
Raw materials	828.2	148.5
Total inventories	$ 4,857.1	$ 635.4

Property, Plant and Equipment70

Property, Plant and Equipment (Summary of Property, Plant and Equipment) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Property, Plant and Equipment, Net
Land	$ 356.3	$ 96.7
Buildings and leasehold improvements	1,999.5	606.4
Machinery, equipment and other	2,440.5	827.4
Assets under construction	2,647	93.7
Property, plant and equipment, gross	7,443.3	1,624.2
Less: Accumulated depreciation	(915.6)	(796.1)
Property, plant and equipment, net	$ 6,527.7	$ 828.1

Property, Plant and Equipment71

Property, Plant and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Depreciation	$ 93.1	$ 32.9	$ 175.3	$ 105.1

Intangible Assets (Summary of I

Intangible Assets (Summary of Intangible Assets) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	$ 41,509.6	$ 11,108.9
Less: Accumulated amortization	(2,638.1)	(1,935.6)
Other intangible assets, net	38,871.5	9,173.3	$ 9,450.6	$ 4,934.4
Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	34,104.6	9,371.9
Less: Accumulated amortization	(2,467.7)	(1,852.1)
Other intangible assets, net	31,636.9	7,519.8
IPR&D
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	6,522.8	1,362
Less: Accumulated amortization	0	0
Other intangible assets, net	6,522.8	1,362
Other intangible assets
Finite-Lived Intangible Assets [Line Items]
Gross acquired intangible assets	882.2	375
Less: Accumulated amortization	(170.4)	(83.5)
Other intangible assets, net	$ 711.8	$ 291.5

Intangible Assets (Roll Forward

Intangible Assets (Roll Forward) (Details) - USD ($) $ in Millions	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Other Intangible Assets Roll Forward
Beginning balance	$ 9,173.3	$ 4,934.4	$ 4,934.4
Acquisitions	30,377.7	5,473.7
Amortization charged	(702.5)	(352.3)
Impairment charges	(8.9)	(523.3)	(523.3)
Foreign currency translation	31.9	(81.9)
Ending balance	$ 38,871.5	$ 9,450.6	$ 9,173.3

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	Jun. 03, 2016	Jan. 22, 2016	Sep. 30, 2016	Sep. 30, 2015
Finite-Lived Intangible Assets [Line Items]
Acquisitions			$ 30,377.7	$ 5,473.7
Baxalta | Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Acquisitions	$ 24,150
Baxalta | In-Process Research and Development (IPR&D)
Finite-Lived Intangible Assets [Line Items]
Acquisitions	1,480
Baxalta | Contract based arrangements
Finite-Lived Intangible Assets [Line Items]
Acquisitions	$ 82.2
Dyax | Currently marketed products
Finite-Lived Intangible Assets [Line Items]
Acquisitions		$ 135
Dyax | In-Process Research and Development (IPR&D)
Finite-Lived Intangible Assets [Line Items]
Acquisitions		4,100
Dyax | Royalty rights
Finite-Lived Intangible Assets [Line Items]
Acquisitions		$ 425

Intangible Assets (Future Amort

Intangible Assets (Future Amortization Expense) (Details) $ in Millions	Sep. 30, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2016 (remaining three months)	$ 358.1
2,017	1,429.9
2,018	1,424.2
2,019	1,344.8
2,020	1,340.9
2,021	$ 1,336.5

Goodwill (Rollforward of Goodwi

Goodwill (Rollforward of Goodwill) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Goodwill [Roll Forward]
Beginning balance	$ 4,147.8	$ 2,474.9
Acquisitions	10,689.8	1,837
Foreign currency translation	13	(22.3)
Ending balance	$ 14,850.6	$ 4,289.6

Fair Value Measurement (Assets

Fair Value Measurement (Assets and Liabilities Measured on a Recurring Basis) (Details) - Recurring Basis - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	$ 69.7	$ 17.2
Marketable debt securities	3.7
Contingent consideration receivable	0	0
Derivative instruments	0	0
Total assets	73.4	17.2
Derivative instruments	0	0
Contingent consideration payable	0	0
Total liabilities	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	0	0
Marketable debt securities	12.8
Contingent consideration receivable	0	0
Derivative instruments	50.6	1.9
Total assets	63.4	1.9
Derivative instruments	13.3	11.5
Contingent consideration payable	0	0
Total liabilities	13.3	11.5
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	0	0
Marketable debt securities	0
Contingent consideration receivable	15.7	13.8
Derivative instruments	0	0
Total assets	15.7	13.8
Derivative instruments	0	0
Contingent consideration payable	996.7	475.9
Total liabilities	996.7	475.9
Fair value
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Marketable equity securities	69.7	17.2
Marketable debt securities	16.5
Contingent consideration receivable	15.7	13.8
Derivative instruments	50.6	1.9
Total assets	152.5	32.9
Derivative instruments	13.3	11.5
Contingent consideration payable	996.7	475.9
Total liabilities	$ 1,010	$ 487.4

Fair Value Measurement (Asset78

Fair Value Measurement (Assets and Liabilities Measure at Fair Value on Recurring Basis using Level 3 Inputs) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	$ 13.8	$ 15.9
Change in fair value included in earnings	3.6	9.8
Other	(1.7)	(10.8)
Balance at end of period	15.7	14.9
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at beginning of period	475.9	629.9
Additions	557	92.8
Change in fair value included in earnings	(34.8)	(196.5)
Other	(1.4)	(5.6)
Balance at end of period	$ 996.7	$ 520.6

Fair Value Measurement (Qualita

Fair Value Measurement (Qualitative Information About Assets Measured at Fair Value on Recurring Basis Using Level 3 Inputs) (Details) - Recurring Basis - Contingent Consideration Receivable - Income approach (probability weighted discounted cash flow) $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Assets	$ 15.7
Assumed market participant discount rate	8.40%
Minimum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability weightings applied to different sales scenarios (in percent)	10.00%
Future forecast consideration receivable based on contractual terms with purchaser	$ 0
Maximum
Fair Value Inputs, Assets, Quantitative Information [Line Items]
Probability weightings applied to different sales scenarios (in percent)	90.00%
Future forecast consideration receivable based on contractual terms with purchaser	$ 23

Fair Value Measurement (Quali80

Fair Value Measurement (Qualitative Information About Liabilities Measured at Fair Value on Recurring Basis Using Level 3 Inputs) (Details) - Recurring Basis - Contingent Consideration Payable $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)
Income approach (probability weighted discounted cash flow)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Liabilities	$ 996.7
Minimum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cumulative probability of milestones being achieved (in percent)	4.00%
Assumed market participant discount rate	1.20%
Periods in which milestones are expected to be achieved	2,016
Forecast quarterly royalties payable on net sales of relevant products	$ 3.5
Maximum
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Cumulative probability of milestones being achieved (in percent)	90.00%
Assumed market participant discount rate	10.50%
Periods in which milestones are expected to be achieved	2,036
Forecast quarterly royalties payable on net sales of relevant products	$ 7.1

Fair Value Measurement (Financi

Fair Value Measurement (Financial Assets and Liabilities Not Measured on a Recurring Basis) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	$ 12,037	$ 0
Capital lease obligation	348.6
Fair value | Nonrecurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	12,080.9	0
Capital lease obligation	348.6	13.4
Carrying value | Nonrecurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	12,037	0
Capital lease obligation	348.6	13.4
Baxalta
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	5,104.4	0
Baxalta | Fair value | Nonrecurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	5,467.7	0
Baxalta | Carrying value | Nonrecurring Basis
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Senior notes	$ 5,104.4	$ 0

Fair Value Measurement (Narrati

Fair Value Measurement (Narrative) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Liability	$ 996.7	$ 475.9	$ 520.6	$ 629.9
Contingent consideration payable, current	48
Contingent consideration payable, noncurrent	$ 948.7

Financial Instruments (Narrativ

Financial Instruments (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016USD ($)derivative	Sep. 30, 2015USD ($)	Dec. 31, 2015USD ($)
Derivative [Line Items]
Number of instruments | derivative	270
Deferred gains to be reclassified in next 12 months	$ 5,000,000
Potential effect of rights of set off associated with the foreign exchange contracts	7,900,000
Derivative asset	42,700,000
Derivative liability	5,400,000
Designated as Hedging Instrument
Derivative [Line Items]
Derivative liability, fair value	6,100,000
Assets	46,500,000
Not Designated as Hedging Instrument
Derivative [Line Items]
Derivative liability, fair value	13,300,000
Assets	50,600,000
Foreign Exchange Contract | Designated as Hedging Instrument
Derivative [Line Items]
Notional amount	350,000,000
Derivative liability, fair value	3,300,000		$ 0
Fair value portion of Derivative recognized in OCI, Loss	100,000
Amount of net gains/(losses) recognized in OCI	(100,000)	$ 0
Foreign Exchange Contract | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional amount	508,800,000	639,600,000
Interest Rate Swap | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional amount	5,100,000,000
Other Noncurrent Assets | Interest Rate Contract | Designated as Hedging Instrument
Derivative [Line Items]
Assets	43,700,000	0
Interest Expense | Interest Rate Contract
Derivative [Line Items]
Amount of losses recognized in income	1,100,000	0
Interest Expense | Interest Rate Contract | Designated as Hedging Instrument
Derivative [Line Items]
Amount of net gains/(losses) recognized in OCI	2,100,000	0
Interest Expense | Interest Rate Contract | Not Designated as Hedging Instrument
Derivative [Line Items]
Amount of losses recognized in income	1,100,000	0
Baxalta | Foreign Exchange Contract | Not Designated as Hedging Instrument
Derivative [Line Items]
Notional amount	659,300,000
Derivative liability, fair value	2,000,000		$ 0
Baxalta | Foreign Exchange Contract | Not Designated as Hedging Instrument | Cash Flow Hedging
Derivative [Line Items]
Notional amount	26,100,000
Baxalta | Interest Rate Swap | Designated as Hedging Instrument | Fair Value Hedging
Derivative [Line Items]
Notional amount	1,000,000,000
November 2015 Facilities Agreement | Interest Expense | Interest Rate Contract
Derivative [Line Items]
Amount of losses recognized in income	$ 1,100,000	$ 0

Financial Instruments (Derivati

Financial Instruments (Derivative Income Statement Location, Gains & Losses) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Foreign Exchange Contract | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in OCI	$ (100,000)	$ 0
Foreign Exchange Contract | Other income/(expense), net | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	(50,000,000)	12,000,000
Interest Rate Contract | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	(1,100,000)	0
Interest Rate Contract | Interest expense | Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in OCI	2,100,000	0
Interest Rate Contract | Interest expense | Not Designated as Hedging Instrument
Derivative Instruments, Gain (Loss) [Line Items]
Amount of net gains/(losses) recognized in income	(1,100,000)	0
Reclassification out of AOCI | Accumulated Net Gain (Loss) from Cash Flow Hedges | Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from AOCI into income	$ 0	$ 0

Financial Instruments (Foreign

Financial Instruments (Foreign Exchange Risk and Its Classification on Balance Sheet) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Designated as Hedging Instrument
Derivatives, Fair Value
Assets	$ 46,500,000
Liabilities	6,100,000
Not Designated as Hedging Instrument
Derivatives, Fair Value
Assets	50,600,000
Liabilities	13,300,000
Foreign Exchange Contract | Designated as Hedging Instrument
Derivatives, Fair Value
Liabilities	3,300,000	$ 0
Foreign Exchange Contract | Prepaid expenses and other current assets | Designated as Hedging Instrument
Derivatives, Fair Value
Assets	2,800,000
Foreign Exchange Contract | Prepaid expenses and other current assets | Not Designated as Hedging Instrument
Derivatives, Fair Value
Assets	4,100,000
Foreign Exchange Contract | Accounts payable and accrued expenses | Designated as Hedging Instrument
Derivatives, Fair Value
Liabilities	6,100,000
Foreign Exchange Contract | Accounts payable and accrued expenses | Not Designated as Hedging Instrument
Derivatives, Fair Value
Liabilities	6,100,000
Interest Rate Contract | Prepaid expenses and other current assets | Not Designated as Hedging Instrument
Derivatives, Fair Value
Assets	0
Interest Rate Contract | Accounts payable and accrued expenses | Not Designated as Hedging Instrument
Derivatives, Fair Value
Liabilities	1,100,000
Interest Rate Contract | Long-term borrowings | Designated as Hedging Instrument
Derivatives, Fair Value
Assets	43,700,000
Liabilities	$ 0

Borrowings and Capital Lease 86

Borrowings and Capital Lease Obligations (Short-term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Short-term Debt [Line Items]
Other borrowings	$ 20.8	$ 11.5
Short-term Debt, Total	2,737.1	1,511.5
Revolving Credit Facility
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	920	750
November 2015 Facilities Agreement
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	1,796.3	0
January 2016 Facilities Agreement
Short-term Debt [Line Items]
Borrowings under the Facilities Agreement	$ 0	$ 750

Borrowings and Capital Lease 87

Borrowings and Capital Lease Obligations (Long-term Borrowings) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Senior notes	$ 12,037	$ 0
Other borrowings	59.2	69.9
Capital lease obligations (long term portion)	348.6	0
Long-term Debt, Gross, Total	24,074.6	1,581.4
November 2015 Facilities Agreement
Debt Instrument [Line Items]
Borrowings under the Facilities Agreement	3,788.3	0
Baxalta
Debt Instrument [Line Items]
Senior notes	$ 5,104.4	$ 0

Borrowings and Capital Lease 88

Borrowings and Capital Lease Obligations (Maturities of Long-term Debt & Capital Lease Obligations) (Details) $ in Millions	Sep. 30, 2016USD ($)
Maturities of Long-term Debt and Capital Lease Obligations [Abstract]
2016 (remaining three months)	$ 605.7
2,017	2,626.7
2,018	3,184.1
2,019	3,344.1
2,020	1,960.1
2,021	3,318.7
Thereafter	9,110.7
Total obligations	24,150.1
Fair value hedges, unamortized bond premium and deferred financing costs	(75.5)
Total debt and capital lease obligations	$ 24,074.6

Borrowings and Capital Lease 89

Borrowings and Capital Lease Obligations (Senior Notes Issued by SAIIDAC) (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Aggregate Amount	$ 5,000,000,000
Carrying amount	24,074,600,000	$ 1,581,400,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes
Debt Instrument [Line Items]
Aggregate Amount	12,100,000,000
Carrying amount	12,037,000,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2019
Debt Instrument [Line Items]
Aggregate Amount	$ 3,300,000,000
Coupon Rate	1.90%
Effective Interest Rate	2.05%
Carrying amount	$ 3,286,500,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2021
Debt Instrument [Line Items]
Aggregate Amount	$ 3,300,000,000
Coupon Rate	2.40%
Effective Interest Rate	2.53%
Carrying amount	$ 3,282,400,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2023
Debt Instrument [Line Items]
Aggregate Amount	$ 2,500,000,000
Coupon Rate	2.875%
Effective Interest Rate	2.97%
Carrying amount	$ 2,487,800,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes | Fixed-rate notes due 2026
Debt Instrument [Line Items]
Aggregate Amount	$ 3,000,000,000
Coupon Rate	3.20%
Effective Interest Rate	3.30%
Carrying amount	$ 2,980,300,000

Borrowings and Capital Lease 90

Borrowings and Capital Lease Obligations (Senior Notes Related to Baxalta Acquisition) (Details) - USD ($)	9 Months Ended
	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Aggregate Amount	$ 5,000,000,000
Carrying amount	24,074,600,000	$ 1,581,400,000
Baxalta
Debt Instrument [Line Items]
Aggregate Amount	5,000,000,000
Baxalta | Senior Notes
Debt Instrument [Line Items]
Carrying amount	5,104,400,000
Baxalta | Senior Notes | Variable-rate notes due 2018
Debt Instrument [Line Items]
Aggregate Amount	$ 375,000,000
Effective Interest Rate	1.65%
Carrying amount	$ 370,900,000
Baxalta | Senior Notes | Variable-rate notes due 2018 | LIBOR
Debt Instrument [Line Items]
Effective Interest Rate, Variable Rate	0.78%
Baxalta | Senior Notes | Fixed-rate notes due 2018
Debt Instrument [Line Items]
Aggregate Amount	$ 375,000,000
Coupon Rate	2.00%
Effective Interest Rate	2.20%
Carrying amount	$ 374,800,000
Baxalta | Senior Notes | Fixed-rate notes due 2020
Debt Instrument [Line Items]
Aggregate Amount	$ 1,000,000,000
Coupon Rate	2.875%
Effective Interest Rate	2.80%
Carrying amount	$ 1,014,800,000
Baxalta | Senior Notes | Fixed-rate notes due 2022
Debt Instrument [Line Items]
Aggregate Amount	$ 500,000,000
Coupon Rate	3.60%
Effective Interest Rate	3.30%
Carrying amount	$ 508,800,000
Baxalta | Senior Notes | Fixed-rate notes due 2025
Debt Instrument [Line Items]
Aggregate Amount	$ 1,750,000,000
Coupon Rate	4.00%
Effective Interest Rate	3.90%
Carrying amount	$ 1,803,000,000
Baxalta | Senior Notes | Fixed-rate notes due 2045
Debt Instrument [Line Items]
Aggregate Amount	$ 1,000,000,000
Coupon Rate	5.25%
Effective Interest Rate	5.20%
Carrying amount	$ 1,032,100,000

Borrowings and Capital Lease 91

Borrowings and Capital Lease Obligations (Narrative) (Details)	Feb. 22, 2016USD ($)	Sep. 30, 2016USD ($)	Sep. 30, 2015USD ($)	Sep. 23, 2016USD ($)	Jun. 03, 2016USD ($)	Jan. 11, 2016USD ($)contract	Dec. 31, 2015USD ($)	Nov. 02, 2015USD ($)contract	Sep. 28, 2015USD ($)	Jan. 11, 2015USD ($)	Dec. 12, 2014USD ($)
Line of Credit Facility [Line Items]
Aggregate Amount		$ 5,000,000,000
Repayment of lines of credit		14,632,900,000	$ 2,486,100,000
Long-term borrowings		20,988,900,000					$ 69,900,000
Capital lease obligation		$ 348,600,000
January 2016 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement initiation date		Jan. 11, 2016
Facility agreement total amount						$ 18,000,000,000
Number of term loan facilities | contract						2
November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement initiation date		Nov. 2, 2015
Facility agreement total amount								$ 5,600,000,000
Number of term loan facilities | contract								3
January 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement total amount										$ 850,000,000
Reduction in borrowing capacity									$ 100,000,000
Repayment of lines of credit	$ 100,000,000
November 2015 Facility A | November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement expiration date		Nov. 2, 2016
Term loan facility								$ 1,000,000,000
November 2015 Facility A - Matures November 2, 2017 | November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Term loan facility								400,000,000
November 2015 Facility A - Matures November 2, 2016 | November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Term loan facility								600,000,000
November 2015 Facility B | November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement expiration date		Nov. 2, 2017
Term loan facility								2,200,000,000
November 2015 Facility C | November 2015 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement expiration date		Nov. 2, 2018
Term loan facility								$ 2,400,000,000
January 2016 Facility B | January 2016 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement expiration date		Jul. 11, 2016
Term loan facility						$ 5,000,000,000
January 2016 Facility A | January 2016 Facilities Agreement
Line of Credit Facility [Line Items]
Facility agreement expiration date		Jan. 11, 2017
Term loan facility						$ 13,000,000,000
Long-term borrowings					$ 12,390,000,000
Revolving Credit Facility
Line of Credit Facility [Line Items]
Aggregate Amount											$ 2,100,000,000
Facility agreement initiation date		Dec. 12, 2014
Facility amount outstanding		$ 920,000,000
Facility agreement expiration date		Dec. 12, 2020
Swingline Facility											$ 250,000,000
Senior Notes | SAIIDAC Notes
Line of Credit Facility [Line Items]
Aggregate Amount				$ 12,100,000,000
Shire Acquisitions Investment Ireland Designated Activity Company | Senior Notes
Line of Credit Facility [Line Items]
Aggregate Amount		$ 12,100,000,000
Deferred financing costs				$ 62,700,000

Retirement and Other Benefit 92

Retirement and Other Benefit Programs (Narrative) (Details) - USD ($)	4 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Jun. 03, 2016
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	7.00%	7.00%
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.50%	4.50%
Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target plan asset allocations range variance		5.00%
Baxalta | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated other comprehensive income (loss), net gains (losses)			$ 369,200,000
Discount rate			4.10%
Baxalta | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Accumulated other comprehensive income (loss), net gains (losses)			$ 386,800,000
Discount rate			1.00%
Expected contributions in current year		$ 1,000,000
Baxalta | OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate			4.20%
Contributions by employer	$ 4,000,000
Expected net cash outflow in current year		$ 1,000,000
Equity | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation for plan assets		75.00%
Fixed income | Baxalta
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Target allocation for plan assets		25.00%

Retirement and Other Benefit 93

Retirement and Other Benefit Programs (Summary of Fair Value of Pension and OPEB-Related Balances) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	$ 945.4
Plan assets	358.5
Net liability recognized as of June 3, 2016	(610.4)
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	441.6
Plan assets	218
Funded status as of June 3, 2016	(223.6)
Other current liabilities	(0.2)
Other non-current liabilities	(223.4)
Net liability recognized as of June 3, 2016	(223.6)
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	503.8
Plan assets	140.5
Funded status as of June 3, 2016	(363.3)
Other current liabilities	(3.1)
Other non-current liabilities	(360.2)
Net liability recognized as of June 3, 2016	(363.3)
OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Projected benefit obligation	23.5
Plan assets	0
Funded status as of June 3, 2016	(23.5)
Other current liabilities	0
Other non-current liabilities	(23.5)
Net liability recognized as of June 3, 2016	$ (23.5)

Retirement and Other Benefit 94

Retirement and Other Benefit Programs (Summary of Funded Status of Plan) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Fair value of plan assets	$ 358.5
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
ABO	369.2
Fair value of plan assets	218
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
ABO	364.9
Fair value of plan assets	$ 118.2

Retirement and Other Benefit 95

Retirement and Other Benefit Programs (Expected Net Pension and OPEB Plan Payments for the Next 10 Years) (Details) - Baxalta $ in Millions	Sep. 30, 2016USD ($)
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2016 (after June 3, 2016)	$ 0.9
2,017	3.6
2,018	5.4
2,019	7.3
2,020	9.3
2021 through 2025	75.6
Total expected benefit payments for next 10 years	102.1
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2016 (after June 3, 2016)	7.3
2,017	14.7
2,018	14.6
2,019	16.2
2,020	16.7
2021 through 2025	104.8
Total expected benefit payments for next 10 years	174.3
OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
2016 (after June 3, 2016)	0
2,017	0.2
2,018	0.3
2,019	0.4
2,020	0.5
2021 through 2025	3.5
Total expected benefit payments for next 10 years	$ 4.9

Retirement and Other Benefit 96

Retirement and Other Benefit Programs (Weighted-Average Assumptions Used for Benefit Obligation and Net Periodic Benefit Cost) (Details)	Jun. 03, 2016	Sep. 30, 2016
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate		7.00%
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate		4.50%
Baxalta | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.10%
Rate of compensation increase	3.80%
Baxalta | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	1.00%
Rate of compensation increase	3.20%
Baxalta | OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Discount rate	4.20%
Annual rate of increase in the per-capita cost	6.50%
Rate decreased to	5.00%
by the year ended	2,022

Retirement and Other Benefit 97

Retirement and Other Benefit Programs (Fair Value Measurements of Plan Assets and Liabilities) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	$ 358.5
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	140.5
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	218
Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	129.1
Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	17
Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	9.6
Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Cash and cash equivalents | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	9.7
Fixed income | Cash and cash equivalents | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	4.4
Fixed income | Cash and cash equivalents | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	9.7
Fixed income | Cash and cash equivalents | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Cash and cash equivalents | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Cash and cash equivalents | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Cash and cash equivalents | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Cash and cash equivalents | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Collective trust funds | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	42.7
Fixed income | Collective trust funds | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Collective trust funds | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Collective trust funds | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Government agency issues | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.5
Fixed income | Government agency issues | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.5
Fixed income | Government agency issues | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Government agency issues | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Corporate bonds | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	30.1
Fixed income | Corporate bonds | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	30.1
Fixed income | Corporate bonds | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Corporate bonds | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Mutual funds | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	40.5
Fixed income | Mutual funds | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	10.7
Fixed income | Mutual funds | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	40.5
Fixed income | Mutual funds | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Mutual funds | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Mutual funds | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Mutual funds | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Fixed income | Mutual funds | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Collective trust funds | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	96.5
Equity | Collective trust funds | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Collective trust funds | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Collective trust funds | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Hedge funds | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	10.7
Equity | Hedge funds | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Hedge funds | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Hedge funds | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mutual funds | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.5
Equity | Mutual funds | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	53
Equity | Mutual funds | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	21.5
Equity | Mutual funds | Level 1 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	17
Equity | Mutual funds | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mutual funds | Level 2 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mutual funds | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mutual funds | Level 3 | U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Common stock | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	17.3
Equity | Common stock | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	17.3
Equity | Common stock | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Common stock | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Large cap | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	15.7
Equity | Large cap | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	15.7
Equity | Large cap | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Large cap | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mid cap | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.6
Equity | Mid cap | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	1.6
Equity | Mid cap | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Mid cap | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Real estate funds | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	10.2
Equity | Real estate funds | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	8.4
Equity | Real estate funds | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Equity | Real estate funds | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0
Other holdings | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	9.7
Other holdings | Level 1 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	0.1
Other holdings | Level 2 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	9.6
Other holdings | Level 3 | International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Plan assets	$ 0

Retirement and Other Benefit 98

Retirement and Other Benefit Programs (Plan Valuation Methods) (Details) - Baxalta	9 Months Ended
	Sep. 30, 2016
Cash and cash equivalents
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	These largely consist of a short-term investment fund, U.S. dollars and foreign currency. The fair value of the short-term investment fund is based on the net asset value
Government agency issues
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	Values are based on quoted prices in an active market
Corporate bonds
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	Values are based on the valuation date in an active market
Common stock
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	Values are based on the closing prices on the valuation date in an active market on national and international stock exchanges
Mutual funds
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	Values are based on the net asset value of the units held in the respective fund which are obtained from national and international exchanges or as reported by the fund managers
Collective Trust Funds and Hedge Funds
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	Values are based on the net asset value of the units held at year end
Real estate funds
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	The value of these assets are either determined by the net asset value of the units held in the respective fund which are obtained from national and international exchanges or based on the net asset value of the underlying assets of the fund provided by the fund manager
Hedge funds | Other holdings
Defined Benefit Plan Disclosure [Line Items]
Valuation Methodology	The value of these assets vary by investment type and are primarily based on reputable pricing vendors that typically use pricing matrices or models

Retirement and Other Benefit 99

Retirement and Other Benefit Programs (Net Periodic Benefit Cost) (Details) - Baxalta - USD ($) $ in Millions	3 Months Ended	4 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
U.S. pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	$ 5.5	$ 7.4
Interest cost	4.8	6.4
Expected return on plan assets	(3.8)	(5.1)
Net periodic benefit cost	6.5	8.7
International pensions
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	7.9	10.5
Interest cost	1.4	1.8
Expected return on plan assets	(1.7)	(2.2)
Net periodic benefit cost	7.6	10.1
OPEB
Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]
Service cost	0.4	0.5
Interest cost	0.2	0.3
Expected return on plan assets	0	0
Net periodic benefit cost	$ 0.6	$ 0.8

Retirement and Other Benefit100

Retirement and Other Benefit Programs (Funded and Unfunded Statuses of Plans) (Details) - Baxalta $ in Millions	Jun. 03, 2016USD ($)
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 358.5
PBO	$ 945.4
Funded status percentage	38.00%
U.S. pensions
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	$ 218
PBO	441.6
U.S. pensions | Qualified plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	218
PBO	$ 410.9
Funded status percentage	53.00%
U.S. pensions | Nonqualified plans
Defined Benefit Plan Disclosure [Line Items]
PBO	$ 30.7
International pensions
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140.5
PBO	503.8
International pensions | Funded plans
Defined Benefit Plan Disclosure [Line Items]
Fair value of plan assets	140.5
PBO	$ 324
Funded status percentage	43.00%
International pensions | Unfunded plans
Defined Benefit Plan Disclosure [Line Items]
PBO	$ 179.8

Accumulated Other Comprehens101

Accumulated Other Comprehensive Loss (Summary of Changes in Accumulated Other Comprehensive Loss) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As at January 1,	$ (183.8)
Net current period other comprehensive income	49.6
As at September 30,	(134.2)
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As at January 1,	(182.1)	$ (25.7)
Net current period other comprehensive income	38.8	(124.9)
As at September 30,	(143.3)	(150.6)
Unrealized holding (loss)/gain on available-for-sale securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As at January 1,	(1.7)	(5.8)
Net current period other comprehensive income	10.4	1.3
As at September 30,	8.7	(4.5)
Hedging activities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As at January 1,	0	0
Net current period other comprehensive income	0.4	0
As at September 30,	0.4	0
Accumulated other comprehensive loss
AOCI Attributable to Parent, Net of Tax [Roll Forward]
As at January 1,	(183.8)	(31.5)
Net current period other comprehensive income	49.6	(123.6)
As at September 30,	$ (134.2)	$ (155.1)

Earnings Per Share (Calculation

Earnings Per Share (Calculation of EPS) (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
(Loss)/Income from continuing operations, net of taxes	$ (368.5)	$ 477.1	$ 127.6	$ 1,054.1
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Numerator for basic and diluted (loss)/earnings per share	$ (386.8)	$ 452.8	$ (129.9)	$ 1,022.8
Basic (in shares)	900.2	590.9	725.5	590.2
Share-based awards to employees (in shares)	0	2.5	0	3
Diluted (in shares)	900.2	593.4	725.5	593.2

Earnings Per Share (Summary of

Earnings Per Share (Summary of Antidilutive Securities) (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	14.6	3.9	9.7	3.3

Taxation (Details)

Taxation (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Effective Income Tax Rate Reconciliation
Effective rate of tax	38.00%	(5.00%)	246.00%	(1.00%)

Segment Reporting (Revenue by P

Segment Reporting (Revenue by Product) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue from External Customer [Line Items]
Product sales	$ 3,315.4	$ 1,576.8	$ 7,264.8	$ 4,476.2
Royalties and Other revenues			325.7	224.8
Total revenues	$ 3,452.1	$ 1,655	7,590.5	4,701
Hematology
Revenue from External Customer [Line Items]
Product sales			1,233.7	0
HEMOPHILIA
Revenue from External Customer [Line Items]
Product sales			978	0
INHIBITOR THERAPIES
Revenue from External Customer [Line Items]
Product sales			255.7	0
Genetic Diseases
Revenue from External Customer [Line Items]
Product sales			1,977.2	1,781.4
CINRYZE
Revenue from External Customer [Line Items]
Product sales			502.6	474.4
ELAPRASE
Revenue from External Customer [Line Items]
Product sales			424.3	405.5
FIRAZYR
Revenue from External Customer [Line Items]
Product sales			411.3	319.8
REPLAGAL
Revenue from External Customer [Line Items]
Product sales			340.5	325.5
VPRIV
Revenue from External Customer [Line Items]
Product sales			259.3	256.2
KALBITOR
Revenue from External Customer [Line Items]
Product sales			39.2	0
Neuroscience
Revenue from External Customer [Line Items]
Product sales			1,901.8	1,610.5
VYVANSE
Revenue from External Customer [Line Items]
Product sales			1,539.5	1,268.9
ADDERALL XR
Revenue from External Customer [Line Items]
Product sales			281.1	259.7
Other Neuroscience
Revenue from External Customer [Line Items]
Product sales			81.2	81.9
Immunology
Revenue from External Customer [Line Items]
Product sales			796	0
IMMUNOGLOBULIN THERAPIES
Revenue from External Customer [Line Items]
Product sales			610.7	0
BIO THERAPEUTICS
Revenue from External Customer [Line Items]
Product sales			185.3	0
Internal Medicine
Revenue from External Customer [Line Items]
Product sales			1,266.3	1,084.3
LIALDA/MEZAVANT
Revenue from External Customer [Line Items]
Product sales			570.3	483
PENTASA
Revenue from External Customer [Line Items]
Product sales			222.3	232.7
GATTEX/REVESTIVE
Revenue from External Customer [Line Items]
Product sales			154.3	95.2
NATPARA
Revenue from External Customer [Line Items]
Product sales			58.8	12.8
Other Internal Medicine
Revenue from External Customer [Line Items]
Product sales			260.6	260.6
Oncology
Revenue from External Customer [Line Items]
Product sales			75.7	0
Opthalmology
Revenue from External Customer [Line Items]
Product sales			14.1	0
SENSIPAR Royalties
Revenue from External Customer [Line Items]
Royalties and Other revenues			112.2	80
3TC and ZEFFIX Royalties
Revenue from External Customer [Line Items]
Royalties and Other revenues			43.3	29.9
FOSRENOL Royalties
Revenue from External Customer [Line Items]
Royalties and Other revenues			34.3	32.4
ADDERALL XR Royalties
Revenue from External Customer [Line Items]
Royalties and Other revenues			15.7	22.2
Other Royalties and Revenues
Revenue from External Customer [Line Items]
Royalties and Other revenues			$ 120.2	$ 60.3

Segment Reporting (Narrative) (

Segment Reporting (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016segment
Segment Reporting [Abstract]
Number of operating segments	1
Number of reportable segments	1

Commitments and Contingencie107

Commitments and Contingencies (Leases, and LC and Guarantees ) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Future Minimum Lease Payments under Operating Leases
2016 (remaining three months)	$ 42.6		$ 42.6
2,017	118.9		118.9
2,018	94.8		94.8
2,019	84.5		84.5
2,020	80.1		80.1
2,021	74.6		74.6
Thereafter	333.7		333.7
Future minimum lease payments, total	829.2		829.2
Operating Leases, Rent Expense
Lease and rental expense	32.7	$ 6.3	63	$ 30.6
Letters of credit and guarantees
Irrevocable standby letters of credit and guarantees	$ 130		$ 130

Commitments and Contingencie108

Commitments and Contingencies (Commitments and Loss Contingency) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015
Clinical Testing
Other Commitments [Line Items]
Commitment amount	$ 1,202	$ 490
Contract Manufacturing
Other Commitments [Line Items]
Commitment amount	608	325
Commitments expected to be paid in next year	213
Other Purchasing Commitment
Other Commitments [Line Items]
Commitment amount	1,993	485
Commitments expected to be paid in next year	865
Investment Commitment
Other Commitments [Line Items]
Commitment amount	70	22
Capital Commitment
Other Commitments [Line Items]
Commitment amount	130	$ 60
Baxter related tax indemnification
Other Commitments [Line Items]
Deferred Tax Assets (Liabilities), Net	$ 42.2

Legal and other proceedings (Na

Legal and other proceedings (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Legal Proceedings [Abstract]
Provisions for litigation loss, insurance claims and other disputes	$ 399.7	$ 9.9
Settlement amount	$ 350

Share-based Compensation Pla110

Share-based Compensation Plans (Share-based Compensation Expense) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 73.9	$ 26.7	$ 268.7	$ 70.8
Less tax	(26.9)	(7.5)	(73.2)	(19.5)
Share-based compensation expense, net	47	19.2	195.5	51.3
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	7.9	6	15.5	6
Research and development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	14.4	9.4	33.4	21
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	24.9	4.6	49.1	28.5
Integration and acquisition costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	26.7	0	170.7	0
Reorganization costs
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense	$ 0	$ 6.7	$ 0	$ 15.3

Share-based Compensation Pla111

Share-based Compensation Plans (Replacement Awards Issued to Baxalta Employees) (Details) - Baxalta $ / shares in Units, shares in Thousands, $ in Thousands	Jun. 03, 2016USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value of awards granted (in usd per share)	$ 79.31
Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards, issued and outstanding (in shares) | shares	13,290
Number of awards, vested and exercisable (in shares) | shares	5,691
Weighted average exercise price of awards, issued and outstanding (in usd per share)	$ 43.12
Weighted average exercise price of awards, vested and exercisable (in usd per share)	$ 40.72
Weighted average remaining contractual term, issued and outstanding	7 years 8 months 8 days
Weighted average remaining contractual term, vested and exercisable	6 years 1 month 13 days
Intrinsic value of share-based awards, issued and outstanding | $	$ 242,467
Vested and exercisable as at end of period Intrinsic Value | $	$ 117,453
Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards, issued and outstanding (in shares) | shares	3,285
Weighted average grant date fair value of awards granted (in usd per share)	$ 49.55

Share-based Compensation Pla112

Share-based Compensation Plans (Fair Value Assumptions) (Details) - Baxalta	Jun. 03, 2016$ / shares
Fair Value Assumptions and Methodology
Risk-free interest rate	1.20%
Expected dividend yield	0.35%
Expected life	3 years 10 months 24 days
Volatility	29.10%
Fair Value per Option	$ 79.31

Share-based Compensation Pla113

Share-based Compensation Plans (Narrative) (Details) - USD ($) shares in Millions, $ in Millions	Jun. 03, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 73.9	$ 26.7	$ 268.7	$ 70.8
Baxalta
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		45.4		191.7
Shares issued for acquisition (in shares)	305.2
Baxalta | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to share based compensation awards		46.7		$ 46.7
Unrecognized compensation cost relating to non-vested in the money awards, expected period for recognition				1 year 3 months 18 days
Baxalta | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to share based compensation awards		72		$ 72
Unrecognized compensation cost relating to non-vested in the money awards, expected period for recognition				1 year 10 months 24 days
Baxalta and Baxter Combined | Replacement Awards Issued, Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for acquisition (in shares)	22.2
Baxalta and Baxter Combined | Replacement Awards Issued, Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued for acquisition (in shares)	3.9
Integration and acquisition costs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		26.7	$ 0	$ 170.7	$ 0
Integration and acquisition costs | Certain employee terminations
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense		$ 22.1		$ 160.5

Agreements and Transactions wit

Agreements and Transactions with Baxter (Narrative) (Detail) - USD ($) $ in Millions	3 Months Ended		4 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Agreements and Transactions by Party [Line Items]
Selling, general and administrative	$ 875.6	$ 442.3		$ 2,025.8	$ 1,356.6
Inventories	4,857.1		$ 4,857.1	4,857.1		$ 635.4
Prepaid expenses and other current assets	665.3		665.3	665.3		197.4
Other current liabilities	352.1		352.1	352.1		$ 144
Prepaid expenses and other current assets related indemnification liabilities	191		191	191
Other non current assets	34		34	34
Current tax related indemnification liabilities	124		124	124
Long-term tax related indemnification liabilities	86		86	86
Operations Not Yet Transferred to Baxalta
Agreements and Transactions by Party [Line Items]
Revenue	38		60
Inventories	43		43	43
Prepaid expenses and other current assets	47		47	47
Other current liabilities	3		3	$ 3
Manufacturing and Supply Agreement with Baxter
Agreements and Transactions by Party [Line Items]
Revenue	31		47
Transition Service Agreement with Baxter
Agreements and Transactions by Party [Line Items]
Selling, general and administrative	$ 24		$ 32

Guarantor Financial Informat115

Guarantor Financial Information (Senior Notes) (Details) - Senior Notes	Sep. 30, 2016	Jun. 03, 2016
Senior Notes, 2.0 % due 2018
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)		2.00%
Senior Notes, 2.875% due 2020
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)		2.875%
Senior Notes, 3.6 Percent due 2022
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)		3.60%
Senior Notes, 4.0% due 2025
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)		4.00%
Senior Notes, 5.25% due 2045
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)		5.25%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2019
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)	1.90%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2021
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)	2.40%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2023
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)	2.875%
Shire Acquisitions Investment Ireland Designated Activity Company | Fixed-rate notes due 2026
Debt Instrument [Line Items]
Debt Interest Rate (Stated Rate)	3.20%

Guarantor Financial Informat116

Guarantor Financial Information (Condensed Consolidating Balance Sheet) (Details) - USD ($) $ in Millions	Sep. 30, 2016	Dec. 31, 2015	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 728.6	$ 135.5	$ 44.9	$ 2,982.4
Restricted cash	20.1	86
Accounts receivable, net	2,633.4	1,201.2
Inventories	4,857.1	635.4
Prepaid expenses and other current assets	665.3	197.4
Intercompany receivables	0	0
Short term intercompany loan receivable	0
Total current assets	8,904.5	2,255.5
Non-current assets:
Investments	191.8	50.8
Property, plant and equipment, net	6,527.7	828.1
Goodwill	14,850.6	4,147.8	4,289.6	2,474.9
Intangible assets, net	38,871.5	9,173.3	9,450.6	4,934.4
Long term intercompany loan receivable	0
Other non-current assets	405.2	154.3
Total assets	69,751.3	16,609.8
Current liabilities:
Accounts payable and accrued expenses	4,021.7	2,050.6
Short-term borrowings	2,737.1	1,511.5
Intercompany payables	0	0
Short term intercompany loan payable	0
Other current liabilities	352.1	144
Total current liabilities	7,110.9	3,706.1
Non-current liabilities:
Long-term borrowings	20,988.9	69.9
Deferred tax liability	9,326.5	2,205.9
Long term intercompany loan payable	0
Other non-current liabilities	2,539.3	798.8
Total liabilities	39,965.6	6,780.7
Equity:
Total equity	29,785.7	9,829.1
Total liabilities and equity	69,751.3	16,609.8
Eliminations
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0	0
Intercompany receivables	(4,225.1)	(3,164.9)
Short term intercompany loan receivable	(1,796.3)
Total current assets	(6,021.4)	(3,164.9)
Non-current assets:
Investments	(84,559.9)	(14,477.2)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long term intercompany loan receivable	(15,825.3)
Other non-current assets	(217)	0
Total assets	(106,623.6)	(17,642.1)
Current liabilities:
Accounts payable and accrued expenses	0	0
Short-term borrowings	0	0
Intercompany payables	(4,225.1)	(3,164.9)
Short term intercompany loan payable	(1,796.3)
Other current liabilities		0
Total current liabilities	(6,021.4)	(3,164.9)
Non-current liabilities:
Long-term borrowings	0	0
Deferred tax liability	(217)	0
Long term intercompany loan payable	(15,825.3)
Other non-current liabilities	0	0
Total liabilities	(22,063.7)	(3,164.9)
Equity:
Total equity	(84,559.9)	(14,477.2)
Total liabilities and equity	(106,623.6)	(17,642.1)
Shire plc (Parent Guarantor)
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	1.8	1.9
Intercompany receivables	0	0
Short term intercompany loan receivable	0
Total current assets	1.8	1.9
Non-current assets:
Investments	36,448.3	14,477.2
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long term intercompany loan receivable	0
Other non-current assets	4.2	5.3
Total assets	36,454.3	14,484.4
Current liabilities:
Accounts payable and accrued expenses	4.7	10
Short-term borrowings	920	1,500
Intercompany payables	4,225.1	3,145.3
Short term intercompany loan payable	0
Other current liabilities	0	0
Total current liabilities	5,149.8	4,655.3
Non-current liabilities:
Long-term borrowings	0	0
Deferred tax liability	0	0
Long term intercompany loan payable	1,110.3
Other non-current liabilities	408.5	0
Total liabilities	6,668.6	4,655.3
Equity:
Total equity	29,785.7	9,829.1
Total liabilities and equity	36,454.3	14,484.4
SAIIDAC (Subsidiary Issuer)
Current assets:
Cash and cash equivalents	0	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	0.7	9.6
Intercompany receivables	50.2	0
Short term intercompany loan receivable	1,796.3
Total current assets	1,847.2	9.6
Non-current assets:
Investments	0	0
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long term intercompany loan receivable	15,825.3
Other non-current assets	0	8.3
Total assets	17,672.5	17.9
Current liabilities:
Accounts payable and accrued expenses	18.4	0
Short-term borrowings	1,796.3	0
Intercompany payables	0	19.6
Short term intercompany loan payable	0
Other current liabilities	1.1	0
Total current liabilities	1,815.8	19.6
Non-current liabilities:
Long-term borrowings	15,825.3	0
Deferred tax liability	0	0
Long term intercompany loan payable	0
Other non-current liabilities	2	0
Total liabilities	17,643.1	19.6
Equity:
Total equity	29.4	(1.7)
Total liabilities and equity	17,672.5	17.9
Baxalta Inc. (Subsidiary Issuer)
Current assets:
Cash and cash equivalents	308.6	0	0	0
Restricted cash	0	0
Accounts receivable, net	0	0
Inventories	0	0
Prepaid expenses and other current assets	12.7	0
Intercompany receivables	432.6	0
Short term intercompany loan receivable	0
Total current assets	753.9	0
Non-current assets:
Investments	35,740.2	0
Property, plant and equipment, net	25.9	0
Goodwill	0	0
Intangible assets, net	0	0
Long term intercompany loan receivable	0
Other non-current assets	437.3	0
Total assets	36,957.3	0
Current liabilities:
Accounts payable and accrued expenses	101.5	0
Short-term borrowings	0	0
Intercompany payables	0	0
Short term intercompany loan payable	0
Other current liabilities	48.4	0
Total current liabilities	149.9	0
Non-current liabilities:
Long-term borrowings	5,104.8	0
Deferred tax liability	0	0
Long term intercompany loan payable	0
Other non-current liabilities	64	0
Total liabilities	5,318.7	0
Equity:
Total equity	31,638.6	0
Total liabilities and equity	36,957.3	0
Non-Guarantor Non-Issuer Subsidiaries
Current assets:
Cash and cash equivalents	420	135.5	44.9	2,982.4
Restricted cash	20.1	86
Accounts receivable, net	2,633.4	1,201.2
Inventories	4,857.1	635.4
Prepaid expenses and other current assets	650.1	185.9
Intercompany receivables	3,742.3	3,164.9
Short term intercompany loan receivable	0
Total current assets	12,323	5,408.9
Non-current assets:
Investments	12,563.2	50.8
Property, plant and equipment, net	6,501.8	828.1
Goodwill	14,850.6	4,147.8
Intangible assets, net	38,871.5	9,173.3
Long term intercompany loan receivable	0
Other non-current assets	180.7	140.7
Total assets	85,290.8	19,749.6
Current liabilities:
Accounts payable and accrued expenses	3,897.1	2,040.6
Short-term borrowings	20.8	11.5
Intercompany payables	0	0
Short term intercompany loan payable	1,796.3
Other current liabilities	302.6	144
Total current liabilities	6,016.8	2,196.1
Non-current liabilities:
Long-term borrowings	58.8	69.9
Deferred tax liability	9,543.5	2,205.9
Long term intercompany loan payable	14,715
Other non-current liabilities	2,064.8	798.8
Total liabilities	32,398.9	5,270.7
Equity:
Total equity	52,891.9	14,478.9
Total liabilities and equity	85,290.8	19,749.6
Non-Guarantor Subsidiaries of SAIIDAC Notes
Current assets:
Cash and cash equivalents	728.6	135.5	44.9	2,982.4
Restricted cash	20.1	86
Accounts receivable, net	2,633.4	1,201.2
Inventories	4,857.1	635.4
Prepaid expenses and other current assets	662.8	185.9
Intercompany receivables	4,174.9	3,164.9
Short term intercompany loan receivable	0
Total current assets	13,076.9	5,408.9
Non-current assets:
Investments	48,303.4	50.8
Property, plant and equipment, net	6,527.7	828.1
Goodwill	14,850.6	4,147.8
Intangible assets, net	38,871.5	9,173.3
Long term intercompany loan receivable	0
Other non-current assets	618	140.7
Total assets	122,248.1	19,749.6
Current liabilities:
Accounts payable and accrued expenses	3,998.6	2,040.6
Short-term borrowings	20.8	11.5
Intercompany payables	0	0
Short term intercompany loan payable	1,796.3
Other current liabilities	351	144
Total current liabilities	6,166.7	2,196.1
Non-current liabilities:
Long-term borrowings	5,163.6	69.9
Deferred tax liability	9,543.5	2,205.9
Long term intercompany loan payable	14,715
Other non-current liabilities	2,128.8	798.8
Total liabilities	37,717.6	5,270.7
Equity:
Total equity	84,530.5	14,478.9
Total liabilities and equity	122,248.1	19,749.6
Non-Guarantor Subsidiaries of Baxalta Notes
Current assets:
Cash and cash equivalents	420	135.5	$ 44.9	$ 2,982.4
Restricted cash	20.1	86
Accounts receivable, net	2,633.4	1,201.2
Inventories	4,857.1	635.4
Prepaid expenses and other current assets	650.8	195.5
Intercompany receivables	3,792.5	3,164.9
Short term intercompany loan receivable	1,796.3
Total current assets	14,170.2	5,418.5
Non-current assets:
Investments	12,563.2	50.8
Property, plant and equipment, net	6,501.8	828.1
Goodwill	14,850.6	4,147.8
Intangible assets, net	38,871.5	9,173.3
Long term intercompany loan receivable	15,825.3
Other non-current assets	180.7	149
Total assets	102,963.3	19,767.5
Current liabilities:
Accounts payable and accrued expenses	3,915.5	2,040.6
Short-term borrowings	1,817.1	11.5
Intercompany payables	0	19.6
Short term intercompany loan payable	1,796.3
Other current liabilities	303.7	144
Total current liabilities	7,832.6	2,215.7
Non-current liabilities:
Long-term borrowings	15,884.1	69.9
Deferred tax liability	9,543.5	2,205.9
Long term intercompany loan payable	14,715
Other non-current liabilities	2,066.8	798.8
Total liabilities	50,042	5,290.3
Equity:
Total equity	52,921.3	14,477.2
Total liabilities and equity	$ 102,963.3	$ 19,767.5

Guarantor Financial Informat117

Guarantor Financial Information (Consolidating Statements of Income) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenues:
Product sales	$ 3,315.4	$ 1,576.8	$ 7,264.8	$ 4,476.2
Royalties and other revenues	136.7	78.2	325.7	224.8
Total revenues	3,452.1	1,655	7,590.5	4,701
Costs and expenses:
Cost of sales	1,736.2	262.7	2,762.9	718.5
Research and development	511.1	241.2	1,023	1,210.8
Selling, general and administrative	875.6	442.3	2,025.8	1,356.6
Amortization of acquired intangibles	354.9	132.7	702.5	352.3
Integration and acquisition costs	284.5	89.9	738.6	(46.8)
Reorganization costs	101.4	31.1	115.7	59.6
Other operating expenses		(0.7)		(13)
Gain on sale of product rights	(5.7)	(0.7)	(12.2)	(13)
Total operating expenses	3,858	1,199.2	7,356.3	3,638
Operating (loss)/income from continuing operations	(405.9)	455.8	234.2	1,063
Interest income/(expense), net	(177.6)	(9.9)	(306.9)	(28.2)
Other income, net	(13.7)	9.6	(16.2)	11.9
Total other expense, net	(191.3)	(0.3)	(323.1)	(16.3)
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(597.2)	455.5	(88.9)	1,046.7
Income tax benefit/(expense)	229.6	22.3	218.4	9
Equity in income/(losses) of equity method investees, net of taxes	0.9	0.7	1.9	1.6
(Loss)/income from continuing operations, net of taxes	(368.5)	477.1	127.6	1,054.1
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Net (loss)/income	(386.8)	452.8	(129.9)	1,022.8
Comprehensive (loss)/income	(135.2)	409.2	(80.3)	899.2
Eliminations
Revenues:
Product sales	0	0	0	0
Royalties and other revenues	0	0	0	0
Total revenues	0	0	0	0
Costs and expenses:
Cost of sales	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	0	0	0	0
Amortization of acquired intangibles	0	0	0	0
Integration and acquisition costs	0	0	0	0
Reorganization costs	0	0	0	0
Other operating expenses		0		0
Gain on sale of product rights	0		0
Total operating expenses	0	0	0	0
Operating (loss)/income from continuing operations	0	0	0	0
Interest income/(expense), net	0	0	0	0
Other income, net	0	0	0	0
Total other expense, net	0	0	0	0
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	0	0	0	0
Income tax benefit/(expense)	0	0	0	0
Equity in income/(losses) of equity method investees, net of taxes	(871)	477.8	(667.5)	1,089.2
(Loss)/income from continuing operations, net of taxes	871	(477.8)	667.5	(1,089.2)
Loss from discontinued operations, net of taxes	0	0	0	0
Net (loss)/income	871	(477.8)	667.5	(1,089.2)
Comprehensive (loss)/income	871	(434.2)	1,055.8	(965.6)
Shire plc (Parent Guarantor)
Revenues:
Product sales	0	0	0	0
Royalties and other revenues	0	0	0	0
Total revenues	0	0	0	0
Costs and expenses:
Cost of sales	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	(2.5)	9	33.3	22.5
Amortization of acquired intangibles	0	0	0	0
Integration and acquisition costs	0	0	0	0
Reorganization costs	0	0	0	0
Other operating expenses		0		0
Gain on sale of product rights	0		0
Total operating expenses	(2.5)	9	33.3	22.5
Operating (loss)/income from continuing operations	2.5	(9)	(33.3)	(22.5)
Interest income/(expense), net	(23.2)	(16.5)	(67.7)	(46.9)
Other income, net	(0.1)	0.1	0.8	1.3
Total other expense, net	(23.3)	(16.4)	(66.9)	(45.6)
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(20.8)	(25.4)	(100.2)	(68.1)
Income tax benefit/(expense)	0	0.4	1.9	1.7
Equity in income/(losses) of equity method investees, net of taxes	366	(477.8)	31.6	(1,089.2)
(Loss)/income from continuing operations, net of taxes	(386.8)	452.8	(129.9)	1,022.8
Loss from discontinued operations, net of taxes	0	0	0	0
Net (loss)/income	(386.8)	452.8	(129.9)	1,022.8
Comprehensive (loss)/income	(135.2)	409.2	(80.3)	899.2
SAIIDAC (Subsidiary Issuer)
Revenues:
Product sales	0	0	0	0
Royalties and other revenues	0	0	0	0
Total revenues	0	0	0	0
Costs and expenses:
Cost of sales	0	0	0	0
Research and development	0	0	0	0
Selling, general and administrative	0	0	0	0
Amortization of acquired intangibles	0	0	0	0
Integration and acquisition costs	0	0	0	0
Reorganization costs	0	0	0	0
Other operating expenses		0		0
Gain on sale of product rights	0		0
Total operating expenses	0	0	0	0
Operating (loss)/income from continuing operations	0	0	0	0
Interest income/(expense), net	61.7	0	41.5	0
Other income, net	0	0	0	0
Total other expense, net	61.7	0	41.5	0
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	61.7	0	41.5	0
Income tax benefit/(expense)	(15.4)	0	(10.3)	0
Equity in income/(losses) of equity method investees, net of taxes	0	0	0	0
(Loss)/income from continuing operations, net of taxes	46.3	0	31.2	0
Loss from discontinued operations, net of taxes	0	0	0	0
Net (loss)/income	46.3	0	31.2	0
Comprehensive (loss)/income	46.3	0	31.2	0
Baxalta Inc. (Subsidiary Issuer)
Revenues:
Product sales	0	0	0	0
Royalties and other revenues	0	0	0	0
Total revenues	0	0	0	0
Costs and expenses:
Cost of sales	0	0	0	0
Research and development	0	0	0.4	0
Selling, general and administrative	10.8	0	19.4	0
Amortization of acquired intangibles	0	0	0	0
Integration and acquisition costs	50	0	259.7	0
Reorganization costs	0	0	0	0
Other operating expenses		0		0
Gain on sale of product rights	0		0
Total operating expenses	60.8	0	279.5	0
Operating (loss)/income from continuing operations	(60.8)	0	(279.5)	0
Interest income/(expense), net	(26.1)	0	(32.4)	0
Other income, net	(0.1)	0	7.6	0
Total other expense, net	(26.2)	0	(24.8)	0
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(87)	0	(304.3)	0
Income tax benefit/(expense)	18.9	0	77.7	0
Equity in income/(losses) of equity method investees, net of taxes	505	0	635.9	0
(Loss)/income from continuing operations, net of taxes	(573.1)	0	(862.5)	0
Loss from discontinued operations, net of taxes	0	0	0	0
Net (loss)/income	(573.1)	0	(862.5)	0
Comprehensive (loss)/income	(333.4)	0	(809)	0
Non-Guarantor Non-Issuer Subsidiaries
Revenues:
Product sales	3,315.4	1,576.8	7,264.8	4,476.2
Royalties and other revenues	136.7	78.2	325.7	224.8
Total revenues	3,452.1	1,655	7,590.5	4,701
Costs and expenses:
Cost of sales	1,736.2	262.7	2,762.9	718.5
Research and development	511.1	241.2	1,022.6	1,210.8
Selling, general and administrative	867.3	433.3	1,973.1	1,334.1
Amortization of acquired intangibles	354.9	132.7	702.5	352.3
Integration and acquisition costs	234.5	89.9	478.9	(46.8)
Reorganization costs	101.4	31.1	115.7	59.6
Other operating expenses		(0.7)		(13)
Gain on sale of product rights	(5.7)		(12.2)
Total operating expenses	3,799.7	1,190.2	7,043.5	3,615.5
Operating (loss)/income from continuing operations	(347.6)	464.8	547	1,085.5
Interest income/(expense), net	(190)	6.6	(248.3)	18.7
Other income, net	(13.5)	9.5	(24.6)	10.6
Total other expense, net	(203.5)	16.1	(272.9)	29.3
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(551.1)	480.9	274.1	1,114.8
Income tax benefit/(expense)	226.1	21.9	149.1	7.3
Equity in income/(losses) of equity method investees, net of taxes	0.9	0.7	1.9	1.6
(Loss)/income from continuing operations, net of taxes	(325.9)	502.1	421.3	1,120.5
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Net (loss)/income	(344.2)	477.8	163.8	1,089.2
Comprehensive (loss)/income	(583.9)	434.2	(278)	965.6
Non-Guarantor Subsidiaries of SAIIDAC Notes
Revenues:
Product sales	3,315.4	1,576.8	7,264.8	4,476.2
Royalties and other revenues	136.7	78.2	325.7	224.8
Total revenues	3,452.1	1,655	7,590.5	4,701
Costs and expenses:
Cost of sales	1,736.2	262.7	2,762.9	718.5
Research and development	511.1	241.2	1,023	1,210.8
Selling, general and administrative	878.1	433.3	1,992.5	1,334.1
Amortization of acquired intangibles	354.9	132.7	702.5	352.3
Integration and acquisition costs	284.5	89.9	738.6	(46.8)
Reorganization costs	101.4	31.1	115.7	59.6
Other operating expenses		(0.7)		(13)
Gain on sale of product rights	(5.7)		(12.2)
Total operating expenses	3,860.5	1,190.2	7,323	3,615.5
Operating (loss)/income from continuing operations	(408.4)	464.8	267.5	1,085.5
Interest income/(expense), net	(216.1)	6.6	(280.7)	18.7
Other income, net	(13.6)	9.5	(17)	10.6
Total other expense, net	(229.7)	16.1	(297.7)	29.3
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(638.1)	480.9	(30.2)	1,114.8
Income tax benefit/(expense)	245	21.9	226.8	7.3
Equity in income/(losses) of equity method investees, net of taxes	505.9	0.7	637.8	1.6
(Loss)/income from continuing operations, net of taxes	(899)	502.1	(441.2)	1,120.5
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Net (loss)/income	(917.3)	477.8	(698.7)	1,089.2
Comprehensive (loss)/income	(917.3)	434.2	(1,087)	965.6
Non-Guarantor Subsidiaries of Baxalta Notes
Revenues:
Product sales	3,315.4	1,576.8	7,264.8	4,476.2
Royalties and other revenues	136.7	78.2	325.7	224.8
Total revenues	3,452.1	1,655	7,590.5	4,701
Costs and expenses:
Cost of sales	1,736.2	262.7	2,762.9	718.5
Research and development	511.1	241.2	1,022.6	1,210.8
Selling, general and administrative	867.3	433.3	1,973.1	1,334.1
Amortization of acquired intangibles	354.9	132.7	702.5	352.3
Integration and acquisition costs	234.5	89.9	478.9	(46.8)
Reorganization costs	101.4	31.1	115.7	59.6
Other operating expenses		(0.7)		(13)
Gain on sale of product rights	(5.7)		(12.2)
Total operating expenses	3,799.7	1,190.2	7,043.5	3,615.5
Operating (loss)/income from continuing operations	(347.6)	464.8	547	1,085.5
Interest income/(expense), net	(128.3)	6.6	(206.8)	18.7
Other income, net	(13.5)	9.5	(24.6)	10.6
Total other expense, net	(141.8)	16.1	(231.4)	29.3
(Loss)/income from continuing operations before income taxes and equity in losses of equity method investees	(489.4)	480.9	315.6	1,114.8
Income tax benefit/(expense)	210.7	21.9	138.8	7.3
Equity in income/(losses) of equity method investees, net of taxes	0.9	0.7	1.9	1.6
(Loss)/income from continuing operations, net of taxes	(279.6)	502.1	452.5	1,120.5
Loss from discontinued operations, net of taxes	(18.3)	(24.3)	(257.5)	(31.3)
Net (loss)/income	(297.9)	477.8	195	1,089.2
Comprehensive (loss)/income	$ (537.6)	$ 434.2	$ (246.8)	$ 965.6

Guarantor Financial Informat118

Guarantor Financial Information (Condensed Consolidating Statement of Cash Flows) (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	$ 1,506	$ 1,575.2
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	0	0
Movements in restricted cash	68.3	(48)
Purchases of businesses, net of cash acquired	(17,476.2)	(5,553.4)
Purchases of PP&E and non-current investments	(402.5)	(67.3)
Proceeds from short-term investments	0	67
Proceeds from sale of product rights	7.8	14.5
Proceeds from disposal of non-current investments and PP&E	0.6	18.5
Other, net	(9.3)	2.7
Net cash used in investing activities	(17,811.3)	(5,566)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	31,742.3	3,650.8
Repayment of revolving line of credit, long term and short term borrowings	(14,632.9)	(2,486.1)
Proceeds from intercompany borrowings	0	0
Payment of dividend	(130.2)	(110.2)
Debt issuance costs	(171)	(3.3)
Proceeds from exercise of options	98.9	0
Other, net	(6.5)	3.7
Net cash provided by financing activities	16,900.6	1,054.9
Effect of foreign exchange rate changes on cash and cash equivalents	(2.2)	(1.6)
Net increase (decrease) in cash and cash equivalents	593.1	(2,937.5)
Cash and cash equivalents at beginning of period	135.5	2,982.4
Cash and cash equivalents at end of period	728.6	44.9
Eliminations
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	0	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	23,425.7	6,113.3
Movements in restricted cash	0	0
Purchases of businesses, net of cash acquired	0	0
Purchases of PP&E and non-current investments	0	0
Proceeds from short-term investments		0
Proceeds from sale of product rights	0	0
Proceeds from disposal of non-current investments and PP&E	0	0
Other, net	0	0
Net cash used in investing activities	23,425.7	6,113.3
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	0	0
Repayment of revolving line of credit, long term and short term borrowings	0	0
Proceeds from intercompany borrowings	(23,425.7)	(6,113.3)
Payment of dividend	0	0
Debt issuance costs	0	0
Proceeds from exercise of options	0
Other, net	0	0
Net cash provided by financing activities	(23,425.7)	(6,113.3)
Effect of foreign exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Shire plc (Parent Guarantor)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	(79.8)	(107.2)
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(2,390)	(3,570)
Movements in restricted cash	0	(1.1)
Purchases of businesses, net of cash acquired	0	0
Purchases of PP&E and non-current investments	0	0
Proceeds from short-term investments		0
Proceeds from sale of product rights	0	0
Proceeds from disposal of non-current investments and PP&E	0	0
Other, net	0	0
Net cash used in investing activities	(2,390)	(3,571.1)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	1,655	3,631.1
Repayment of revolving line of credit, long term and short term borrowings	(2,215.8)	(2,486.1)
Proceeds from intercompany borrowings	3,045.3	2,543.3
Payment of dividend	(15)	(5.6)
Debt issuance costs	0	(3.3)
Proceeds from exercise of options	0.3
Other, net	0	(1.1)
Net cash provided by financing activities	2,469.8	3,678.3
Effect of foreign exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
SAIIDAC (Subsidiary Issuer)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	182.3	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(18,172)	0
Movements in restricted cash	0	0
Purchases of businesses, net of cash acquired	0	0
Purchases of PP&E and non-current investments	0	0
Proceeds from short-term investments		0
Proceeds from sale of product rights	0	0
Proceeds from disposal of non-current investments and PP&E	0	0
Other, net	0	0
Net cash used in investing activities	(18,172)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	30,079.9	0
Repayment of revolving line of credit, long term and short term borrowings	(12,409.2)	0
Proceeds from intercompany borrowings	490	0
Payment of dividend	0	0
Debt issuance costs	(171)	0
Proceeds from exercise of options	0
Other, net	0	0
Net cash provided by financing activities	17,989.7	0
Effect of foreign exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Baxalta Inc. (Subsidiary Issuer)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	(51.8)	0
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	0	0
Movements in restricted cash	0	0
Purchases of businesses, net of cash acquired	0	0
Purchases of PP&E and non-current investments	(6)	0
Proceeds from short-term investments		0
Proceeds from sale of product rights	0	0
Proceeds from disposal of non-current investments and PP&E	0	0
Other, net	0	0
Net cash used in investing activities	(6)	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	0	0
Repayment of revolving line of credit, long term and short term borrowings	0	0
Proceeds from intercompany borrowings	308.4	0
Payment of dividend	0	0
Debt issuance costs	0	0
Proceeds from exercise of options	87.9
Other, net	(29.9)	0
Net cash provided by financing activities	366.4	0
Effect of foreign exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	308.6	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	308.6	0
Non-Guarantor Non-Issuer Subsidiaries
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	1,455.3	1,682.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(2,863.7)	(2,543.3)
Movements in restricted cash	68.3	(46.9)
Purchases of businesses, net of cash acquired	(17,476.2)	(5,553.4)
Purchases of PP&E and non-current investments	(396.5)	(67.3)
Proceeds from short-term investments		67
Proceeds from sale of product rights	7.8	14.5
Proceeds from disposal of non-current investments and PP&E	0.6	18.5
Other, net	(9.3)	2.7
Net cash used in investing activities	(20,669)	(8,108.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	7.4	19.7
Repayment of revolving line of credit, long term and short term borrowings	(7.9)	0
Proceeds from intercompany borrowings	19,582	3,570
Payment of dividend	(115.2)	(104.6)
Debt issuance costs	0	0
Proceeds from exercise of options	10.7
Other, net	23.4	4.8
Net cash provided by financing activities	19,500.4	3,489.9
Effect of foreign exchange rate changes on cash and cash equivalents	(2.2)	(1.6)
Net increase (decrease) in cash and cash equivalents	284.5	(2,937.5)
Cash and cash equivalents at beginning of period	135.5	2,982.4
Cash and cash equivalents at end of period	420	44.9
Non-Guarantor Subsidiaries of SAIIDAC Notes
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	1,403.5	1,682.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(2,863.7)	(2,543.3)
Movements in restricted cash	68.3	(46.9)
Purchases of businesses, net of cash acquired	(17,476.2)	(5,553.4)
Purchases of PP&E and non-current investments	(402.5)	(67.3)
Proceeds from short-term investments		67
Proceeds from sale of product rights	7.8	14.5
Proceeds from disposal of non-current investments and PP&E	0.6	18.5
Other, net	(9.3)	2.7
Net cash used in investing activities	(20,675)	(8,108.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	7.4	19.7
Repayment of revolving line of credit, long term and short term borrowings	(7.9)	0
Proceeds from intercompany borrowings	19,890.4	3,570
Payment of dividend	(115.2)	(104.6)
Debt issuance costs	0	0
Proceeds from exercise of options	98.6
Other, net	(6.5)	4.8
Net cash provided by financing activities	19,866.8	3,489.9
Effect of foreign exchange rate changes on cash and cash equivalents	(2.2)	(1.6)
Net increase (decrease) in cash and cash equivalents	593.1	(2,937.5)
Cash and cash equivalents at beginning of period	135.5	2,982.4
Cash and cash equivalents at end of period	728.6	44.9
Non-Guarantor Subsidiaries of Baxalta Notes
CASH FLOWS FROM OPERATING ACTIVITIES:
Net cash provided (used in) operating activities	1,637.6	1,682.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Transactions with subsidiaries	(21,035.7)	(2,543.3)
Movements in restricted cash	68.3	(46.9)
Purchases of businesses, net of cash acquired	(17,476.2)	(5,553.4)
Purchases of PP&E and non-current investments	(396.5)	(67.3)
Proceeds from short-term investments		67
Proceeds from sale of product rights	7.8	14.5
Proceeds from disposal of non-current investments and PP&E	0.6	18.5
Other, net	(9.3)	2.7
Net cash used in investing activities	(38,841)	(8,108.2)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from revolving line of credit, long term and short term borrowings	30,087.3	19.7
Repayment of revolving line of credit, long term and short term borrowings	(12,417.1)	0
Proceeds from intercompany borrowings	20,072	3,570
Payment of dividend	(115.2)	(104.6)
Debt issuance costs	(171)	0
Proceeds from exercise of options	10.7
Other, net	23.4	4.8
Net cash provided by financing activities	37,490.1	3,489.9
Effect of foreign exchange rate changes on cash and cash equivalents	(2.2)	(1.6)
Net increase (decrease) in cash and cash equivalents	284.5	(2,937.5)
Cash and cash equivalents at beginning of period	135.5	2,982.4
Cash and cash equivalents at end of period	$ 420	$ 44.9